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SUMMARY 
The pharmacokinetics and pharmacodynamics of nitroglycerin and 
aspirin have been evaluated with emphasis being placed on the in vitro  
and in vivo metabolism of these drugs in various tissues of the body. 
Nitroglycerin (GTN) was metabolized by blood components to the 
dinitro- (GDN) and in turn mononitroglycerin (GMN) metabolites. The 
rate of GTN and GDN metabolism was concentration dependent. The rate 
of GTN metabolism was reduced in the presence of GDNs and prevented by 
iodoacetamide which was used to stabilize GTN in blood samples obtained 
for pharmacokinetic studies. 
Intravenous (IV) bolus doses of GTN administered to sheep evoked 
rapid and substantial changes in haemodynamic parameters in a dose- 
vi 
dependent manner. 
peak GTN femoral 
Large differences 
plasma-time curves 
The magnitude of the responses was related to the 
arterial (A) or venous (V) plasma concentration. 
in peak GTN concentrations and area under the 
(AUC) for A and V plasma were observed. The extent 
across the liver and of this femoral A-V gradient, and of gradients 
lungs, was further examined at apparent steady state plasma GTN concen-
trations attained by continuous IV GTN infusions in sheep. These 
studies demonstrated substantial extra-hepatic metabolism of GTN; the 
availability of GTN was in the rank order leg < liver < lung. In vitro 
studies showed that GTN was metabolized to GDNs and GMNs by sheep 
liver, leg muscle, lung, venous and arterial tissue homogenates and 
that the presence of GDNs reduced the rate of GTN metabolism. Adminis-
tration of bolus doses of GDNs to sheep receiving GTN infusion reversed 
vii 
the femoral A-V gradient and reduced the systemic clearance of GTN. 
GDN and GMN pharmacokinetics were monitored in some sheep receiving GTN 
infusions. 
Extra-hepatic metabolism of aspirin (ASA) was also investigated in 
the sheep. During continuous IV ASA infusions an A-V gradient in 
apparent steady state plasma ASA concentrations across the leg and 
liver was observed but not across the lungs. In vitro studies of the 
metabolism of ASA by sheep leg muscle, liver and lung tissue 
homogenates showed that hydrolysis of ASA to salicylic acid (SA) 
occurred in all three tissues. The presence of SA had no effect on the 
rate of ASA hydrolysis by any of the tissues. Bolus doses of SA 
administered during ASA infusions failed to modify the pharmacokinetics 
or A-V gradients of plasma ASA concentrations except at the largest SA 
dose when the rate of elimination of ASA was increased. This was due 
to the displacement, by SA, of ASA from plasma protein binding sites. 
ASA metabolite pharmacokinetics were monitored in sheep receiving ASA 
infusions. 
Human platelet function was used to evaluate the pharmacodynamics 
of ASA administered as a single 300 mg dose of a soluble or a 
slow-release preparation. Despite marked differences in peak plasma 
ASA concentrations and AUCs, there was similar inhibition of platelet 
function elicited by the two doses of ASA. Dose ranging studies using 
the slow-release preparation once daily for 7 days indicated that 
maximal inhibition of platelet function occurred using doses of 
100-200 mg ASA daily. 
viii 
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CHAPTER1 
INTRODUCTION  
The discipline of therapeutics has made many advances in recent 
years. New substances are continually being evaluated for their 
clinical potential. However, in only a small number of cases is that 
potential ever converted and the new drug eventually marketed. Often 
a drug has only one therapeutic indication and so its clinical use is 
limited. Two drugs which fit neither of these categories are GTN and 
ASA. Both drugs have been in clinical use since the 19th century for 
numerous clinical indications. 
GTN was first synthesized by Sobrero in Italy in 1846. This was 
achieved by mixing glycerin with cold, concentrated sulphuric and 
nitric acids. It was not long before others had repeated the syn-
thesis and found, as Sobrero had, that a small amount of the product 
placed on the tongue evoked throbbing at the temples and a severe 
headache (Krantz, 1975). Two Americans, Constantin Hering and Morris 
Davis, both associated with a Philadelphia medical school, distributed 
GTN to physicians who were requested to record the effects of GTN when 
given to their patients. Hering and Davis were keen to compare the 
effects of GTN and amyl nitrite which had earlier been shown by T. 
Lauder Brunton in England to alleviate the symptoms of angina pectoris 
despite causing severe headaches and an increased pulse rate. It is 
not clear what the results of that study were (Krantz, 1975) and it 
was not until 1879 that Edward Murrell, •an English physician, 
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conducted similar experiments to find that the efficacy of GTN was 
similar to that of amyl nitrite in the treatment of angina pectoris. 
At about the same time as the therapeutic benefits of GTN were 
being realized a Swedish engineer, Alfred Nobel, was devising ways to 
exploit the other major property of GTN, that of its explosiveness. 
By mixing GTN with charcoal or diatomaceous earth, he made possible 
the relatively safe handling of GTN as dynamite (Urbanski, 1965). The 
fortune amassed by Nobel as a result of patents covering dynamite 
makes possible the current award of Nobel Prizes. 
The history of ASA is intricately related to that of other sali-
cylates, all of which have the 2-hydroxy benzoate radical. Sali-
cylates occur naturally in the bark, leaves and fruit of many plants 
and trees. It is the bark of species of Salix and Populus, however, 
which have been most widely used as a source of these compounds. 
Salicylates have been used for many hundreds of years as analgesics 
and anti-pyretics. Full reviews of the history of salicylates have 
been presented by Gross and Greenberg (1948) and most recently by 
Rainsford (1984). 
ASA was first synthesized in 1853 by a French chemist, Charles 
von Gerhardt, by the treatment of sodium salicylate with acetyl 
chloride. However, credit for the therapeutic use of ASA goes to 
Felix Hoffman, a chemist at Friedrich Bayer and Company in Germany, 
who was searching for a better tolerated salicylate than the sodium 
salt of SA for his father suffering rheumatoid arthritis. Heinrich 
Dreser, director of pharmacological research at Bayer, believed ASA to 
be superior to sodium salicylate in terms of less gastrointestinal 
irritation and began marketing ASA in 1899 (Gross and Greenberg, 1948; 
Rainsford, 1984). However, as Rainsford (1984) points out, this 
promise was not substantiated and in fact ASA is more irritant to the 
stomach than either sodium salicylate or SA. Nevertheless, the anal-
gesic, anti-inflammatory and anti-pyretic properties of ASA have made 
it a very valuable drug. 
Although GTN and ASA are two of the oldest drugs still in current 
therapeutics, uses for both drugs have continued to increase. In 
recent years the ability of GTN to decrease the size and/or severity 
of acute myocardial infarction has been investigated (Epstein et al., 
1975; Flaherty et al., 1975, 1976). Moreover new transdermal forma-
tions of GTN have been investigated as alternatives to oral or sub-
lingual dosing of GTN in angina pectoris and in peripheral occlusive 
vascular disease (Black, 1982; Demma and Wilson, 1983). GTN sales 
ranked 152 out of the top 200 prescription drugs in the U.S.A. for 
1982 (U.S. Pharmaceutical Manufacturers' Association, personal com-
munication). Almost 32 million prescriptions were written for GTN in 
1983 in the U.S.A. alone, an increase of about 10 million prescrip-
tions on 1982 (Pharmaceutical Data Services, Arizona, personal com-
munication). 
Interest in ASA has grown based on the work of Vane and coworkers 
who showed that ASA inhibits prostaglandin synthesis generally, and by 
Smith and Willis (1971) who showed that aspirin inhibits platelet 
prostaglandin synthesis. Elwood et al. (1974) reported results sug-
gesting that ASA may be beneficial in reducing the mortality of myo-
cardial re-infarction and it is believed that this is related to ASA's 
anti-platelet effects. A tally of prescriptions for ASA is impossible 
since even with a prescription, pharmacists (in most parts of the 
world) sell it to patients as an OTC product and do not record the 
prescription. Nevertheless, production of ASA in the U.S.A. alone was 
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estimated as 97 million kilograms in 1980, a large increase from the 
1965 figure of 13 million kilograms (Rainsford, 1984). 
Despite the enormous use and therapeutic benefits of these two 
compounds the dosing requirements for, and plasma drug concentrations 
associated with certain aspects of their therapeutic use remain to be 
clarified. This may have been due to technical difficulties with re-
gard to the analysis of plasma drug concentrations or to the relative 
novelty of the therapeutic indication. While empiric dosing of the 
two drugs for certain indications is being performed without apparent 
disadvantage to patients, studies to determine some dose-response and 
plasma drug concentration-response relationships are warranted. More-
over, a fuller understanding of certain aspects of the metabolism of 
these two drugs is needed as a basis for the development of rational 
dosing regimens for various indications. This thesis reports the 
results of studies to examine some of these aspects in sheep and man. 
CHAPTER2 
CLINICAL PHARMACOLOGY OF NITROGLYCERIN AND ASPIRIN  
2.1. SITE AND MODE OF ACTION  
2.1.1. Nitroglycerin  
The principal pharmacological action of GTN is to relax vascular 
smooth muscle. In the peripheral circulation the major effect is to 
cause venodilatation which results in venous pooling and a reduction 
in venous return (preload), left ventricular filling pressure, and 
pulmonary artery and capillary pressures. Myocardial oxygen con-
sumption or demand may be decreased by an associated reduction in 
systemic blood pressure. Reduction in afterload, although to a lesser 
extent than preload, is achieved by dilatation of arteriolar resis-
tance vessels of the peripheral circulation. In the coronary arterial 
circulation GTN dilates both large conductance and small resistance 
vessels (Parratt, 1974; 1979; Williams, 1981; Flaherty, 1982; 
Elkayam and Aronow, 1982). A feature of organic nitrate drug therapy 
can be the development of tolerance towards the drugs with time (Zelis 
and Mason, 1969; Needleman and Johnson, 1973). Other investigators 
(Abrams, 1980; Franciosa and Cohn, 1980) have failed to observe 
nitrate tolerance to be a clinical problem in chronic therapy. 
Many ideas have been put forward to explain the way in which GTN 
relaxes vascular smooth muscle. These range from a specific organic 
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nitrate receptor to a direct effect on Ca 2+ movements (Bennett and 
Marks, 1984). 
Needleman and Johnson (1973) proposed the existence of an organic 
nitrate receptor based on their results obtained with aortic strips 
from GTN7tolerant rats and rabbit aortic trips made tolerant to GTN in 
vitro (Figure 2.1.). Treatment with the sulphydryl (SH) reducing 
agent dithiothreitol reversed the tolerance. Needleman and Johnson 
(1973) suggested that GTN could react with a SH group of the receptor 
and, as a consequence of this reaction, smooth muscle would relax, an 
effect accompanied by partial denitration of GTN and oxidation of the 
SH group to the disulphide form. Tolerance, according to this theory, 
was associated with the SH group of the receptor being in the 
disulphide form, therefore displaying less affinity for GTN. Various 
other substances which react with SH groups were tested for their 
ability to reduce GTN-induced relaxation by Moffat et al. (1982). 
However, because of variations in the lipophilicity of the compounds 
used, and therefore their ability to penetrate tissue to get to the 
"biophase", those workers could not produce conclusive evidence to 
either refute or support the theory of Needleman and Johnson (1973). 
Evidence that increased levels of cGMP may mediate vasodilatation 
has been provided by Diamond and Blisard (1975) and Kobayashi et al. 
(1980) who found that cGMP levels increased prior to vasodilatation. 
The presumed increase in guanylate cylase activity has been suggested 
by Ignarro et al. (1981) to be caused by S-nitrosothiols which form 
when nitric oxide (derived from GTN metabolism) combined with SH-
containing compounds (Figure 2.2.). This theory is dependent on the 
fact that GTN is denitrated to release NO 2 which is then converted 
to nitric oxide. Therefore metabolites of GTN must be formed 
Relaxation 
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in cGMP 
RONO 2 
NO -2  + ROH 
HONO --. NO 	R SNO 
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Figure 2.1 Schematic representation of the reaction of GTN (RONO 2) 
with sulphydryl groups (SH) of the vascular smooth muscle receptor 
as hypothesized by Needleman and Johnson (1973). VSM = vascular 
smooth muscle, ROH = denitrated metabolite. 
VASCULAR SMOOTH MUSCLE 
GTN 	 
(RONO 2 ) 
Figure 2.2 Mbchanism of GTN-induced relaxation hypothesized by 
Ignarro et al. (1981). ROH = denitrated metabolite, R-SNO = 
S-nitrosothiol and R-SH = thiol. 
concomitantly. However, no GTN metabolites were detected in the 
incubation medium during GTN-induced relaxation of isolated canine 
blood vessels (Armstrong et al., 1980b). 
Speculation that prostaglandins (specifically PGI2) may mediate 
GTN-induced relaxation of vascular smooth muscle arose from studies 
which demonstrated that GTN enhanced PGI 2 release (as measured by its 
stable degradation product, 6-oxo-GF 1a) from cultured endothelial 
cells (Levin et al., 1981), isolated bovine coronary artery (Schror et 
al., 1981), human saphenous vein (14ehta et al., 1983) and rat aorta 
(Anderson et al., 1980). All of those studies relied on in vitro  
pharmacological inhibition of the cyclooxygenase enzyme to identify 
the relevance of prostaglandin formation to the action of nitro-
glycerin. Other studies have provided evidence to suggest that PGI 2 
is not involved in the mediation of GTN-induced vascular smooth muscle 
relaxation (Furchgott et al., 1981; Fitzgerald et al., 1984). 
Relaxation of muscle is ultimately dependent on intracellular 
Ca2+ concentrations. GTN could induce relaxation by: 
(i) altering the Ca 2+ content of intracellular storage sites, or 
(ii) altering the flux of Ca 2+ across the plasma membrane. 
Little work has been done on these aspects of GTN-induced relaxation. 
However some support for the second mechanism outlined above comes 
from the work of Ginsburg et al. (1981) who demonstrated increased 
Ca2+ efflux from human coronary arteries after treatment with GTN. 
2.1.2. Aspirin  
It has been suggested that ASA exerts its therapeutic effects by 
uncoupling oxidative phosphorylation (Adams and Cobb, 1958), inhibi-
tion of histamine or serotonin or blockade of tissue response to those 
mediators (Spector and Willoughby, 1968), inhibition of kinin genera-
tion and action (Collier, 1969) or interactions with various enzyme 
systems (Smith and Dawkins, 1971) most particularly the enzymes 
involved with prostaglandin biosynthesis (Vane, 1971). More recently, 
research on this aspect of the mode of action of ASA has included 
inhibition of not only prostaglandins but also thromboxanes and 
leukotrienes (collectively called eicosanoids). Recent reviews on 
these topics have been produced by Rainsford (1984) and Bakhle (1983). 
It is this last effect of ASA which is currently accepted as its mode 
of action, notwithstanding that the inhibition of eicosanoid bio-
synthesis may be intricately linked with any or all of the other 
effects mentioned above. 
Arachidonic acid is the specific precursor for the synthesis of 
eicosanoids. It is released from phospholipid stores in the cell mem-
brane by the action of phospholipases. AA is then available to be 
metabolized to prostaglandins and thromboxanes or to leukotrienes 
(Figure 2.3.). The pathway for the synthesis of prostaglandins and 
thromboxanes proceeds through the combination of the cyclooxygenase/ 
peroxidase catalyzed reactions of the prostaglandin endoperoxides. 
The resulting endoperoxide, PGG 2 , is converted to PGH2 which is 
available for conversion to a variety of substances (Samuelson and 
Hamberg, 1974), (Figure 2.3.). AA is also metabolized to a series of 
hydroxy and hydroperoxyacids such as HETE (hydroxyeicosatetraenoic 
acid) and HPETE (hydroperoxyeicosatetraenoic acid) by the lipoxy-
genases. Comprehensive reviews on the pharmacological roles of 
prostaglandins and other eicosanoids have been presented by Flower 
(1974) and Moncada and Vane (1979). 
cyclo-oxygenase lipoxygenase 
12-HPETE 
Phospholipids 1 phospholipases 
Arachidonic acid 
P GG 2 
endoperoxides 	[0]; 
• free radicals 
P GH 2 
///// 
thromboxane 	prostacyclin N  prostaglandin synthetase 	synthetase 	N isomerase 
Thromboxane A2 	Prostacyclin 	prostaglandins 
Other Hydroxyheptaneoic 
acids 
+ Malondialdehyde 
5 -HPETE 
5-HETE 	• 
LTA 4 \GSH transf erase 
LT C 4 
= SRS-A 
Thromboxane B 2 	6-0xo-RGF la 
Figure 2.3 Schematic representation of pathways of eicosanoid biosynthesis (Adapted from Rainsford,(1984)) 
ASA irreversibly inhibits the cyclooxygenase enzyme (Roth et al., 
1975) thereby preventing the formation of the endoperoxides, prosta-
glandins, thromboxanes and MDA (Figure 2.3.). It is this inhibition 
which is believed responsible for the therapeutic effects of ASA. 
However the inhibition of cyclooxygenase by ASA may be prevented or 
reduced by SA (Vargaftig, 1978; DeJana et al., 1981). 
2.2 CLINICAL USES  
2.2.1 Nitroglycerin  
Angina pectoris due to coronary artery disease is generally con-
sidered to be chest pain due to myocardial ischaemia which occurs 
because the myocardial oxygen demand exceeds the myocardial oxygen 
supply. Up until recent times (the last 20 years) this view empha-
sized that myocardial demand for oxygen exceeded the flow capability 
of narrowed coronary vessels. A review of this topic by Aronow (1975) 
demonstrates that the over-riding line of thinking was that angina was 
due to atherosclerotic disease of coronary vessels. More recently, 
angina has been described as a vasospastic disorder of the arteries of 
the heart, and indeed coronary vasospasm has now been firmly estab-
lished - as the mechanism of ischaemia in Prinzmetal's variant angina. 
Nairn and Friedlander (1983) point out that spasm may be one extreme 
in the concept of dynamic coronary artery obstruction and that more 
modest changes in the tone of larger epicardial coronary vessels can 
vary the degree of obstruction. Endogenous substances such as sero-
tonin, endoperoxides and some prostaglandins and thromboxanes produced 
by the coronary arteries and platelets are potent vasoconstrictors and 
may have a large role to play in the genesis of myocardial ischaemia 
10 
(Nairn and Friedlander, 1983; Hamberg et al., 1975). GTN (and other 
organic nitrate drugs) reduces coronary vasospasm in normal and 
atherosclerotic vessels by virtue of its smooth muscle relaxant 
properties. 
Treatment of acute left ventricular and chronic heart failure is 
achieved by administering GTN to cause a significant reduction in 
afterload by reducing the compensatory peripheral resistance of heart 
failure and thereby improving cardiac output. GTN is also used to 
induce controlled hypotension during diverse surgical procedures 
(Franciosa, 1980; Franciosa and and Cohn, 1980; Hill et al., 1981; 
Flaherty, 1982). 
A more controversial clinical use of GTN is to reduce the size of 
an acute myocardial infarction. Earlier reports (Epstein et al., 
1975; Flaherty et al., 1975; 1976) indicated that IV GTN reduced ST 
segment elevation and infarct size however these results have been 
treated cautiously. Elkayam and Aronow (1982) point out that con-
clusive evidence that GTN can reduce the size of an acute myocardial 
infarction awaits reports of large scale clinical trials in carefully 
selected patients using improved techniques of estimating infarct 
size. 
2.2.2. Aspirin  
ASA is a widely used drug for the relief of pain of moderate 
intensity, postoperative pain and cancer pain (Mahler et al., 1976; 
Ventafridda et al., 1975). Although it appears that ASA does not pre-
vent the formation or release of pain mediators other than prosta-
glandins, it does remove the nerve sensitizing effect of the prosta-
glandins thereby raising the pain threshold (Vane, 1978). 
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Although ASA is used as an anti-pyretic drug the exact mechanism 
by which it lowers the body temperature is not known (Flower et al., 
1980) although prostaglandin synthesis inhibition and/or the augmenta-
tion of heat dissipation are believed to be involved (Rainsford, 
1984). 
ASA and SA are still the most commonly prescribed drugs for the 
treatment of the inflammation associated with rheumatoid arthritis 
(Moncada et al., 1980). No one biochemical action of ASA (and other 
salicylates) is sufficient to account singularly for the therapeutic 
effects of these drugs as anti-inflammatory agents. Recent reviews 
(Atkinson and Collier, 1980; Packham, 1982) have centered their 
attention on the prostaglandin biosynthesis inhibition of salicylates 
as the major mechanism of action in the treatment of the inflammation 
of rheumatoid arthritis and other conditions. Atkinson and Collier 
(1980) regard effects of salicylates on leucocyte migration, lympho-
cyte functions and superoxide production only in relation to prosta-
glandin production, a view which does not consider the fact that such 
functions may be independent of prostaglandins (Rainsford, 1984). 
Indeed Dawson (1979) was unable to find any correlation between the 
ability of drugs to inhibit prostaglandin synthesis and their efficacy 
in in vivo models of inflammation. Bonta and Parnham (1978) showed 
that the effects of prostaglandins in acute inflammation may not be 
the same in chronic inflammation such as is associated with rheumatoid 
arthritis. One example is that capillary permeability appears to 
become desensitized to prostaglandins during the chronic inflammation 
phase. 
ASA is being used clinically as an anti-thrombotic agent to 
reduce the incidence of (further) attacks of transient cerebral 
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ischaemia and hopefully lower the incidence of stroke (Fields et al., 
1977; The Canadian Co-operative Study Group, 1978) and to prevent 
myocardial reinfarction (Elwood and Sweetnam, 1979; Aspirin Myo-
cardial Infarction Study Research Group, 1980). A recent compre-
hensive review by Hirsh (1982) covers the rationale of using ASA for 
these indications and its clinical effectiveness. 
The rationale for the use of ASA as an anti-thrombotic drug is 
intricately related to ASA's ability to inhibit platelet function. 
The contribution of platelets in haemostasis and thrombosis is related 
to their ability to adhere to non-endothelialized surfaces, to undergo 
a platelet release reaction, to aggregate and to potentiate blood 
coagulation. Briefly, platelets do not adhere to normal endothelium 
but adhere to collagen which is exposed when there is a break in the 
endothelial lining of blood vessels (Cazenave et al., 1979). Once 
adherence has occurred, the platelets change shape and release the 
contents of storage granules containing numerous substances including 
coagulation factors (Kaplan et al., 1979). Other granules secrete 
adenosine diphosphate (ADP), serotonin and calcium. ADP induces 
aggregation of platelets and serotonin induces vasoconstriction 
proximal to the release site and helps reduce blood flow so that a 
platelet aggregate can be formed and build (Vreeken, 1982). Other 
mediators of platelet aggregation are thrombin and TXA 2 . 
Thromboxane is produced from AA, a pathway that involves cyclo-
oxygenase and thromboxane synthetase (Figure 2.3.). TKA 2 is a potent 
vasoconstrictor as well as an inducer of platelet aggregation. 
Another eicosanoid, PGI 2' is synthesized, via cyclooxygenase and PGI 2 
synthetase, from AA in the endothelium of blood vessels (Moncada et 
13 
al., 1976). It has been shown to be a potent anti-platelet aggre-
gating factor and vasodilator (Moncada and Vane, 1978). Since ASA 
irreversibly acetylates cyclooxygenase (Roth et al., 1975) it would be 
anticipated that synthesis of TXA2 and PGI 2 would be equally affected 
by ASA. However there is evidence that vascular cyclooxygenase is 
less sensitive to ASA than platelet cyclooxygenase (Burch et al., 
1978a; Basista et al., 1978). Moreover, inactivated vascular cyclo-
oxygenase may be replaced relatively rapidly by the enzyme synthesized 
de novo in the endothelium (Jaffe and Weksler, 1979), whereas plate-
lets do not possess appreciable protein synthesis capabilities and so 
the complete restoration of circulating platelet cyclooxygenase acti-
vity depends on replacement of the total affected platelet population 
which takes 8-14 days (Burch et al., 1978b; Stuart et al., 1975). 
This apparent difference in cyclooxygenase sensitivity to ASA has led 
to the'development of the PGI 2 /TXA2 balance hypothesis which postu-
lates that the ratio of these two substances determines platelet 
aggregability and thrombosis tendency (Moncada and Vane, 1978). 
Studies to investigate the presumed benefits of ASA therapy to 
reduce the risk of thrombosis have as their basis a desire to choose 
the appropriate dosage of ASA which maximally inhibits platelet TXA2 
and thus a degree of aggregation, while leaving intact the PGI 2 syn-
thetic pathways of the endothelium of the vessel wall. Indeed, plate-
let TXA2 production could be almost completely blocked by small daily' 
doses of ASA (Masotti et al., 1979; Hanley et al., 1981). An accu-
rate assessment of the role of ASA in modifying the PGI 2 /TXA2 balance 
in favour of PGI2 has not been forthcoming due to the lack of suitably 
accurate and sensitive assays of PGI 2 production in vivo. 
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To overcome this problem most assays of PGI 2 have involved 
quantitating concentrations of 6-oxo-PGF 1a' a stable metabolite of 
PGI2  (Salmon, 1978). Results obtained using radioimmunoassay 
(Mitchell, 1978) lack the specificity necessary for measurements in 
plasma, while those based on GC-MS operate close to the limit of sensi-
tivity (Hensby et al., 1979). Blair et al (1982) developed a GC-MS 
assay using capillary column GC and negative ion chemical ionization 
MS which offered greater specificity and sensitivity than their pre-
vious GC-MS assay and which was used to show that PGI 2 is probably a 
local hormone rather than a circulating hormone in man. 
As well as TXA 2 (or its more stable metabolite, TX8 2) production 
being used as an index of platelet function, the measurement of plate-
let aggregators to induce in vivo aggregation can be used to assess 
platelet function (Born, 1962). Typical aggregating inducers used 
have been collagen, adrenalin, ADP, thrombin and AA (Born, 1962; 
Siess et al., 1981). Moreover platelet cyclooxygenase activity can be 
assessed by the ability of platelets to produce MDA, an end-product 
from AA metabolism (Figure 2.3.) (Flower et al., 1973). 
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CHAPTER3 
ANALYSIS AND PHARMACOKINETICS OF NITROGLYCERIN AND ASPIRIN  
3.1. METHODS OF ANALYSIS  
3.1.1. Gas Chromatography  
The mainstay of GC assays of GTN plasma concentrations has been 
that developed by Rosseel and Bogaert (1973). This assay involved ex-
traction of GTN from plasma using ethyl acetate, and, after injection 
onto a GC column, quantitation of GTN by means of a 63Ni electron cap-
ture detector. Modifications of this method have mostly entailed 
using hexane instead of ethyl acetate as the extracting solvent 
because a cleaner chromatogram is obtained with hexane (Yap et al., 
1978; Armstrong et al., 1979). However only a limited amount of work 
involving plasma GTN concentrations has appeared in the literature 
despite the above methods appearing some years ago. This may be due 
to the difficulties associated with GTN having a large vapour pressure 
(Urbanski, 1965), and adsorption of small amounts of GTN to diatoma-
ceous earth GC column packings (Urbanski, 1965), or glass (Yap et al., 
1978) or plastic (Cossum et al., 1978) containers. A limitation of GC 
assays of organic nitrates is that GDN metabolites are only slightly 
soluble in hexane and so are not extracted from plasma in quantitative 
amounts, unlike GTN (Yap et al., 1978). Moreover a suitable GC 
packing to separate the GDN isomers and GTN is not available (at the 
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start of these studies). Therefore pharmacokinetic analysis of GDN 
metabolites has not been possible using current GC techniques. 
Rowland and Riegelman (1967) developed a GC method to determine 
plasma ASA concentrations using the trimethylsilyl derivative and 
flame ionization detector after , extraction of ASA from plasma by 
diethyl ether. Later methods have been described which determine ASA 
and SA plasma concentrations simultaneously (Thomas et al., 1973; 
Rance et al., 1975). Complications of GC analysis of plasma sali-
cylate concentrations include multiple product formation with the 
derivatizing agent (Rowland and Riegelman, 1967) and partial hy-
drolysis of aspirin during derivatization (Ali, 1975). These assays 
are also time consuming with extraction and derivatization generally 
taking over 90 min. 
3.1.2. High Performance Liquid Chromatography  
Although HPLC assays of GTN and its metabolites have been des-
cribed using UV detectors (Baaske et al., 1979; Crouthamel and 
Dorsch, 1979), they are only suitable for analyzing large drug con-
centrations (as in pharmaceutical preparations) owing to the limited 
absorptive properties of GTN and its metabolites. Nevertheless, the 
HPLC column is a useful tool for the separation of GTN from its GDN 
and GMN metabolites, and the isomeric GDN metabolites from each other 
and the GMN metabolites from each other. This property has been used 
by Spanggord and Keck (1980) to analyze blood GTN and metabolite con-
centrations following oral administration of GTN to dogs. The method 
of detection was the thermal energy analyzer. 
Several HPLC methods for the determination of salicylates in body 
fluids have been described. Some measure ASA and SA (Caterson et al., 
17 
1978), others measure ASA, SA and salicyluric acid (SU) in plasma but 
with a time-consuming extraction process (Peng et al., 1978), or 
measure SA, SU and GA, but not ASA, in plasma (Cham et al., 1979). 
Rumble et al. (1981) produced a method which offered simultaneous 
determination of ASA, SA, SU and GA plasma concentrations without 
solvent extraction. 
3.2. PHARMACOKINETICS OF NITROGLYCERIN  
The pharmacokinetics of GTN has traditionally been associated 
with a short half-life of elimination, reported to arise from a 
significant or even complete hepatic first-pass effect. These beliefs 
have arisen from the early work of Needleman's and DiCarlo's groups 
using different animal species (Needleman and Hunter, 1965; 
Needleman, 1973; DiCarlo et al., 1968). 
3.2.1 Absorption  
The absorption of GTN was rapid after oral administration of 
14C-GTN to rats (DiCarlo et al., 1968), however this route of admi-
nistration has not been used widely since it is believed that the 
liver is responsible for the complete inactivation of GTN during its 
first-pass through the liver (Needleman, 1973) (see below). For this 
reason the sublingual route of GTN dosing has been the route of choice 
for rapid relief of the pain of angina pectoris, suggesting that sub-
lingual absorption of GTN is rapid. Indeed, peak plasma concentra-
tions of GTN given sublingually appear within 2 to 4 min (Bogaert and 
Rosseel, 1972a; Blumenthal et al., 1977; Armstrong et al., 1979). 
Following administration of a 600 pg GTN tablet, peak venous plasma 
GTN concentrations were 2.3 ng/ml (Armstrong et al., 1979). 
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Percutaneous dosing of GTN is now performed routinely using oint-
ments and, most recently, transdermal patches (an inert matrix re-
leasing GTN at a constant rate). These formulations are used clini-
cally to prolong the absorption of GTN and to avoid substantial 
degradation of GTN due to a liver first-pass effect. Recent reviews 
on the clinical uses and biopharmaceutics of percutaneous GTN formu-
lations have been provided by Black (1982) and Elkayam and Aronow 
(1982). 
Intravenous dosing of GTN is a common route of administration in 
patients following acute myocardial infarction with or without heart 
failure (Hill et al., 1981; Flaherty, 1982). An approximate linear 
relationship between infusion rate and arterial plasma GTN concentra-
tions has been reported by Armstrong et al. (1980a), however this 
report awaits verification using suitable IV administration systems. 
Cossum et al. (1978) showed that the GTN in IV solutions was lost to 
the polyvinyl chloride of IV administration sets in simulated infu-
sions. GTN concentrations in the effluent were a function of the flow 
rate of GTN solution through the polyvinyl chloride tubing of the 
sets, the faster flow rates being associated with the smaller losses 
of GTN (Figure 3.1). It is not clear whether Armstrong et al. (1980a) 
used polyvinyl chloride administration sets or polyethylene tubing 
which was shown by Cossum et al. (1978) to minimize the loss of GTN 
and later by Cossum and Roberts (1981) to prevent the loss of 
diazepam, chlormethiazole and isosorbide dinitrate which occurred when 
these drugs were infused through polyvinyl chloride administration 
sets. 
I- 
to 40 
20 
4 	'6 
Time 	(hr) 
10 
Figure 3.1 Effect of flaw rate on the percentage of nitroglycerin (crila) 
remaining after passage through plastic infusion sets. 
(111) 0.91 ma/Min; (A) 0.30 ma/min; (A) 0.17 ma/min; (0) 0.07 ma/Min 
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3.2.2. Distribution 
It has been estimated that only about 1% of the total body load 
of GTN is in the blood (McNiff et al., 1981). This suggests that 
tissue distribution of the drug is extensive. However pharmacokinetic 
calculations of the volume of distribution (V d) of GTN reported in the 
literature have been widely varying. For example, Armstrong et al. 
(1980a) reported a V of about 10 litres, but McNiff et al. (1981) 
reported a Vd of 210 litres. A major difference in the way the two 
studies were conducted was that Armstrong et al. (1980a) sampled 
arterial blood from their patients, but McNiff et al. (1981) sampled 
venous blood from their volunteers. These data suggest that pharma-
cokinetic data may be dependent on the site of blood sampling. 
No reports are available on the degree of binding of GTN or its 
metabolites to human plasma proteins. However, DiCarlo and Melgar 
(1969) studied the binding of GTN to rat plasma. They found that 
about 60% of the GTN was bound to rat plasma proteins. During the 
course of the binding experiments the GTN was metabolized to 1,3-GDN 
and 1,2-GDN. The 1,2-GDN was about 60% bound to plasma proteins while 
33% of the 1,3-GDN was bound. DiCarlo and Melgar (1969) used a GTN 
concentration of about 1 mg/ml plasma in these studies, a concen-
tration which is many times greater than therapeutic levels. 
3.2.3. Metabolism and Elimination 
GTN is metabolized to the pharmacologically less active GDNs, 
probably by a glutathione-dependent organic nitrate reductase 
(Needleman and Hunter, 1965), which may be one enzyme of the glut-
athione transferase group (Habig et al., 1975). The liver is known to 
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be capable of substantial in vitro GTN metabolism (Needleman and 
Harkey, 1971). Other sites where glutathione transferase activity and 
GTN metabolism have been shown to occur are the kidney (Maier et al., 
1980) and erythrocytes (Marcus et al., 1978; Armstrong et al, 1980c) 
although the enzyme isolated from human erythrocytes is distinct from 
that isolated from human liver. Figure 3.2. shows the patterns of GTN 
metabolism following perfusion of 14C-GTN solutions through isolated 
rat livers (Needleman and Harkey, 1971). A comparison of the maximum 
velocities of the enzymatic transformation of GTN and its metabolites 
indicated that GTN was metabolized more than 20 times faster than the 
GDNs, which were in turn metabolized more rapidly than the GMNs by 
liver organic nitrate reductase (Needleman and Hunter, 1965). 
Needleman and Krantz (1965) found that the GMNs appeared as the pri-
mary urinary metabolites after GTN administration to rats. No GTN was 
detected in the urine. A small percentage of GTN must be degraded to 
glycerol since DiCarlo et al. (1969) reported that about 1% of a 
14C-GTN dose was recovered from the liver as lipid, glycogen, protein, 
RNA and DNA. 
The rapid half-life of elimination of 1 to 2.8 min for GTN from 
blood following administration of GTN to intact rats (Johnson et al., 
1972) or humans (Rosseel and Bogaert, 1973; Armstrong et al, 1980a; 
McNiff et al., 1981) is believed to be due to rapid hepatic elimina-
tion of GTN. Although erythrocytes also metabolize GTN in vitro  
(Armstrong et al., 1980c), it has been calculated that this metabolism 
is responsible for less than 3% of the total body clearance of GTN 
(McNiff et al., 1981). Clearance values reported by investigators 
sampling venous blood after GTN administration (Wei and Reid, 1979; 
Armstrong et al., 1979; McNiff et al., 1981) are in the range 29 to 
/ 
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Figure 3.2 Proposed pathway for the metabolism of GI N in rats. (Adapted from 
Needleman and Harkey, 1971) 
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82.3 1/min, values which are at least several times the value of 
normal human cardiac output. Other workers using arterial blood 
samples have reported GTN clearance values of 4.4 to 13.8 1/min (Idzu 
et al., 1981; Armstrong et al., 1980a), which approximates normal 
cardiac output. Since both arterial and venous clearance of GTN is 
greater than hepatic blood flow, it appears that extra-hepatic meta-
bolism of GTN could play a major role in the clearance of GTN. 
Moreover, the large difference in arterial and venous GTN clearance as 
reported by the various groups mentioned above indicates that GTN 
degradation could occur in the capillary beds and/or muscle tissue 
and/or arterial/venous tissue. The lungs are potentially another site 
of GTN metabolism given their role in other xenobiotic metabolism 
(Mehendale et al., 1981) and the fact that they receive the entire 
cardiac output. 
Studies on another organic nitrate drug, ISDN, may have provided 
some important avenues of study of the metabolism of GTN. Fung et al. 
(1981) reported that after chronic oral dosing, plasma ISDN concentra-
tions were higher than would be expected from single oral dose 
kinetics. ISDN (like GTN) is probably metabolized by an organic 
nitrate reductase (Needleman and Hunter, 1965) to the 5- and 2-ISMNs 
(Dietz, 1967). Both metabolites are eliminated more slowly than ISDN 
(Abshagen and Sporl-Radun, 1981) and this suggests that the increased 
plasma ISDN concentrations seen after chronic ISDN dosing may be due 
to an interaction of metabolites and parent compound. If the same 
were true for GTN and its metabolites then the phenomenon occurring 
with both organic nitrate drugs may provide information to elucidate 
the often observed occurrence of tolerance and cross-tolerance to the 
cardiovascular effects of the drugs in patients on long-term organic 
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nitrate therapy. The relevance of such pharmacokinetic study is 
evident when it is considered that two of the current hypotheses put 
forward to explain organic nitrate drug action on vascular smooth 
muscle, have as their basis a denitration step (Needleman and Johnson, 
1973; Ignarro et al., 1981). 
3.3. PHARMACOKINETICS OF ASPIRIN  
3.3.1. Absorption  
The rate of absorption of ASA is dependent upon many factors; 
the pH of the gastrointestinal tract, the rate of gastric emptying, 
the presence of food in the gastrointestinal tract, the volume of 
fluid ingested with ASA, the formulation of ASA, and others (Levy and 
Leonards, 1966; Mayersohn, 1977; Orton et al., 1979; Sansom, 1983; 
Schanker et al., 1958). 
In relation to formulation factors, slow-release (enteric coated) 
ASA tablets were developed to reduce the gastric side effects associ-
ated with the very large daily doses needed for the treatment of 
rheumatoid arthritis. Moreover, the formulation also offered the 
possibility of prolonged ASA absorption and hence an approximate 
steady-state salicylate plasma concentration. However the bioavail-
ability of the earlier enteric coated ASA formulations was low and 
variable (Clark and Lasagna, 1965; Levy and Jusko, 1967). The 
unpredictable onset of absorption of enteric coated ASA tablets 
appears to be due mainly to the variability of gastric emptying and so 
ASA is absorbed from the neutral small intestine in an unpredictable 
fashion. An enteric coated ASA dosage form which provides more 
reproducible absorption is that consisting of a large number of 
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enteric coated granules (Portek et al., 1981; Alpsten et al., 1982). 
Because of the relatively predictable absorption of ASA from enteric 
coated granules these formulations are suitable for investigating the 
association of low but prolonged ASA plasma concentrations with the 
inhibition of platelet function induced by ASA. Such a study is 
warranted because in most of the studies investigating optimal ASA 
dosage regimens for cardiovascular pathology, the soluble dose form 
has been used with single or chronic dosing (Masotti et al., 1979; 
Preston et al., 1981; Hanley et al., 1981). Ali et al. (1980) 
studied the effects of an enteric coated tablet on platelet function. 
3.3.2. Distribution 
The volume of distribution of ASA in man was reported as 0.1 - 
0.2 1/kg (Rowland and Riegelman, 1968). This value was only slightly 
greater than that found for SA by the same workers. The difference 
was ascribed to SA being bound to plasma proteins to a greater extent 
than ASA (Rowland and Riegelman, 1968). Aarons et al. (1980), noting 
that significant hydrolysis of ASA could occur during in vitro protein 
binding studies of ASA using dialysis, used an ultracentrifugation 
technique to show that the fraction of ASA bound to albumin was 0.85. 
They also showed that SA, which is 95% bound, displaced ASA from 
albumin binding sites and noted that this result may have implications 
during continuous ASA therapy since SA is the major metabolite of ASA. 
The binding of SA itself is concentration dependent, a greater unbound 
fraction of SA being found at the larger SA concentrations (Aarons et 
al., 1980). 
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3.3.3. Metabolism and Eliminations  
ASA administered orally in aqueous solution is rapidly absorbed 
•but only about 68% of the intact drug reaches the systemic circulation 
(Rowland et al., 1972). The rest of the dose is hydrolyzed to SA by 
non-specific esterases in the gut wall and by the liver (Rowland et 
al., 1972) and blood (Harris and Riegelman, 1967). Moreover, ASA 
acetylates a variety of proteins in various tissues and salicylate is 
released from this reaction (Rainsford et al., 1983; Rainsford, 
1984). The extent to which other extra-hepatic sites play in the 
metabolism of ASA is not known. 
Rowland et al. (1972) found the half-life of the elimination 
phase after oral ASA dosing to be in the range 14 to 20.5 min which 
was slower than the 13 to 19 min observed for the elimination phase 
after IV ASA dosing (Rowland and Riegelman, 1968). The difference was 
assumed to be due to the continued absorption of ASA during the eli-
mination phase following oral dosing. 
SA, which is formed from the hydrolysis of ASA, undergoes further 
metabolism; conjugation with glycine to form SU, conjugation with 
glucuronic acid to form salicyl acyl glucuronide and salicyl phenolic 
glucuronide, hydroxylation to GA (Figure 3.3). In addition SA is it-
self renally excreted. The various metabolites of SA are excreted as 
rapidly as they are formed except in renal failure (Levy, 1978). The 
kinetics of elimination of SA are characterized by the two quantita-
tively most important pathways (formation of SU and salicyl phenolic 
glucuronide) displaying Michaelis-Menten kinetics (Levy et al., 1972). 
This results in larger SA doses being eliminated at a slower rate than 
smaller doses (Levy, 1978). As noted in Section 3.3.2. the binding of 
SA to plasma proteins is concentration dependent also. Therefore an 
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Figure 3.3 Pathway of the metabolism of aspirin. 
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investigation of the action of SA on ASA plasma protein binding in 
vivo may reveal that continuous ASA dosing at a sufficiently high 
level could eventually bring about an increase in the elimination of 
ASA due to the SA metabolite action. 
3.4. OBJECTIVES OF THE CURRENT STUDIES  
The objectives of the current work were to: 
(i) investigate the basis for an apparent difference in GTN 
concentrations in arterial and venous blood having first 
overcome stability problems of GTN in blood in vitro and in 
conventional IV administration sets; 
(ii) examine the influence of GDNs on the disposition of GTN; 
(iii) perform the same studies as above using ASA and to monitor 
the effects of SA on ASA disposition; 
(iv) study the influence of the rate of GTN and ASA admini-
stration on their kinetics and on some pharmacological 
responses evoked by them. 
CHAPTER4 
EXPERIMENTAL 
4.1 MATERIALS  
4.1.1. Chemicals and Drugs  
Acetic acid, glacial, analytical grade 
Ajax Chemicals, Sydney. 
acetonitrile, liquid chromatography grade, 
Waters Associates, Melbourne. 
(-) adrenalin, 1 mg/ml, 
David Bull Laboratories, Victoria. 
allyl alcohol, laboratory grade, 
May and Baker, Dagenham, United Kingdom. 
ammonium hydroxide, analytical grade, 
Commonwealth Ammonia Corporation, Melbourne. 
arachidonic acid, Grade 1, porcine liver, 
Sigma Chemical Co., St. Louis. 
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benzene, analytical grade, 
Ajax Chemicals. 
carbon tetrachloride, analytical grade, 
Ajax Chemicals. 
collagen, equine, 1 mg/ml, 
Hormon-Chemie, Brussels. 
ethyl acetate, analytical grade, 
Ajax Chemicals. 
N-ethylmaleimide, 
Sigma Chemical Company. 
glucose-6-phosphate, monosodium salt, 
Boehringer, West Germany. 
glucose,6-phosphate dehydrogenase, 
Grade 1 suspension, Boehringer. 
glutathione, reduced, 
Sigma Chemical Company. 
glycerol, analytical grade, 
Ajax Chemicals. 
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heparin, 
Commonwealth Serum Laboratories. 
hexane, pesticide grade, 
Fisher. 
hydrochloric acid, analytical grade, 
May and Baker. 
iodoacetamide, 
Sigma Chemical Company. 
isooctane, analytical grade, 
Ajax Chemicals. 
isosorbide dinitrate, 40% on lactose, 
Schweiz, Sprengstoff-Fabrik. 
methanol, liquid chromatography grade, 
Waters Associates. 
NADPH, tetrasodium salt, 
Boehringer 
nitric acid, fuming, analytical grade, 
Ajax Chemicals. 
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pentobarbitone sodium (Nembutal) 60 mg/ml, 
Abbott Laboratories, Melbourne. 
perchloric acid, analytical grade, 
British Drug Houses. 
phenol, analytical grade, 
May and Baker, Australia. 
phosphoric acid, analytical grade, 
Drug Houses of Australia. 
potassium fluoride, laboratory grade, 
BDH, Australia. 
potassium nitrate, analytical grade, 
By-Products and Chemicals, Sydney. 
silica gel, GF, 
Sigma Chemical Company. 
sodium hydrogen citrate, laboratory grade, 
British Drug Houses. 
sodium carbonate, analytical grade, 
Hopkin and Williams Ltd., Essex. 
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sodium edatate, laboratory grade, 
British Drug Houses. 
sodium salicylate, laboratory grade, 
May & Baker. 
sulphuric acid, fuming, analytical grade, 
Ajax Chemicals. 
thiobarbituric acid, 
Ajax Chemicals. 
3H - Toluene, certified calibration quality, 
New England Nuclear, North Ryde, New South Wales. 
trichloroacetic acid, analytical grade, 
Ajax Chemicals. 
4.1.2 General  
All glassware was washed in "Pyroneg", rinsed with distilled 
water and air dried before soaking overnight in chromic acid. 
Following thorough rinsing with distilled water the glassware was 
dried in an oven at 70 ° C. 
Glassware used in experiments involving GTN was silanized by 
soaking for 2 hr in a 5% solution of trimethyl chlorosilane in 
toluene. Tubes, flasks, pipettes and syringes were then rinsed in 
toluene and then oven dried. 
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Preparation of Drug Solutions  
GTN solutions were prepared in glass. Solutions for infusion 
were prepared immediately prior to an experiment commencing. 
GDNs for infusion were prepared by evaporation of the ethyl 
acetate/hexane of ethanol in which they were dissolved and reconsti-
tuted in normal saline immediately prior to their infusion. 
ASA solutions for infusion were prepared from commercially avail-
able tablets (Aspro Clear). The desired number of tablets were dis-
solved in a known volume of normal saline 30 min before an experiment 
commenced. At the time of infusion the aspirin solutions were gener-
ally free of bubbles. 
NaSA was dissolved in normal saline immediately before its 
infusion. 
ISDN was purified by ether extraction of the powder and re-
crystallization from an ethanol/water mixture. It was stored as 
crystals which were dissolved in hexane when needed. 
4.2. ANALYTICAL PROCEDURES  
4.2.1. Synthesis of Glyceryl Nitrates  
Tritiated Nitroglycerin  
Prior to the synthesis of 3H-GTN, small scale synthesis of GTN 
was developed using unlabelled glycerol. In these experiments 1.8 mg 
glyceryl in 0.1 ml ethanol was transferred to each of 5 tapered glass 
test tubes and the ethanol evaporated under vacuum to leave about 
2.5 ul glycerol which was centrifuged to the bottom of the test tube. 
Ten ul of a mixture (1:1) of fuming nitric and sulphuric acids 
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(Urbanski, 1965) was added to the glycerol and each mixture was 
incubated on ice for 15-90 min. At desired times the reaction in any 
test tube was terminated by the addition of 5 ml of a 4% aqueous 
solution of sodium carbonate. The resulting mixed glyceryl nitrates 
were washed twice with water, which was discarded, and then the small 
drop of mixed glyceryl nitrates was dissolved in 5 ml ethanol before 
determining the GTN concentration of the ethanolic solution by HPLC. 
Calibration curves were constructed using aqueous dilutions of etha-
nolic GTN commercial solution (Tridil, American Critical Care) which 
had been analyzed by the USP XX (1979) method. Yields of GTN were 
calculated as the percentage of theoretical maximal yield from the 
available mass of glycerol. Incubation times for the maximal yield of 
GTN were then used in planning the radiochemical synthesis of labelled 
GTN. 
Unlabelled glycerol (1.8 mg in 0.1 ml ethanol) was added to 5 ml 
of an ethanolic tritium labelled glycerol solution (0.18 mg (1(3)- 3H) 
glycerol, 2.5 Ci/mmol, Amersham Australia). The solutions were incu-
bated using the procedure developed for the synthesis of unlabelled 
GTN. However for the synthesis of 3H-GTN the incubation time was 
reduced to give a submaximal GTN yield and an enhanced yield of 
3H-labelled GDNs (as they were also required for metabolic studies). 
The resulting drop of tritiated glyceryl nitrates was dissolved 
in 1 ml ethanol and purified by HPLC (Section 4.2.2.). Each compound 
was obtained in a solvent fraction eluting from the column. Most of 
the methanol was later evaporated from the collected solution giving 
an aqueous solution of each of the tritiated glyceryl nitrates. 
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Unlabelled Glyceryl Mono- and Di-Nitrates  
The metabolite 1,2-GDN was synthesized from allyl alcohol using 
the procedure of Dunstan et al. (1965). 1,3-GDN was prepared by 
denitration of GTN by reaction with sodium nitrite (Dunstan et al., 
1965). 1-GMN and 2-GMN was prepared from the partial nitration of 
glycerol (Dunstan et al., 1965). The purity of all metabolites was 
established by thin-layer chromatography (Crew and Di Carlo, 1968). 
Aqueous solutions of the glyceryl nitrates were assayed using the USP 
XX (1979) method. 
4.2.2. High Performance Liquid Chromatography 
Glyceryl Nitrates  
A HPLC method based on that of Crouthamel and Dorsch (1979) was 
used for the analysis of tritiated GTN, 1,3-GDN, 1,2-GDN, 1-GMN and 
2-GMN in supernatant buffer of resuspended erythrocytes or plasma. 
Aliquots of sample solutions were injected into a Waters Associates 
HPLC system equipped with a p Bondapak C I8 column. A mobile phase of 
water and methanol (70:30) was pumped at a flow rate of 1.0 ml/min. A 
Waters Associates Model 441 fixed wavelength detector set at 214 nm 
was used to identify the different glyceryl nitrates when their 
concentration was sufficient to allow their detection by the UV wave-
length detector. 
Samples (20-200p1) of buffer supernatant of erythrocyte sus-
pensions, deproteinated plasma or plasma filtrate were injected 
directly into the HPLC system. Samples of plasma or tissue homoge-
nates had been deproteinated with an equal volume of methanol. After 
centrifuging the sample tubes the clear supernatant was injected into 
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the HPLC system. With each injection of sample containing tritiated 
glyceryl nitrates, 5 pl of an aqueous solution (at least 10 pg/ml) of 
each of the unlabelled glyceryl nitrates was included in order to 
visualize the retention times of each of the compounds on the HPLC 
column using the UV detector. Collection of individual radio-labelled 
GDNs and mixed GMNs was facilitated by calculating the delay time 
between a peak exhibiting a UV response, and its efflux from the 
tubing draining the UV detector. For this calculation, the mobile 
phase flow rate, and the length and internal diameter of the HPLC 
tubing were used to calculate a delay time of 7 seconds. 
Salicylates  
The method of Rumble et al. (1981) was used to determine plasma, 
plasma filtrate or tissue homogenate concentrations of ASA, SA and SU. 
In essence this procedure involves injecting deproteinated plasma or 
tissue homogenates onto a C 18 HPLC column. A mobile phase of 30% 
phosphoric acid, pH 2.5, in acetonitrile and a wavelength setting of 
237 nm allows for the detection and quantitation of the above sali-
cylates. 
4.2.3. Liquid Scintillation Spectrometry  
Tritiated glyceryl nitrates were quantitated by liquid scin-
tillation spectrometry after HPLC separation. Fractions of the HPLC 
column eluant containing the eluting nitrates were collected into 15 
ml plastic scintillation vials (Packard). Ten ml of scintillation 
cocktail (Biofluor, New England Nuclear) were added and samples were 
counted for their tritium content in a LKB 1215 Rackbeta 11 scintil-
lation counter for 10 min or until 10,000 counts accumulated, which 
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ever occurred first. The counting efficiency was corrected in each 
sample by the external standard ratio method. Quench curves for 3H in 
10 ml scintillation cocktail had been determined using 3H-toluene with 
carbon tetrachloride as the quenching agent. The efficiency values 
were plotted against the degree of quenching which was expressed in 
terms of the ratio of counts in 2 channels. The disintegration/min 
(dpm) for an unknown sample were then calculated, knowing the counting 
efficiency E and the counts/min (cpm), from the following expression: 
OE dpm = E 	(4.1) 
The amount of glyceryl nitrate in a given volume of plasma, plasma 
filtrate or buffer was determined from the specific activity of the 
3H-toluene. It was assumed that the glyceryl nitrate metabolites had 
specific activities per mole which were identical to that of the 
3H-GTN. 
4.2.4. Gas Chromatography 
Extractions and Evaporation Procedures  
3H-GTN was used extensively in the development of an assay of 
plasma GTN concentrations. Fresh blank sheep plasma was spiked with 
3H-GTN and extracted by 2 means: 
(i) a rapid injection technique (Yap et al., 1978) 
and 
(ii) a vortexing technique. 
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In the injection technique, plasma (200 pl) was placed in a 
pointed glass test tube and rapidly injected with 200 ul hexane using 
a 1 ml glass syringe and 21 gauge needle. After injection the hexane 
was removed from the plasma to a scintillation vial for counting of 
tritium content. This process was repeated 11 times and the hexane 
extracts added to 11 separate scintillation vials for counting. 
The vortexing technique involved adding hexane to spiked sheep 
plasma samples (200 ul) in a final volume ratio of either 3:1 or 6:1. 
The glass tubes were sealed with glass tops and the tubes were vigor-
ously vortexed for 1 min while ensuring that hexane did not touch the 
top and so escape through the glass/glass interface. Hexane was 
removed into scintillation vials for counting. The process was re-
peated 4 times. 
In both extraction techniques the tritium content of each volume 
of hexane used to extract GTN from plasma was compared to the tritium 
content of a 200 ul aliquot of the pre-extracted plasma and the recov-
eries of the drug from plasma were determined. 
The effect of evaporating the hexane in the pooled extracts on the 
recovery of GTN was also determined using 3H_GTN. Spiked plasma sam-
ples were extracted with hexane and the pooled extracts were slowly 
evaporated under a gentle stream of high purity nitrogen. The nitrogen 
was delivered from a cylinder (C.I.G. Australia) connected via metal 
gas lines through a hydrocarbon trap (Model GFMSX, S.E.G., Melbourne). 
The hexane was evaporated to about 20 ul and an aliquot was assayed for 
tritium content and compared to the tritium content of an aliquot of 
the pre-evaporated hexane extracts to determine the loss of GTN during 
the evaporation step. 
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In the extraction technique used in this work 200 pl plasma was 
mixed, by vortexing for 1 min, with 1200 pl hexane twice and the hexane 
supernatant was aspirated and pooled. An internal standard, isosorbide 
dinitrate (ISDN) in hexane (100 pl), was then added to the extract. 
Three ISDN stock solutions of different strengths (0.6, 6, 15 pg/ml) 
were used to meet the varying GTN plasma concentrations being analyzed. 
A preliminary analysis was used to ascertain the appropriate internal 
standard concentration required. The extent of evaporation of the 
hexane eluants was adjusted for the approximate GTN concentration pre-
sent to ensure that less than 1 ng GTN was injected on column and the 
electron capture detector did not become saturated. The final volumes 
of hexane after evaporation ranged from 20 to 250 pl. 
Separation and Quantitation  
Aliquots (2-5 pl) of the evaporated hexane extracts were injected 
onto a 2 M glass column (i.d. 2 mm) packed with 3% SP 2401 on 100/120 
mesh (Supelco) in a Shimadzu Model 6A GC equipped with a 63Ni electron 
capture detector. The column was prepared by silanizing and then being 
connected in series with a pre-column containing 3% Carbowax 20 M-TPA 
on Diatomite 70-80 mesh. The temperature of the oven was raised to 
300 ° C at which temperature degradation of the packing occurs and the 
decomposition products were deposited on the walls of the empty 
silanized column, which was downstream of the pre-column (with relation 
to gas flow), coating any remaining active sites (Taylor et al., 1981). 
The prepared column was then packed with 3% SP 2401 and conditioned at 
200 ° C overnight. 
The operating conditions of the GC assay were; column temperature 
145 ° C, injection and detector temperature 180 ° C, nitrogen carrier gas 
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flow rate 80 ml/min At the start of each day's operation, the column 
was primed by 2 injections of 0.5 ng GTN in 2 ul hexane. 
4.3 IN VITRO METABOLISM AND DISTRIBUTION  
4.3.1 Sources and Preparation of Tissues  
Blood 
Human and sheep venous blood was collected from three human 
volunteers and three sheep into heparinized plastic tubes which were 
centrifuged at 1100 rpm for 15 min. The plasma was removed and stored 
at 4 °C until required. The erythrocytes were washed in a volume of 
buffer (equal to the volume of plasma removed) consisting of 10 mM KC1, 
10 mM glucose and 20 mM Tris-HC1, pH 7.4 (Mircevova et al., 1977). 
Packed erythrocytes were obtained following centrifugation at 1100 rpm 
for 15 min and were then resuspended in a fresh volume of buffer. The 
haematocrit was maintained at 0.45 by adjustment of the buffer volume. 
Other Tissues  
Pieces of liver, lung, leg muscle, vena cava and aorta were 
removed from three sheep anaesthetized with sodium pentobarbitone. The•
pieces of tissue were placed in ice cold 0.1M phosphate buffer at pH 
7.4, weighed and briefly dried on blotting paper. After slicing into 
small pieces, the tissues were homogenized in two volumes of fresh 
phosphate buffer in a Sorvall blender to form a final tissue suspen-
sion. The protein content of each suspension was measured by the 
method of Lowry et al. (1951). The mean protein content (mg/ml) of 
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tissue homogenates was liver, 28.5; lung, 8.5; muscle, 15.8; vein, 2.7; 
artery, 1.5. 
4.3.2. Tissue Incubations With Nitroglycerin 
Human Studies  
Blood. In initial studies, a known volume (10-50 pl) of buffer 
containing known amounts of GTN, 1,3-GDN and 1,2-GDN, was added to 
erythrocyte suspensions (6-8 l) in 10 ml silanized glass centrifuge 
tubes pre-heated to 37 °C in a water bath. The resulting GTN con-
centrations ranged from 100 pg/ml to 50 ng/ml suspension while the GDN 
concentrations ranged from 60 to 1 pg/ml suspension. After mixing by 
inversion for 1 min aliquots (200 pl) of resuspended erythrocytes were 
removed into chilled, silanized glass centrifuge tubes containing 20 pl 
iodoacetamide (final concentration of 4 mM). Thereafter aliquots were 
removed at known time intervals. Samples were immediately centrifuged 
and the supernatant buffer was analyzed for GTN and its metabolites 
using HPLC (see Section 4.2.2.). 
The results of those initial experiments (see Section 5.2.1.) 
showed the "zero-time" buffer GTN concentrations to be always less than 
intended initial GTN concentrations calculated using the known amount 
of GTN added to the known volume of erythrocyte suspension. In order 
to accurately quantitate this initial rapid uptake of GTN (apparently 
into the erythrocytes) the method of preparing GTN incubations was 
changed. 
Blood and resuspended erythrocytes (8 ml) were pipetted into 10 ml 
glass centrifuge tubes which were placed in a water bath at 37 °C for 
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15 min. The blood and suspension were centrifuged and the supernatant 
plasma or buffer quickly removed. Equivalent volumes of plasma or 
buffer pre-heated to 37 °C and containing specified amounts of tritiated 
glyceryl nitrates were then added. The amounts of the tritiated GTN, 
1,2-GDN or 1,3-GDN added resulted in final GTN concentrations in the 
range of 600 to 0.8 ng/ml and separate 1,2-GDN and 1,3-GDN concen-
trations of about 20 ng/ml. The reconstituted blood and erythrocyte 
suspension containing GTN or GDNs were thoroughly mixed for 5 sec on a 
vortex mixer and aliquots (0.5 ml) were removed at frequent intervals 
and placed into glass tubes containing 20 pl iodoacetamide (final con-
centration of 4 mM). These samples were centrifuged at 3000 rpm for 3 
min and the supernatant plasma or buffer removed for analysis. Drug 
concentrations in the spiked stock plasma or buffer solutions were used 
to quantitate the rapid fall in the GTN, 1,2-GDN and 1,3-GDN concen-
trations on the addition of erythrocytes. The decline in drug concen-
trations in plasma and buffer allowed calculations of apparent erythro-
cyte/plasma and erythrocyte/buffer partition coefficients. 
Plasma. In initial studies investigating the metabolism of GTN by 
human plasma, unlabelled GTN in 10-50 pl buffer was added to plasma to 
give final GTN concentrations in the range 50 pg/ml to 50 ng/ml plasma. 
After mixing, aliquots were removed for zero-time GTN analysis (and 
thereafter at known time intervals) by HPLC (see section 4.2.2.). In 
later experiments labelled GTN was used to study the metabolism of GTN 
in plasma at concentrations of 50 and 10 . ng/m1 plasma. 
Inhibition of GTN Metabolism by GDN. The inhibition of GTN metabolism 
by 1,2-GDN and 1,3-GDN in erythrocytes was tes ‘ted by adding unlabelled 
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1,2-GDN and 1,3-GDN in varying concentrations to the buffer containing 
the GTN. Final GDN concentrations ranged from 0 to 600 ng/ml and a GTN 
concentration of about 10 ng/ml was used. 
Inhibition of GTN Metabolism by Iodoacetamide. The inhibition of GTN 
metabolism in blood by iodoacetamide was studied by adding labelled GTN 
to pre-warmed plasma to give a final GTN concentration in reconstituted 
blood of about 1.5 ng/ml. After rapid mixing of plasma and packed 
erythrocytes, blood samples were removed for analysis of plasma GTN 
concentrations in order to monitor the loss of GTN at 37 °C. After 
6 min of incubation at 37 ° C the contents of the centrifuge tubes were 
divided into two equal volumes and each volume was placed in a glass 
centrifuge tube pre-cooled to 2 °C. One tube contained 100 pl of an 
aqueous iodoacetamide solution (final concentration 4mM) and the other 
tube contained 100 pl buffer. Aliquots (500 pl) were removed from each 
of the cooled tubes after 3 min and thereafter at known time intervals 
to determine the plasma GTN concentration. 
Sheep Studies  
Blood. The in vitro metabolism of GTN by sheep blood, resuspended 
erythrocytes and plasma was studied using the procedures described 
above for human blood components. Initial GTN concentrations in resus-
pended erythrocytes and plasma were 50 and 10 ng/ml. A GTN blood con-
centration of 1.5 ng/ml was used to investigate inhibition of GTN meta-
bolism by iodoacetamide. The metabolism of 1,2-GDN and 1,3-GDN (23.6 
ng/ml and 20.7 ng/ml respectively) by sheep blood and resuspended 
erythrocytes was also investigated. 
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Other tissues. Aliquots (4 ml) of the sheep liver, lung, leg muscle, 
vena cava and aorta homogenates were transferred to glass centrifuge 
tubes in a water bath heated to 37 °C. As recommended by Needleman and 
Hunter (1965) the following co-factors were added to the homogenates; 
reduced glutathione, glucose-6-phosphate, glucose-6-phosphate dehydro-
genase and NADPH. Tritiated GTN was added in 100 pl saline to give 
concentrations of about 50 and 10 ng/ml suspension. GTN was also added 
to tubes containing buffer and co-factors but no tissue. The possibi-
lity of metabolite inhibition of GTN metabolism was studied by adding 
1,3-GDN and 1,2-GDN (each at final concentrations of about 100 ng/ml 
suspension) to some of the tubes. 
At specified time intervals 200 pl aliquots were removed from the 
homogenates incubated at 37 ° C. The inhibition reaction was terminated 
in 200 pl samples by the addition of 200 pl methanol. After vortexing 
and centrifugation the samples were stored at -20 °C until analyzed. 
4.3.3. Incubations With Aspirin  
ASA was incubated with homogenates of liver, lung and leg muscle 
at 37 °C in a manner similar to that described in Section 4.3.2. 
However, no co-factors were added to the homogenates in these studies. 
Incubations were also performed using buffer only. In tissue and buf-
fer incubations, initial ASA concentrations of 50 and 5 pg/ml were 
employed. SA, at a final concentration of about 50 pg/ml homogenate, 
was added to some of the homogenates. The incubation reaction was ter-
minated by addition of 20 pl of 3% perchloric acid and 200 pl 
methanol. After vortexing and centrifugation the samples were stored 
at -20 °C until assayed. 
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4.3.4. Plasma Protein Binding  
The unbound fraction of GTN, 1,2-GDN, 1,3-GDN, ASA, SA and SU was 
determined using an ultrafiltration technique (Amicon Micropartition 
System with YMT membranes). Control experiments using aqueous solu-
tions of the unlabelled drugs (except SU) were performed to assess 
whether any sorption to the plastic apparatus and membranes occurred. 
Glyceryl Nitrates. Blank human and sheep plasma (1 ml) pre-warmed to 
37 ° C and then spiked with labelled drug was loaded into the donor side 
of the ultrafiltration apparatus (previously equilibrated at 37 °C in an 
oven). The apparatus was then centrifuged at 3000 rpm for 10 min at 
37 ° C. Aliquots of the pre-centrifuged plasma (total) and filtrate 
(free) were assayed for glyceryl nitrate content by HPLC and liquid 
scintillation spectrometry as described in Section 4.2. 
Salicylates. Blank sheep plasma was used for in vitro experiments to 
investigate the binding of ASA and SA to plasma proteins under various 
simulated experimental conditions. Conditions studied were plasma 
dilution, the presence of pentobarbitone (anaesthetic) and potassium 
fluoride (for inhibition of ASA hydrolysis in vitro). Salicylates (ASA 
and SA) in 0.1M phosphate buffer pH 7.4 (10 iii) were added to glass 
tubes containing 10 pl potassium fluoride in buffer (final concen-
tration 2.5 mg/ml) and 10 pl pentobarbitone in saline (final concen-
tration 10 pg/ml). Pre-warmed (37 ° C) plasma or dilute plasma (1:1 in 
buffer) were added to give final ASA concentrations of 10 or 50 pg/ml 
and SA concentrations of 0, 10 and 50 pg/ml in various combinations. 
Samples of the plasma (1 1) were thoroughly mixed by vortexing for 1 
(a)  
(b)  
(c)  
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Figure 4.1 Fluoroscopic images of blood sampling catheters in the 
(a) pulmonary artery, (b) Hepatic vein and (c) femoral vein. 
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min and loaded into the donor side of the ultrafiltration devices, 
previously equilibrated at 37 °C in an oven. The devices were then 
centrifuged at 3000 rpm for 15 min at 37 °C. Aliquots of the pre-
centrifuged plasma (total) and filtrate (free) were assayed for 
salicylate content by HPLC as in 4.2.2. 
4.4. PHARMACOKINETICS AND PHARMACODYNAMICS OF NITROGLYCERIN 
4.4.1 Preparation of Sheep. 
:Sheep, with weights ranging from 25 to 49 kg, were anaesthetized 
with sodium pentobarbitone (Nembutal, Abbott Laboratories) using a dose 
of 90 mg/kg injected into a jugular vein, and maintained under anaes-
thesia by a continuous intravenous infusion of sodium pentobarbitone at 
a rate of 10 mg/hr/kg. The pulmonary artery was visualized via a left 
thoracotomy at the level of the 3rd rib. A Narco Biosystems electro-
magnetic flow transducer was placed around the pulmonary artery and 
blood flow (cardiac output) was measured on a Narcomatic electromag-
netic flow meter. 
Drug solutions were administered through polyolefin tubing 
(Tridil, American Critical Care) into the right femoral vein of the 
sheep. Blood samples were withdrawn from sites immediately before and 
after the liver (portal and hepatic veins), before and after the lungs 
(pulmonary artery and left ventricle) and before and after the left 
hind leg (femoral artery at the bifurcation of the aorta, and femoral 
vein). The stomach was exposed via a left lateral incision and a 
catheter was placed in the portal vein via a large gastric vein. Using 
fluoroscopy, a catheter was inserted into the hepatic vein via a 
jugular vein (see Figure 4.1.(b)). 
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• 
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Figure 4.2 Schematic representation of the blood sampling sites 
in sheep receiving intravenous infusions. 
LV=left ventricle; LFV=left femoral vein; LFA=left femoral artery. 
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Pre-lung blood samples were taken from the pulmonary artery via a' 
Swan-Ganz catheter inserted into a jugular vein and guided into the 
pulmonary artery using fluoroscopy (See Figure 4.1.(a)). Post-lung 
samples were taken from a catheter in the left ventricle which was 
inserted via a femoral artery and which was also used to measure left 
ventricular pressure. 
Pre-hind leg blood samples were taken from a catheter placed in 
the aorta at the bifurcation and which was inserted via a femoral 
artery. The catheter was also used to measure arterial blood pressure. 
Post-hind leg blood samples were taken from a catheter in the left 
femoral vein which had been inserted via a jugular vein using fluoro-
scopy (see Figure 4.1.(c)). 
A schematic representation of the blood sampling sites in the 
sheep is presented in Figure 4.2. Baseline blood flow in the femoral 
artery was measured in two of the later experiments by placement of an 
electromagnetic flow transducer around a femoral artery. 
Each sheep received a continuous intravenous infusion of normal 
saline at a rate of about 1 ml/min into a jugular vein throughout the 
course of an experiment. At the completion of most of the sheep exper-
iments, the liver and associated major blood vessels were exposed and 
examined in situ to corroborate the fluoroscopic evidence that blood 
sampling lines were indeed in the correct vessels. 
4.4.2. Bolus Intravenous Infusion Dosing Schedules  
Solutions of GTN were made by dissolving the appropriate number of 
Anginine tablets (Burroughs Australia) in normal saline and filtering 
before use. For the largest concentrations of GTN used and where the 
solubility of GTN in saline was exceeded, ethanolic solutions of GTN 
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(Tridil, American Critical Care) were made up in saline. In an initial 
study, doses of GTN (2.7, 5.4, 13.6, 27.2, 54.4, 108.8 jig/kg) were 
administered in 15 ml saline and were injected, over 1 min, into the 
left femoral vein of three sheep. At least 20 min elapsed between 
administering each bolus dose. Five seconds prior to completing the 
bolus dose, blood samples were withdrawn from the femoral artery and 
femoral vein for analysis of 'zero-time' plasma GTN concentrations. 
Thereafter blood samples were withdrawn at 1, 2, 3, 4, 5, 6, 8, 10, 12 
and 15 min for analysis of plasma GTN concentrations. Sampling across 
the liver and lungs was not possible during these experiments as 
insufficient time existed to collect all samples rapidly during the 
fast elimination phase of GTN in vivo. 
Arterial blood pressures and left ventricular pressures (measured 
against 100 cm H20) were monitored continuously during these experi-
ments as was cardiac output. 
4.4.3. Continuous Intravenous Infusion Dosing Schedules  
GTN Pharmacokinetics  
Doses of GTN in saline were infused from a 60 ml polyethylene 
syringe (Terumo Australia) via polyethylene tubing inserted into the 
left femoral vein. Previous studies had shown that the availability of 
GTN infused through polyethylene tubing was about 96% (Cossum et al., 
1978). The syringe was compressed by a syringe pump (Sage Instruments, 
Model 355) to give a flow rate of infusion solution of 0.99 ml/min. 
This flow rate, with appropriate GTN concentrations in saline, was used 
to produce rates of GTN infusion of 0.4, 5.7 and 22.1 pg/min/kg sheep 
with any one dose being delivered to three sheep. Infusions lasted for 
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40 min during which time blood samples were withdrawn from the portal 
and hepatic veins, pulmonary artery and left ventricle, and femoral 
artery and femoral vein. On cessation of the infusion blood samples 
were taken from the femoral artery and femoral vein for up to 25 min 
for analysis of plasma GTN concentrations. (Preliminary studies sug-
gested that the disappearance of GTN was too rapid to allow for blood 
sampling from all available sites). 
Two of the 3 GTN infusions at the rate of 0.4 pg/min/kg were per-
formed using 3H-GTN in order to follow the time course of 1,3-GDN, 
1,2-GDN and mixed GMNs. After terminating the infusion at 40 min, 
blood samples were taken during the next 90 min from all sampling sites 
(portal and hepatic veins, pulmonary artery and left ventricle, femoral 
artery and femoral vein) for the analysis of plasma concentrations of 
the tritiated glyceryl nitrates. 
Effects of GDNs on GTN Pharmacokinetics  
Continuous GTN infusions (5.7 pg/min/kg sheep) were commenced in 
two sheep and blood samples taken from all sampling sites as described 
above. After 30 min of GTN infusion, a bolus dose of 1,3-GDN and 
1,2-GDN (total 5 mg in 15 ml saline) was infused into the aorta over a 
period of 1 min. The GTN infusion was maintained for a further 5 min 
in one sheep and 10 min in the other sheep after which blood samples 
were withdrawn from the femoral artery and femoral vein at 1, 2, 3, 4, 
5, 6, 8, 10, 12, 15, 20 and 25 min post-infusion for analysis of plasma 
GTN concentrations. 
Arterial blood pressure and cardiac output were monitored continu-
ously during these experiments. 
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4.4.4. Collection of Blood Samples  
All blood samples (2 ml) were collected in silanized glass 
syringes and quickly transferred to chilled silanized glass tubes 
containing heparin and 10 pl of a solution of iodoacetamide in saline 
(final concentration 4 mM). The contents of the tubes were mixed by 
inversion before centrifuging at 3000 rpm for 3 min. The resulting 
plasma was transferred to silanized glass tubes, using silanized glass 
pipettes, and stored at -20 °C until the samples were analyzed for their 
glyceryl nitrate content, which always occurred within two days of an 
experiment being performed. 
4.4.5. Stability of Glyceryl Nitrates in Plastic Catheters  
Simulated experiments were performed to assess the extent of 
sorption of organic nitrates by the plastic catheters used in the work 
for blood sampling. Labelled glyceryl nitrates in normal saline were 
infused from glass beakers through plastic catheters using a glass 
syringe. Flow rates of 5 and 40 ml/min were used for GTN solutions and 
40 ml/min was used for the other drugs. 
4.5. PHARMACOKINETICS AND PHARMACODYNAMICS OF ASPIRIN  
4.5.1 Studies in Sheep  
Preparation of Sheep  
Sheep were prepared in the same manner as described in Section 
4.4.1. for GTN experiments. 
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Continuous Intravenous Infusion Dosing Schedules  
ASA (Aspro Clear, Nicholas Pty. Ltd.) was dissolved in saline to 
give appropriate ASA concentrations for infusion (pH 5.9). Solutions 
were infused in the same manner described for GTN in Section 4.4.3. but 
at a flow rate of 0.81 ml/min. This flow rate, with appropriate ASA 
concentrations in saline, was used to produce rates of ASA infusion of 
61 and 485 pg/min/kg sheep. 
Four sheep received an ASA infusion at the rate of 61 pg/min/kg. 
Blood samples were taken from portal and hepatic veins, pulmonary 
artery and left ventricle, and femoral artery and femoral vein. 
Infusions of ASA lasted for 75 min. Three of the four sheep also 
received, at the 50th min of ASA infusion, a bolus dose of NaSA in 15 
ml saline administered over 1 min into the aorta. One sheet received a 
bolus dose of NaSA equivalent to 30 mg SA, another sheep a dose 
equivalent to 300 mg SA and the third sheep a dose equivalent to 1200 
mg SA. At the termination of the ASA infusion after 75 min, blood 
samples were taken from the femoral artery and femoral vein at 5, 10, 
20, 30, 45, 60, 75 and 90 min post-infusion. Some blood samples were 
also taken from liver and blood vessel sampling sites during that time. 
Four other sheep received an ASA infusion at the rate of 
485 pg/min/kg. Blood sampling was performed as described for the 
61 pg/min/kg infusions, however, no bolus doses of NaSA were admi-
nistered to these sheep. 
Collection of Blood Samples  
Blood samples (2 ml) containing salicylates were collected into 
chilled glass tubes containing heparin and 50 pl potassium fluoride 
solution in normal saline (final concentration in blood, 5 mg/ml) 
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(Rowland and Riegelman, 1967). Samples were centrifuged at 3000 rpm 
for 10 min and the resulting plasma was removed and stored at -20 °C 
until analyzed for salicylate content using the HPLC assay of Rumble et 
al. (1981). 
4.5.2. Studies in Man  
Single Dose Study  
After overnight fasting, nine healthy male volunteers, aged 
between 19 and 24 years and weighing between 67 and 79 kg, received, 
with 200 ml water, equimolar oral doses of salicylate (230 mg) in the 
form of soluble ASA, NaSA and an enteric coated and microencapsulated 
formulation of ASA at different times. An interval of at least two 
weeks elapsed between the administration of each dose-form to the same 
subjects. Blood samples were collected immediately before ingestion of 
the dose and at fixed times thereafter. 
Continuous Dose Study  
Sixteen healthy volunteers (eight male and eight female) were 
used. The ages of volunteers ranged from 20 to 30 years (average 22.6 
years) and with body weights ranging from 54 to 105 kg, (average 
68.8 kg). The study was conducted in a cross-over manner using two 
groups of eight subjects, each subject ingesting three different doses 
of either 20, 50, 100, 200, 650 and 1300 mg ASA in the slow release 
formulation. The appropriate amount of microencapsulated drug granules 
were weighed out and placed in gelatin capsules. Each group of eight 
subjects consisted of four males and four females. A group of males 
(4) only, taking either 20, - 50, 100 or 200 mg doses and all subjects in 
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the groups taking 650 and 1300 mg were used specifically to determine 
the degree of inhibition of platelet function induced by AA. 
Control values of platelet aggregation and MDA production were 
estimated before the commencement of each dosing schedule. Subjects 
ingested one capsule of a given dose of the slow release product each 
morning for six days. On the seventh morning, blood samples were taken 
for assessment of trough values of platelet function and plasma ASA 
concentrations. Subjects ingested the last capsule and 3 hr later peak 
values of platelet function and plasma ASA concentrations were deter-
mined. This time was chosen to correspond with the time (3 hr) to 
reach mean peak plasma ASA concentration determined in the single dose 
study (Fig. 5.63.). 
Subjects in both groups were not permitted to take any drugs for 
two weeks prior to the study or during the study. The experiments were 
performed according to the principles of the Declaration of Helsinki. 
Approval was obtained from the University of Tasmania Committee on 
ethical aspects of human biological research, and informed written con-
sent was obtained from each subject. 
Collection of Blood Samples  
Blood was collected into a plastic syringe either by venepuncture 
(18-19 G needles) or from an indwelling catheter (Jeltec 17-18 G) in a 
forearm vein. The blood was immediately distributed to tubes , contain-
ing anticoagulants and /or potassium fluoride for the appropriate 
determination. Blood for platelet function tests was used within 3 hr. 
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Assays of Platelet Function 
Platelet Aggregation. Platelets from 9 ml blood mixed with 1 ml 3.8% 
sodium acid citrate solution were obtained by centrifugation at 190 g 
for 15 min to produce platelet rich plasma (PRP). Further centri-
fugation at 2,000 g for 15 min gave platelet poor plasma (PPP). 
Platelet counts for PRP were obtained as before and PRP was diluted 
with PPP to give final platelet counts of 200-250 x 10 9 per litre. 
Platelet aggregation was measured by the method of Born (1962) using a 
Chronolog aggregometer. Aggregation of 450 pl PRP was initiated by 
adrenalin (2.5 pM) and collagen (2.5 pg). AA (0.87 mM) was also used 
in some experiments. Inhibition of platelet aggregation was measured 
as the decrease in light transmission and expressed as the percentage 
of control aggregation. 
MDA Production. MDA production induced by stimulation of PRP with NEM 
was measured spectrophotometrically by a modified method of Catalano et 
al., (1981). PRP was obtained from 7.5 ml blood collected into 1 ml 
3.8% w/v sodium edetate. Saline (1.5 ml) was added and the mixture 
centrifuged at 190 g for 15 min. Two ml of the resultant PRP were 
added to 5 ml saline and centrifuged at 2000 g for 10 min. The 
supernatant was decanted and the tube inverted and drained onto absor-
bent paper for 2 min. The platelet button so obtained was resuspended 
in 900 pl 14 mM Tris buffer (pH 7.4) and incubated for 15 min with 0.1 
100 pl 50 mIti NEM or 100 pl 2 mM AA. The reaction was stopped by the 
addition of 1 ml of 20% trichloracetic acid in 0.6 M HC1 and cooled in 
ice for 5 min. The mixture was centrifuged at 2000 g for 15 min and 
1.5 ml of the clear supernatant was mixed with 300 pl of 0.13 pl TBA 
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reagent and heated in a water bath at 70 ° C for 3 min using marbles as 
condensers. The TBA reagent was prepared by dissolving 1.73 g TBA in 
0.25 M Tris buffer, adjusting the pH to 7 with 10 M HC1 and filtering 
through a number 3 sintered glass funnel. The reaction mixture was 
cooled to room temperature and the absorbance of the pink chromagen was 
measured at 532 nm on a Pye Unicam SP6-550 spectrophotometer against a 
control from PRP with NEM or AA. Platelet counts were made on a 
Thrombocounter C (Coulter Electronics Ltd.) and MDA production was cal-
culated as nanomoles per 109  platelets. 
4.6. TREATMENT OF DATA 
4.6.1. Pharmacokinetic Parameters  
The elimination rate constant k was estimated by linear regression 
of the second phase of the post-infusion log drug plasma concentration 
versus time plots. 
The area under the plasma drug concentration versus time curve 
(AUC) was estimated from the sum of the AUC0->t (where t is the time of 
the last data point) and AUC t->co AUC0->t was obtained using the 
trapezoidal rule on a desk top computer. AUC t_>. was calculated by the 
equation: 
AUCt->.= =C t/k 
	(4.2) 
where C t= concentration of drug at time t and k = elimination rate con-
stant. 
The area under the first moment curve (AUMC) is defined by the 
area under a plot of the product of concentration and time versus time. 
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This area from time zero to the time t of the final data point was cal-
culated using the trapezoidal rule on a desk top computer. AUMC t->c* 
was calculated from the following equation (Gibaldi and Perrier, 1982): 
AUMC t->00 	
Ct = tC t (4.3) 
Mean residence time (MRT), the first moment, was calculated as 
the ratio AUMC/AUC (Gibaldi and Perrier, 1982) and the MRT of the 
solute in an organ was calculated as the difference of the arterial 
MRT and venous MRT. 
Availability of a drug is calculated as the ratio of the amount 
of drug leaving an organ or system to that entering. Thus, organ 
availability (Fo) was calculated from the venous and arterial AUCs: 
AUCvenous  
AUC arterial •(4.4) 
and the systemic availability (F) from dose (D) and AUC (venous unless 
specified otherwise): 
F= o AUC (4.5) 
The fraction of substance unbound (1 u) was calculated from the 
following equation: 
fu — C (4.6) 
where Cu is the unbound plasma drug concentration and C the total 
plasma drug concentration. 
C V o• E 
•Ai - CV oT K= (4.8) 
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Intrinsic clearance (Cl int ) of all substances was calculated from: 
Clint = Q (1 - F)  f x F U (4.7) 
where Q = blood flow to the organ, F = availability, and f u = unbound 
fraction of the drug in plasma. Equation 4.7 is a rearrangement of 
the equation used to relate clearance, blood binding and blood flow 
assuming a "well-stirred" model (Gibaldi and Perrier, 1982). As blood 
flows to individual organs were not routinely monitored, average esti-
mated values were employed. Blood flows to the lungs and liver were 
•assumed to be 1.0 and 0.25 time cardiac output respectively. A blood 
flow of 0.1 times cardiac output was used for calculation of hind-leg 
intrinsic clearance based on results of the baseline blood flow mea-
surements in the femoral artery of two sheep. Average data were also 
•used for binding in calculations of intrinsic clearance. The fraction 
unbound, fu , for GTN, 1,2-GDN and 1,3-GDN were assumed to be 0.39, 
0.77 and 0.89 respectively. The fraction unbound for salicylates was 
based on individual data obtained. The protein binding of salicylates 
was not monitored in two sheep given 485 pg/min/kg of ASA. The mean 
fu data from the other sheep given this dose were therefore used to 
calculate intrinsic clearances for these sheep. 
• Apparent erythrocyte/plasma and erythrocyte/buffer partition co-
efficients were calculated as the ratio of the GTN concentrations in 
erythrocytes and the GTN concentration in plasma or buffer. The par-
tition coefficients (k) were determined using equation 4.8. 
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Where Ai is the amount of GTN added to volume V T of erythrocyte 
suspension, VE is the volume occupied by the erythrocytes and Co is 
the concentration of GTN in buffer or plasma immediately on mixing. 
Co was estimated by back extrapolating the terminal phase of the plot 
of log concentration versus time to zero-time. 
4.6.2. Statistical Analysis  
Data are presented as mean ± S.E. 	Statistical comparisons 
between groups were performed using Students t-test or analysis of 
variance. A p value of 5 0.05 was taken as statistically significant. 
CHAPTERS 
RESULTS  
5.1 ANALYTICAL TECHNIQUES  
5.1.1. Analysis of Glyceryl Nitrates  
Synthesis of Glyceryl Nitrates  
Figure 5.1 shows the time course of GTN yield using the reaction 
conditions outlined in 4.2.1. The greatest yield of unlabelled GTN 
under the conditions used occurs between 45 and 60 min of incubation. 
The incubation time of 30 min used in the synthesis of 3H-GTN resulted 
in the yield of 3H-GTN being reduced to about 50% but enabled adequate 
quantities of 3H-GDNs to also be synthesized. 
Purification of the reaction products gave 3H-GTN with a specific 
activity of 0.125 Ci/mmol (2100 dpm/ng, in September, 1982) and radio-
chemical purity of 98.9%. 3H=GTN was stored in aqueous solution (40 
pg/m1) in glass vials at -20 °C until used. 
The specific activity of the 3H-GDNs was assumed to be the same 
as that of 3H-GTN on a molar basis (2619 dpm/ng, in September, 1982). 
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Figure 5.1 Optimization of the yield of nitroglycerin from 
incubations of glycerol, fuming nitric acid and fuming sulph-
uric acid under the conditions described in Section 4.2.1. 
Concentration 
(ng/ml plasma) 
0.8 
10.0 
98.8 
with marker 	without marker 
(n = 5) (n = 5) Drug 
GTN 
	
95.9 + 0.6 	73.0 ±1.2 
99.2 + 1.0 	79.5 + 1.8 
99.4 + 0.7 	78.4 + 1.0 
Table 5.1 
Comparison of recoveries of labelled nitroglycerin (GTN), 
1, 3- and 1, 2- dinitroglycerins (1, 3- GDN, 1, 2- CON) and 
Mixed mononitroglycerins (GMN) from a C 18 HPLC column with 
and without a similar but unlabelled compound added as a 
marker of retention time. (mean + S.E.) 
% Recovery  
3- CON 	0.5 	99.5 + 0.6 	84.5 + 1.6 
10.5 99.7 ±0.3 	86.2 + 2.0 
115.0 	98.9 + 0.3 	89.8 + 1.0 
2- GDN 	0.5 	97.8 + 0.5 	86.0 + 1.1 
10.0 99.1 + 0.7 	87.5 + 0.8 
112.0 	99.9 + 1.2 	89.1 + 0.7 
GMN's 	0.6 	98.8 + 0.4 	87.7 + 1.1 
11.0 99.4 + 0.6 	87.4 + 1.7 
92.7 	100.0 + 0.7 	89.2 + 0.5 
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Table 5.2 Recoveries of labelled glyceryl nitrates from 
plasma by deproteination with methanol. 
(Mean ± S.E. (n = 3)). 
 
Drug Drug  
concentration 
(ng/ml) 
% Recovery 
GTN 1.1 99.2 ± 0.07 
10.7 99.9 ± 0.06 
3-GDN 5.0 97.1 ± 	0.21 
2-GDN 4.6 100.0 ± 0.03 
GMNs 9.9 99.6 ± 0.08 
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High Performance Liquid Chromatography  
Retention times for injections of 20 pl solution of glyceryl 
nitrates on the HPLC system used were as follows: 
1-CNN 3 min, 2-GMN 3.6 min, 1,3-GDN 6 min 
1,2-GDN 	7 min, 	GTN 20 	min (Figure 5.2 (a)). 
Increasing the injection volume of 150 pl affected the chro-
matographic behaviour of the glyceryl nitrates (Figure 5.2(b)). At 
the larger injection volume the GMNs cannot be satisfactorily 
resolved. 
In initial studies plots of dpm versus concentration (range 
0.2-100 ng/ml, 3H-GTN and 3H-GDNs, 150 pl injections) were non-linear. 
Addition of unlabelled GTN and GDNs (5p1 of aqueous glyceryl nitrate 
solution containing 10-50 pg/ml) was required in each 150 pl injection 
• of deproteinated plasma or buffer containing labelled drug to obtain 
linear calibration plots for the labelled drugs. Recovery experiments 
for labelled drugs in the concentration range 0.5-115.5 ng/ml plasma 
(or buffer) showed that the poor linearity of calibration plots was 
due to a poor recovery of small amounts of labelled drug from the 
chromatography column (Table 5.1). 
Deproteination of plasma with methanol resulted in recoveries for 
all of the labelled glyceryl nitrates of 97-100% (Table 5.2). None of 
the glyceryl nitrates was degraded in methanol during the work-up pro-
cedure. 
Liquid Scintillation Spectrometry  
The efficiency (E) values obtained for different degrees of 
3 quenching for the H-toluene standard solutions in 10 ml scintillation 
(5) 
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( b) 
(3) 
2) 
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4) 
(2) 
1 
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Figure 5.2 High performance liquid chromatograms of glyceryl 
nitrates ( 1, 1-GMN; 2, 2-GIN; 3, 1,3-GDN; 4, 1,2-GDN; 4, GTN ) 
arising from (a) 20 pl and, (b) 150 pl injections of aqueous 
solutions using the chromatographic conditions described in 
Section 4.2.2. 
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cocktail were plotted against the ratio of counts in the channels to 
counts in an external standard channel in the machine (ESR). The 
equation describing the plot was: 
E = -0.065 (ESR) 2  + 0.391 (ESR) - 0.149 
The minimum detectability of all labelled glyceryl nitrates was 
set at 20 cpm above background counts. 
Gas Chromatography  
Figure 5.3 shows that two extractions of sheep plasma using a 
hexane/plasma volume ratio of 6:1 and vortexing vigorously for 1 min 
gave a 94% recovery of the 3H-GTN. Similar results were found for 
sheep and human plasma. When the volume ratio was reduced to 3:1 two 
extractions removed only 84% of the 3H-GTN (Figure 5.3). The rapid 
injection technique for extracting GTN from plasma with equal volumes 
of hexane (Yap et al., 1978) provided recovery values of 3H-GTN which 
were both low and variable. 
Evaporation of the 2.4 ml of pooled hexane extracts to 20-250 pl 
resulted in a further loss of GTN of 3-4%. Using the adopted method 
an overall recovery of about 90% was achieved for the extraction of 
GTN from sheep plasma. 
GC tracings of blank sheep plasma and an actual sample containing 
GTN and the internal standard ISDN are presented in Figure 5.4 (a) and 
5.4 (b) respectively. It is seen that the GTN peak is clear from any 
interfering peaks while ISDN is only marginally affected by a small 
interfering peak. The retention times of GTN and ISDN for the CC 
conditions used were 6.6 and 14.4 min respectively. 
100 
25 
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Figure 5.3 Characterization of the vortexing technique used 
to extract nitroglycerin fram plasma with hexane (Section 4.2.4.) 
(0) volume ratio of hexane : plasma of 6 : 1. 
(•) volume ratio of hexane : plasma of 3 : 1. 
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Figure 5.4 Gas chromatograms of (a) blank sheep plasma and, 
(b) a sample containing 15.9 ng GTN/ml plasma and the internal 
standard ISDN obtained using the conditions described in 
Section 4.2.4. 
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Figure 5.5 Calibration plot for the GC assay of sheep plasma GTN 
concentrations. 
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Figure 5.6 Calibration plot for the GC assay of sheep plasma GTN 
concentrations. 
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Figure 5.7 Calibration plot for the GC assay of sheep plasma GrN 
concentrations. 
Table 	5.3 Precision of the gas chromatography assay of nitroglycerin (GTN) in sheep plasma. 
Amount (ng) GTN in 
200 pl plasma 0.20 10.0 100.0 
Mean of 5 separate 
determinations 0.19 9.90 101.1 
Range 0.17 0.21 9.61 10.32 97.2 10.43 
Standard 
Deviation 0.013 0.41 3.0 
% C.V. 6.8 4.1 3.0 
1 	n 	(a) (b) 
(3) 
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Figure 5.8 High performance liquid chromatograms of 
(a) blank sheep plasma and, (b) a sample of sheep plasma 
containing SU (1), ASA (2) and SA (3). Chromatographic 
conditions are described in Section 4.2.2. 
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Figure 5.9 Calibration plots for the HPLC assay of sheep (and human) 
plasma SU (A), ASA (•) and SA (II) concentrations. 
Table 5.4 	Precision of the high pressure liquid chromatography assay of aspirin (ASA) 
and salicylic acid (SA) 
ASA 
in sheep plasma. 
SA 
Amount (pg) in 
200 pl plasma 0.20 10.0 0.20 10.0 
Mean of 5 
separate deter-
minations 0.21 10.0 0.19 9.9 
Range 0.18 - 	0.22 9.85 - 	10.20 0.17 - 	0.22 9.81 - 	10.09 
Standard 
Deviation 0.012 0.37 0.010 0.33 
% C.V. 5.7 3.7 5.3 3.3 
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Calibration plots for three concentration ranges are presented in 
Figures 5.5 to 5.7. All calibration plots are linear and pass through 
the origin. The use of three calibration plots was made necessary by 
the fact that the electron capture detector in the system became sat-
urated when more than 1 ng GTN was injected on column. Day-to-day 
variation in the detector response to GTN although small (<57.), made 
it necessary to analyze three freshly prepared plasma samples con-
taining known amounts of GTN each day before analysis of real samples 
began. 
The precision of the GC assay of GTN in sheep plasma is shown in 
Table 5.3. The coefficient of variation ranged from 6.8% to 3.0% for 
plasma GTN concentrations ranging from 1.0 to 500.0 ng/ml respectively. 
The minimum detectability of the assay was about 0.2 ng GTN/ml plasma. 
5.1.2. Analysis of Salicylates  
HPLC tracings of blank sheep plasma and an actual sample contain-
ing ASA, SA and SU are presented in Figure 5.8. Tests of precision 
and reproducibility of the HPLC assay of Rumble et al. (1981) for ASA 
and SA in the range 1 to 50 pg/m1 sheep (or human) plasma (or buffer) 
showed the assay to be precise (Table 5.4) and to be reproducible 
with coefficients of variation in the range 5.7 to 3.7% respectively 
for ASA. Corresponding values for SA are 5.3 to 3.3% respectively 
(Table 5.4). Figure 5.9 shows typical calibration curves used to 
quantitate the concentrations of ASA, SA and SU in plasma. 
The lower limit of detection of ASA and SA concentrations for the 
HPLC conditions used was about 0.1 pg/m1 plasma or buffer. No tests 
of precision or reproducibility for plasma SU concentrations were per-
formed. 
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Figure 5.10 PLatelet aggregation charts from platelet-rich plasma 
treated with adrenalin (ADR), collagen (COLL) and arachidonic acid 
(AA) before commencing Astrix (a) and 3 hr after the seventh daily 
dose of 650 mg Astrix (b) for Subject SG. 
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5.1.3. Assays of Platelet Function 
Platelet Aggregation  
The intra- and inter-subject variability in platelet aggregation 
induced by adrenalin, collagen and AA is shown in Tables Al to A3. 
Examples of platelet aggregation curves induced by adrenalin, collagen 
and arachidonic acid before and after 650 mg Astrix daily for one week 
are shown in Figure 5.10. 
Platelet Malondialdehyde Production  
Platelet counts determined after resuspending the platelet button 
in Tris buffer showed that 87% of the platelets were recovered from 
the washing process. The molar absorbance of MDA in saline was found 
to be 1.56 x 10 5 . Using platelet rich plasma from the same blood 
sample for 10 separate determinations for NEM and 7 for AA, the 
overall coefficient of variation was 8%. 
5.1.4. Plasma Protein Binding  
The glyceryl nitrates and salicylates were not sorbed by the 
plastic ultrafiltration devices or membranes (Table 5.5) when tested 
using drug concentrations which fall within the range of plasma con-
centrations commonly encountered in the experimental work described in 
other sections of this thesis. 
During experiments involving the infusion of aspirin into sheep, 
it was observed that the plasma albumin concentrations began to fall 
from control values (when the sheep was conscious) during the anaes-
thetic and surgical procedures necessary to implant the catheters and 
flow-probes, and then settled at about 60% of control values during 
40 
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Figure 5.11 Plasma albumin concentrations of sheep undergoing 
anaesthesia and surgery in preparation for intravenous infusions 
of ASA. ( Sheep 25 (A); Sheep 26 (A); Sheep 2110Sheep 28 (v); 
Sheep 29 (0); Sheep 30 (II). 
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Table 5.5 	Recoveries of drugs in control experiments 
to determine losses to plastic ultra-
filtration apparatus and membranes. 
(Mean + S.E. (n = 3)). 
Drug 	Drug 	% Recovery 
Concentration 
(Pg/m1 ) 
1, 
GTN 
3-GDN 
2-GDN 
ASA 
SA 
0.005 
0.011 
0.012 
5.0 
10.1 
99.0 
99.8 
100.0 
100.2 
99.9 
+ 	1.0 
+ 	0.09 
+ 	0.02 
+ 	0.18 
+ 	0.08 
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Table 5.6 In vitro plasma protein binding of aspirin 
(ASA) in the plasma of untreated Sheep Nos. 
27 a and 29b and the effect of salicylic 
acid (SA), potassium fluoride (KF), Nembutal 
and plasma dilution on the protein binding. 
 
Treatment 
ASA 
(jig/m1) 
SA 
(jig/m1) 
Fraction Unbound 
a 
Plasma 10 0.36 0.34 
10 50 0.48 0.49 
50 0.38 0.36 
50 50 0.49 0.50 
10 0.15 0.18 
50 0.22 0.21 
Dilute Plasma 10 - 0.48 0.50 
1:1 10 50 0.70 0.71 
50 50 0.69 0.73 
- 50 0.27 0.33 
Plasma + KF 10 0.35 0.36 
(2.5 mg/ml) 
Plasma + Nembutal 10 0.37 0.36 
(10 	jig/m1) 
Dilute Plasma 10 0.49 0.50 
+ KF + Nembutal 10 10 0.53 0.51 
10 50 0.68 0.66 
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the infusion of drug and post-infusion drug sampling times (Figure 
5.11) In vitro experiments demonstrated that plasma dilution (which 
simulates reduced plasma albumin concentrations) reduced the binding 
of both ASA and SA when compared to undiluted plasma (Table 5.6). 
Moreover, ASA binding was reduced in the presence of SA in undiluted 
plasma but to a much larger degree in diluted plasma (Table 5.6). 
Potassium fluoride and Nembutal (pentobarbitone) had negligible effect 
on the binding of ASA in undiluted or diluted plasma. 
The binding of GTN to plasma proteins was constant over a wide 
GTN concentration range for human and sheep plasma (Tables 5.7 and 
5.8). 
5.2 IN VITRO DISPOSITION OF NITROGLYCERIN IN BLOOD COMPONENTS  
5.2.1. Metabolism of Nitroglycerin in Erythrocyte Suspensions  
Figure 5.12 shows that GTN is degraded to the dinitrate meta-
bolites when it is incubated with resuspended human erythrocytes. 
Detection of the GMN metabolites is prevented on the HPLC chromatogram 
by interfering endogenous substances with the same retention time as 
the GMNs. Although the concentration of GTN (100 pg/m1) used to 
obtain this chromatogram was very much greater than therapeutic con-
centrations in man, similar patterns of degradation were found for 
initial GTN concentrations of 600, 50, 10, 2 and 0.8 ng/ml blood or 
suspension using the tritiated GTN. Figure 5.13 shows the time course 
of GTN disappearance from and 1,2-GDN and 1,3-GDN and GMN evolution 
into the buffer of the suspension for an initial GTN concentration of 
10 ng/ml suspension. Similar results were obtained for both human and 
sheep erythrocyte suspensions. 
                           
     
( b ) 
        
(c )  
       
(d) 
                        
0-
04
 A
U
FS
 
                     
                     
               
                    
                    
     
CNI 
                    
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                         
                         
                         
                         
                         
                         
                          
                          
                           
                           
                           
                           
                           
	 1 
10 	20 	30 0 	10 	20 	310 0 	I 10 	2 	1 0 3 0 0 6 1 	20 	30 
Time (min) 
Figure 5.12 HPLC tracings showing GTN (initial concentration 
100 pg/ml) metabolism in resuspended human erythrocytes at 37 °C. 
(a) blank suspension; (b) immediately after adding GTN; (c) after 
10 min incubation; (d) after 2 hr incubation. HPLC conditions are 
described in Section 4.2.2. 
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Figure 5.13 Time course of GTN metabolism in resuspended human 
erythrocytes at 37°C. (•) GUN; (A) 1,2-GDN; (II) 1,3-GDN; (1,) GMNs. 
Erythrocytes were collected from Subject B and the initial GTN concent-
ration was 10 ng/ml suspension. Glyceryl nitrate concentrations were 
measured in the supernatant buffer of the suspension. 
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Figure 5.14 Influence of the initial GTN concentration on the rate 
of GTN metabolism in resuspended human erythrocytes of Subject A. 
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Table 5.7 Half-lives of metabolism in blood and resuspended erythrocytes, apparent erythrocyte/buffer 
and erythrocyte/plasma partition coefficients and bound fraction to plasma proteins of 
nitroglycerin (GTN), 1, 2-dinitroglycerin (1, 2-GDN) and 1, 3-dinitroglycerin (1, 3-CDN). 
(Mean + S.E. (n = 3)). 
 
Drug  
concentration 
(ng/ml) 
Half-life of metabolism 
(min) 
Apparent 	Apparent 	Fraction 
erythrocyte/ 	erythrocyte/ 	bound to 
buffer 	plasma 	plasma 
partition partition 	proteins 
coefficient 	coefficient 
  
Plasma Blood Resuspended 
erythrocytes 
ruN 600 - 16.6 + 0.40 17.0 + 0.51 2.14 + 0.04 0.59 + 0.016 0.63 + 0.013 
50 52.7 + 2.1 6.1 7 0.18 6.0 + 0.20 2.09 7 0.04 0.57 7 0.014 0.61 + 0.011 
10 51.3 + 1.9 3.7 7- 0.23 3.6 + 0.19 2.10 7 0.05 0.61 T 0.011 0.64 + 0.0a 
2 - 3.0 7 0.15 3.1 + 0.18 2.09 7 0.05 0.58 7 0.013 0.61 + 0.013 
0.8 - 2.7 7 0.17 2.9 + 0.13 2.06 7 0.08 0.58 T.- 0.011 0.61 + 0.06 
1,2-GDN 23.3 _ 35.2 + 1.10 35.4 + 0.99 2.04 + 0.05 0.84 + 0.024 0.23 + 0.016 
1,3-GDN 21 - 48.1 + 0.95 49.0 + 1.30 2.11 + 0.06 0.88 + 0.018 0.11 + 0.0Z, 
100-- 
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Figure 5.15 Disappearance of 1,2-GDN (•) and 1,3-GDN (()) from 
solutions incubated with resuspended human erythrocytes (Subject PO 
at 37°C. 
Table 5.8 Half-lives of metabolism in sheep blood, resuspended erythrocytes and plasma, apparent 
erythrocyte/buffer and erythrocyte/plasma partition coefficients and bound fraction to 
plasma proteins of nitroglycerin (Cm), 1, 2-dinitroglycerin (1, 2-GDN) and 1, 3-dinitro-
glycerin (1, 3-GDN). (Mean + S.E. (n = 3)). 
 
Drug Half-life of Apparent Apparent Fraction 
concentration metabolism Erythrocyte/ Erythrocyte/ Bound to 
(ng/ml) (min) Buffer Plasma Plasma 
Partition Partition Proteins 
Coefficient Coefficient 
Plasma Blood Resuspended 
Erythrocytes 
GTN 
1,2-CDN 
1,3-CDN 
50 
10 
23.6 
20.7 
51.3 
50.7 
+ 1.7 
+ 1.3 
- 
_ 
6.3 
3.5 
36.8 
49.3 
+ 0.31 
+ 0.11 
+ 1.1 
+ 1.1 
6.3 
3.6 
36.7 
49.9 
+ 0.28 
+ 0.41 
+ 0.58 
+ 0.92 
2.10 
2.17 
2.09 
2.09 
+ 0.03 
+ 0.01 
+ 0.04 
+ 0.04 
0.60 
0.60 
0.82 
0.88 
+ 0.041 
+ 0.013 
+ 0.017 
+ 0.017 
0.62 
0.60 
0.23 
0.12 
+ 0.011 
+ 0.008 
+ 0.014 
+ 0.011 
0 
(c) 
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Figure 5.16 HPLC tracings showing GTN (initial concentration 10 ug/m1) 
metabolism in human plasma at 37 °C. (a) blank plasma; (b) Immediately 
after adding GTN; (c) after 2 hr incubation. HPLC conditions are 
described in Section 4.2.2. 
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Figure 5.17 Influence of the initial GTN concentration on the rate of 
metabolism in human plasma ( Subject A). 
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Table 5.9 
The effect of added 1, 2- dinitroglycerin (1, 2- GDN) and 
1, 3- dinitroglycerin (1, 3- GDN) on the half-life of meta-
bolism of nitroglycerin (GTN) by resuspended erythrocytes. 
(Mean + SE, n=3 ) 
GTN 	1, 2- GDN 
Concentration Concentration 
(ng/ml) 	(ng/ml) 
1, 3- GDN 	Half-life of 
Concentration GTN metabolism 
(ng/ml) (min) 
9.8 
10.0 
9.8 
9.9 
10.0 
50 
600 
0 
0 
50 
600 
3.4 
6.3 
15.9 
6.5 
16.6 
+ 	0.26 _
+ 	0.21 _
± 	0.39 
+ 	0.24 _
+ 	0.41 _
Table 5.10 The effect of initial concentration on the 
  
disappearance of 1, 2- and 1, 3- dinitroglycerin from 
erythrocyte suspensions at 37 °C. '(Mean . + SE, rF3) 
Initial 
concentration (ug/m1) 
Apparent half-life of disappearance 
(hrs) 1 	2- GDN 	 1 	3- GDN 
60 3.4 + 	0.21 5.9 + 	0.26 
1 0 3.0 ± 	0.20 5.1 0.26 
1 2.0 + 	0.26 3.6 + 	0.18 
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Figure 5.14 shows that the time course of GTN disappearance from 
human erythrocyte suspensions is concentration dependent; the rate of 
GTN disappearance increases at the lower initial GTN concentrations. 
In the second study which was designed to quantitate the rapid initial 
uptake of GTN, similar concentration-dependent losses of GTN due to 
metabolism were observed as shown in Figure 5.14. The results of the 
second experiment are presented in Table 5.7 for resuspended human 
erythrocytes and Table 5.8 for resuspended sheep erythrocytes. 
When 1,2-GDN and 1,3-GDN were added to human erythrocyte sus-
pensions containing GTN at a concentration of about 10 ng/ml, the rate 
of GTN metabolism decreased as the added GDN concentrations increased 
(Table 5.9). GDNs were also metabolized in resuspended erythrocytes 
(Fig. 5.15). Table 5.10 shows that the apparent half-lives of the GDN 
metabolites were also concentration dependent. 
5.2.2. Metabolism of Nitroglycerin in Plasma  
GTN was metabolized by both human and sheep plasma to form the 
GDNs. The metabolism of GTN differed between plasma and resuspended 
erythrocytes with the 1,3-GDN being the major metabolite formed in 
plasma (Fig. 5.16) and 1,2-GDN, the major metabolite formed in 
erythrocyte suspensions (Fig. 5.12). 
Tables 5.7 and 5.8 show the half-lives of GTN in human and sheep 
plasma, respectively, for GTN concentrations of 50 and 10 ng/ml. The 
half-lives at these GTN concentrations were 50-52 min for human and 
sheep plasma. When compared to the half-lives of GTN in blood or 
resuspended erythrocytes it can be seen that degradation of GTN in 
plasma is very slow (Tables 5.7 and 5.8). 
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Figure 5.18 The effect of iodoacetamide on the rate of metabolism 
of GTN in human blood (Subject A). GTN (1.5 ng/ml) was incubated with 
blood at 37°C for 6 min after which the contents of the incubation 
vial were split and placed in pre-cooled tubes containing iodoacetamide 
(4mM), (0) or buffer (•. 
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The metabolism of GTN in (human) plasma is concentration depen-
dent; the very large GTN concentrations being associated with the 
longer apparent half-lives (Figure 5.17). 
5.2.3. Distribution of Glyceryl Nitrates in Blood  
and Erythrocyte Suspensions  
Apparent human or sheep erythrocyte/buffer partition coefficients 
were about 2.1 for GTN, 1,3-GDN and 1,2-GDN; however, the presence of 
plasma considerably reduced the initial uptake of the three drugs by 
erythrocytes so that the apparent erythrocyte/plasma partition coeffi-
cient for GTN was about 0.60 while that of the GDNs was about 0.85 
(Tables 5.7 and 5.8). The altered distribution in blood is reflected 
by the relative degree of plasma protein binding of the three drugs 
(Tables 5.7 and 5.8). 
5.2.4. Inhibition of Nitroglycerin Metabolism by Iodoacetamide  
Figure 5.18 shows the time course of GTN in the plasma of blood 
samples containing iodoacetamide. When blood containing GTN was 
removed from incubation at 37 °C and placed in a chilled glass test 
tube containing iodoacetamide at a final concentration of 4mM, the 
degradation of GTN was stopped almost immediately (Figure 5.18). In 
contrast, the degradation of GTN in the absence of iodoacetamide 
continued at 2 ° C but at a much slower rate than observed at 37 ° C 
(Figure 5.18). Similar results were also obtained for sheep blood. 
5.3. IN VITRO METABOLISM OF NITROGLYCERIN IN SHEEP TISSUES  
Figures 5.19 to 5.22 show the extent of GTN loss from tissue 
homogenates when incubated at 37 ° C for various times. Substantial 
10 	20 	1:0 	50 
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Figure 5.19 Metabolism of GTN (50 ng/ml) in suspensions 
of sheep liver (ALA) and lung (• C)) tissue, with (closed 
symbols) and without (open symbols) added GDNs (each 100 ng/ml). 
Control incubations (• 0). Each point represents the mean 
+ se of the results for three animals. 
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Figure 5.20 Metabolism of GTN (50 ng/MI) in suspensions of sheep 
leg muscle (II 0), aorta (AL 	) and vena cava ( III N7 ) tissue with 
(closed symbols) and without (open symbols) added GDNs (each 100 ng/h11). 
Control incubations (• 0 ). Each point represents the mean + se 
of the results for three animals. 
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Figure 5.21 Metabolism of GTN (10ng/m1 ) in suspensions of sheep liver 
(A Li) and lung (• C)) tissue with (closed symbols) and without 
(open symbols) added GDNs (each at 100 ng/ml). Control incubations 
( 11 0). Each point represents the nean of the results for two 
animals. 
20 
Time 	(min) 
Figure 5.22 • Mtabolism of GTN (10 ng/ml) in suspensions of sheep 
leg muscle ( • D) aorta ( A ) and vena cave (y v) tissues 
with (closed symbols) and without (open symbols) added GDNs (each 
100 ng/rn1) . Control incubations ( 	0 ) . Each point represents 
the mean of the reults for two animals. 
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Table 5.11 Percentage a of nitroglycerin (GTN) and its metabolites (GMNs, 1, 3-GDN and 1, 2-GDN) 
in sheep tissue homogenates after incubation for 30 minutes and the effect of added 
unlabelled GDNs (each 100 ng/ml) on the metabolism of CTN. (Data presented as the 
mean + S. E., n = 3, for GTN 50 ng/ml but only the mean, n = 2 for GIN10 ng/ml). 
 
Initial 	Control 	Liver 	Lung 	Muscle 	Vena Cava 	Aorta 
Concentration 
(ng/ml) 	-GDN 	+GDN 	-GDN 	+GDN 	-GDN 	+GDN 	-GDN 	+GDN 	-GDN 	+GDN 	-GDN 	+GDN 
GT!T , 50 95.3 (0.85) 
96.1 
(0.65) 
2.7 
(0.53) 
58.2 
(1.5) 
41.5 
(0.5) 
72.4 
(1.3) 
69.1 
(2.2) 
80.8 
(1.5) 
73.8 
(2.2) 
87.7 
(1.8) 
85.3 
(1.2) 
88.7 
(1.3) 
1,3 -GDN 0 2.3 2.2 37.2 16.3 17.7 9.7 16.3 10.0 16.3 8.0 7.3 5.9 
(0.51) (0.48) (2.1) (1.2) (0.54) (1.0) (0.84) (0.9) (2.6) (1.0) (0.58) (1.1) 
1,2 --GDN 2.3 1.7 52.7 25.4 38.0 17.3 13.7 9.1 10.1 4.1 7.1 5.4 
0.61) (0.51) (1.8) (0.82) (1.2) (0.98) (0.81) (1.3) (1.4) (1.0) (1.0) (0.83) 
avnis 0 0 0 7.1 0.12 2.1 0.86 0.31 0 0 0 0 0 
(0.81) (0.08) (0.04) (0.04) (0.09) 
GTN 10 94.9 95.1 2.4 56.5 41.2 73.0 68.0 80.7 73.6 84.7 83.6 87.7 
1,3-MN 0 3.1 3.0 36.8 14.0 17.3 10.4 16.3 11.1 14.9 10.5 8.2 6.0 
1,2-GDN 0 2.0 1.8 53.3 28.9 40.0 15.8 15.0 8.4 11.3 4.7 8.2 6.1 
oANs 0 0 0 6.9 0.30 1.9 0.75 0.48 0 0 0 0 0 
aexpressed as the percentage of the total radioactivity injected into the HPLC column. 
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Figure 5.23 Metabolism of ASA (50 pg/m1) in suspensions of sheep 
liver (AL z ), leg muscle ( II 0 ) and lung (41, 0) tissue with 
(closed symbols) and without (open symbols) added SA (50 jig/m1). 
Control incubations ( lIN7 ). Each point represents the mean + se 
of the results for three animals. 
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Figure 5.24 Metabolism of ASA (5 pg/ml) in suspensions of sheep 
liver (AL 	), leg muscle (11 0) and lung • 0 ) tissue with 
(closed symbols) and without (open symbols) added SA (50 pg/ml). 
Control incubations (1I V). Each point represents the mean + se 
of the results for three animals. 
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Table 5.12 Percentage a of aspirin (ASA) and its metabolite (salicylic acid, SA) in sheep tissue 
homogenates after incubation for 90 min and the effect of added SA (50 ug/m1) on the 
metabolism of ASA (Mean (+ S.E.) n = 3). 
 
	
Initial 	Control 	Liver 	Lung 	Muscle 
ASA 
concentration 
• (ug/m1) 	-SA 	+SA 	-SA 	+SA 	-SA 	+SA 	-SA 	+SA 
50 99.7 99.7 10.3 9.6 68.3 64.4 59.3 58.0 
(0.1) (0.1) (1.0) (0.8) (1.8) (1.6) (1.1) (1.2) 
0 88.9 31.3 40.1 
(1.1) (0.8) (0.7) 
99.8 99.7 11.3 11.2 64.3 63.8 57.2 59.1 
(0.1) (0.2) (1.0) (0.7) (1.7) (1.4) (1.9) (1.0) 
0 86.0 36.0 42.9 
(0.3) (0.9) (1.3) 
aexpressed as the percentage of ASA mass equivalents. 
bonly calculated for those samples not containing initial SA concentration of 50 pg/ml. 
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losses of GTN are observed in each of the homogenates studied - sheep 
liver, lung, leg muscle, vena cava and aorta. Metabolism of GTN to 
GDNs accounted for most of the loss (Table 5.11). Detectable amounts 
of GMNS were produced in liver, lung and muscle homogenates (Table 
5.11). The rates of GTN loss from tissue homogenates appeared to be 
independent of the GTN initial concentrations employed (Figures 5.19 
to 5.22). 
The presence of 1,3-GDN and 1,2-GDN each at concentrations of 
about 100 ng/ml greatly reduced the rate of GTN metabolism by all 
tissue homogenates for both initial GTN concentrations studied 
(Figures 5.19 to 5.22, Table 5.11). 
5.4. IN VITRO METABOLISM OF ASPIRIN IN SHEEP TISSUES  
ASA was lost from homogenates of sheep liver, lung and leg muscle 
stored at 37 °C with metabolism of ASA to SA quantitatively accounting 
(except for a small percentage in liver homogenates) for all ASA lost 
(Table 5.12). Figures 5.23 and 5.24 and Table 5.12 show that the rate 
of ASA loss in any given tissue appeared to be independent of the 
initial ASA concentrations employed. 
The presence of SA added at a concentration of 50 ug/m1 had 
negligible effect on the rate at which tissue homogenates metabolized 
ASA (Figures 5.23 and 5.24 and Table 5.12). 
5.5. PHARMACOKINETICS AND PHARMACODYNAMICS OF BOLUS DOSES  
OF NITROGLYCERIN IN SHEEP  
Simulated experiments showed that neither GTN nor its metabolites 
were sorbed by the - plastic catheters used in these studies (Table 
5.13). 
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Table 5.13 
	Recoveries of labelled glyceryl nitrates after 
passage through plastic catheters. 
Drug Drug 
Concentration 
(ng/ml) 
Flow 
Rate 
(ml/min) 
% Recovery 
(n = 1) 
GTN 1.2 5 98.4 
40 99.7 
1, 3-GDN 6.3 40 99.6 
1, 2-GDN 7.8 40 100.3 
GMNs 7.3 40 99.8 
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Figure 5.25 Plasma GTN concentrations in blood sampled from a 
femoral artery of sheep after bolus doses of GTN administered 
into the right femoral vein. (()) 2.7 pg/kg; (A) 5.4 pg/kg; 
(0) 13.6 pg/kg; (v) 27.2 pg/kg; (II) 54.4 pg/kg; (A) 108.8 pg/kg. 
Each point represents the mean + se of the results for three sheep. 
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Figure 5.26 PLasma GTN concentrations in blood sampled from 
the right femoral vein of sheep after bolus doses of GTN admin-
istered into the left femoral vein. (0) 2.7 ug/kg; (A) 5.4 
pg/kg; (0) 13.6 pg/kg; (v) 27.2 pg/kg; (II) 54.4 pg/kg and 
(A) 108.8 pg/kg. Each point represents the mean + se of the 
results for three sheep. 
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Individual data for arterial and venous plasma GTN levels in 
three sheep that received bolus doses of GTN are presented in Tables 
A4 to A6. Mean data are presented in Figures 5.25 and 5.26. In both 
arterial and venous plasma, GTN concentrations decreased in a bi-
exponential manner. The terminal half-lives showed an increase at the 
larger doses of GTN administered (Table 5.14). Figure 5.27 shows that 
peak GTN concentrations in arterial plasma increase proportionately 
with increasing dose of GTN; however, Figure 5.27 shows a dispropor-
tionate increase in peak venous plasma GTN concentrations with 
increasing doses of GTN. The dose dependence of plasma GTN concen-
trations is emphasized in Figure 5.28 which shows a relatively linear 
increase in the AUC for GTN in arterial plasma but a pronounced non-
linear increase in the AUG for GTN in venous plasma. At the larger 
GTN doses the AUC for GTN in venous plasma exceeds that in arterial 
plasma (Figure 5.28) and this is emphasized in Table 5.14 where the 
venous availability (Fvenous = AUCvenous /AUCarterial) increases with 
increasing dose of GTN. As the dose of GTN is increased, the intrin-
sic clearance of GTN in the leg and the mean residence time of the 
drug in the leg decrease (Table 5.14). 
Systemic clearance values for GTN in arterial and venous plasma 
are presented in Table 5.15 where it is evident that the arterial 
clearance, although variable, shows little overall reduction with 
increasing GTN dose. However, the venous systemic clearance shows a 
marked reduction for the two largest doses of GTN. 
Individual data for peak % reductions in mean arterial blood 
pressure and mean left ventricular pressure in the same three sheep as 
above are presented as log GTN dose - response curves in Figures 5.29 
and 5.30 (and Table A7) along with individual points to show that 
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Figure 5.27 The relationship between bolus GTN doses and peak arterial (()) and venous (10) plasma 
GTN concentrations. Each point represents the mean + se of the results for three sheep. 
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Figure 5.28 The relationship between bolus GTN doses and the area under the arterial (()) and 
venous (0) plasma GTN concentration-time profiles (AUC). Each point represents the mean + se 
of the results for three sheep. 
Table 5.14 	Pharmacokinetic parameters of nitroglycerin (GTN) after bolus doses in sheep Mean + SE, n=3) 
Dose 	Availability 	Intrinsic 	Mean 	Venous a 	Arterial a 
(mg / kg) Across Leg Clearance Across Residence Half-life Half-life 
Leg (1/min) 	Time (min) 	(min) (nin) 
2.7 
5.4 0.21 + 0.03 2.70 + 0.63 1.16 + 0.19 1.13 + 0.33 
1.13 + 0.17 
1.10 + 0.35 
13.6 0.29 + 0.02 l.68± 0.23 1.10 + 0.12 1.73 + 0.32 1.80 + 0.31 
27.2 0.35 + 0.12 1.61 + 0.57 0.95 + 0.29 2.13.+ 0.17 2.30 + 0.35 
54.4 0.70 + 0.10 0.34 + 0.18 0.46 + 0.20 2.07 + 0.26 2.13 + 0.23 
C 108.8 1.04 + 0.27 0.16 + 0.16 0.70 + 0.16 3.20 + 0.47 2.77 + 0.35 
aCalculated from the terminal phase of log GTN concentration-time profiles where detectability limits allowed. 
bInsufficient data because of venous nlasma GTN concentration detectahility limits. cSignificantly different from the results obtained for the smallest dose administered. 
Table 5.15  Systemic clpArances ( calculated as dose/AUC) 
of nitroglycerin after bolus doses in Sheep 13, 14 and 15. 
( Mean + SE ). 
Dose 
ugAg) 
Systemic 
Arterial 
Clearance 
(1/min) 
Systemic 
Venous 
Clearance 
(1/min) 
2.7 9.43 + 1.18 _a 
5.4 5.90 + 0.61b 29.51 + 5.30 
13.6 8.50 + 1.44 30.28 + 6.83 
27.2 9.40 + 0.91 31.74 + 6.40 
54.4 5.93 + 0.39b 8.71 + 1.04b 
108.8 5.86 + 0.56b 6.42 + 2.07b 
aPlasma data did not allow calculation of AUC. 
bSignificantly different from the value for the smallest 
dose administered. 
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Figure 5.29 Log GTN dose-response curves for the effects of bolus 
doses of GTN on the mean arterial blood pressure (M7V140) of Sheep 13 (C)), 
14 (Li) and 15 (0). The mean + se of the results for the three sheep 
is also plotted (). 
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Figure 5.30 Log GTN dose-response curves for the effects of bolus doses 
of GTN on the mean left ventricular pressure (MP) of Sheep 13 (0), 
14 (A) and 15 (a. The mean + se of the results for the three sheep 
is also plotted •). 
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Figure 5.31 Relationship between the log of the peak arterial (open) 
and venous (closed symbol) plasma CTN concentration and the percent 
reduction in mean arterial blood pressure(C) •) and mean left vent-
ricular pressure (A A ) in sheep receiving bolus doses of GTN. 
Each point represents the mean of the results for 3 sheep. 
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Figure 5.32 Relationship between the log of the area under the arterial 
(open symbols) and venous (closed symbols) plasma GIN concentration-time 
curves (AUC), and the percent reduction in mean arterial blood pressure 
( C) II) and mean left ventricular pressure (A Al.) in sheep receiving 
bolus doses of GIN. Each point represents the mean of the results for 
3 sheep. 
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Figure 5.33 Log GTN dose-response curves for the effects of bolus 
doses of GTN on the duration of reduction in mean arterial blood 
pressure (()) and on cardiac output (A) in Sheep 13, 14 and 15. 
Each point represents the mean + se of the results. 
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there were no discernible differences in responses to GTN for dif-
ferent dosing sequences. Two sheep (0 ) received serially 
increasing doses of GTN while one sheep (o) received doses in a random 
fashion. 
Relationships between % reduction in mean arterial blood pressure 
and left ventricular pressure versus the log of the peak arterial and 
peak venous plasma GTN concentrations are seen in Figure 5.31. Simi-
lar relationships are seen in Figure 5.32 for GTN plasma AUCs. 
Figure 5.33 (and Table A8) shows that increasing bolus doses of 
GTN result in a greater duration of reduction in mean arterial blood 
pressure (i.e., time for blood pressure to return from maximal reduc-
tion to baseline). When these results are studied along with the 
results presented in Figure 5.29, it is evident that increasing bolus 
doses of GTN result in greater reductions in mean arterial blood pres-
sure which have a longer duration of depression. Both of these 
effects are also associated with changes in cardiac output (Figure 
5.33). Small bolus doses of GTN caused a slight increase in cardiac 
output but the larger doses resulted in the cardiac output falling. 
The duration of the fall in cardiac output was always less than the 
duration of the fall in blood pressure. 
5.6. PHARMACOKINETICS AND PHARMACODYNAMICS OF NITROGLYCERIN 
AFTER CONTINUOUS INFUSIONS IN SHEEP  
5.6.1. Nitroglycerin Kinetics and Dose-Response Relationships  
Tables A9 to A17 and Figures 5.34, 5.35 and 5.36 present indi-
vidual and mean data respectively for plasma GTN concentrations in 
blood samples taken from different sites in the sheep receiving con- 
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Figure 5.36 Plasma GTN concentration-time profiles after continuous 
infusions of GTN into the right femoral vein of Sheep 18, 19 and 20. 
(A) pulmonary artery; (A) left ventricle; (C)) femoral artery; 
(• left femoral vein; (0) portal vein; (II) hepatic vein. Each 
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Table 5.16 Pharmacokinetic parameters of nitroglycerin mo after continuous 
. intravenous infusions in sheep (Mean + SE, n=3). 
GTN Infusion 	Availability 	Intrinsic Clearance (1/Min) 	Mean Residence Time (nth') Terminal a 
Rate Half-life 
(pig/min/kg) 	leg 	lung 	liver 	leg 	lung 	liver, 	leg 	lung 	liver 	(ITULn) 
	
0.4 	0.12 	0.58 	0.13 	4.07 	4.14 	10.6 	3.57 	0.16 	10.0 
± 0.02 ± 0 . 05 	± 0 . 03 +0.53 +0.76 	+ 3.6 ±1.18 ±0.12 	+ 3.9 _ 	_ 
5.7 	0.17 	0.72b 0.31b 3.18 	2.40b 370b 	1.68 	0.07 . 
+ 0.02 +0.02 	+0.03 	+0.33 +0.13 	+0.88 	+1.00 +0.08 
3.02 
+ 0.19 
.. .
• 22.1 	0 	0 49b .29b 0.53 	1.64b 	5.41 	190b 024b 0.95 	0 3.58 + 0.04 +0.04 	+0.09 	+ 0.17 -1-1.06 	+ 0.48 	+0.09 0 	+0.08 	+0.33 _ _ _ _ 	_ 	_ 	_ 	_ _ 
Calculated fram the terminal phase of log GTN concentration-time profiles where detectability limits allowed. 
Significantly different from the values for the smallest dose administered. 
Insufficient data because of venous plasma (TN concentration detectability limits. 
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tinuous IV infusions of GTN at rates of 0.4, 5.7 and 22.1 ug/min/kg. 
For each infusion rate studied, apparent steady-state plasma GTN 
concentrations were generally achieved within 20 min of the commence-
ment of GTN infusion (Figures 5.34 to 5.36). 
There was an approximate linear relationship between the GTN 
infusion rate and the apparent steady-state plasma GTN concentration 
in blood samples taken from all sampling sites (Figure 5.37). This 
relationship is translated into an approximate linear increase in 
plasma AUCs (Figure 5.38). 
On termination of an infusion, femoral venous and arterial plasma 
concentrations fell rapidly in a bi-exponential manner. The two 
phases are evident in Figures 5.35 and 5.36 but not in Figure 5.34 
where the plasma GTN concentrations fell rapidly below detectable 
limits (0.2 ng/ml). The terminal half-life, when measurable, was 
found to be 3-4 min (Table 5.16). 
The GTN concentration in the plasma of blood leaving an organ 
(i.e., hepatic vein, left ventricle, femoral vein) was substantially 
less than that in the plasma of blood entering the organ (i.e., portal 
vein, pulmonary artery, femoral artery) (Figures 5.34 to 5.36). 
Losses of GTN during passage through each organ were in the rank order 
hind-leg>liver>lung. This is also evident from Table 5.16 which shows 
that the availability (calculated as the ratio of AUCS of plasma GTN 
concentrations leaving an organ to those entering the organ) is in the 
same rank order. 
Table 5.16 also shows that the intrinsic clearance for a given 
vascular bed varies from organ to organ for each infusion rate. At 
greater GTN infusion rates, the availability of GTN across the leg and 
liver appears to increase. A concomitant decrease in the clearance of 
325- 
300- 
275- 
250- 
-g 
a+ 
225- 
200- 
cu 
C. 175- 
1- 150 
in 125 
100 
75 
50 
25 
6 	12 
	
18 
	
24 
Rate of GIN Infusion 	(Jag /min /kg) 
Figure 5.37 Apparent steady-state plasma CTN concentrations 
resulting from continuous intravenous infusions of GTN in sheep. 
(A) pulmonary artery; (A) left ventricle; (0) femoral artery; 
(0) femoral vein; (0) portal vein; (II) hepatic vein. Each 
point represents the mean + se of the results for 3 sheep. 
E 
cn 
L.) 
ro 
E 
tn 
ro 
6000- 
5000- 
4000- 
3000- 
20 00- 
1000- 
4 	16 	20 	214 
GIN Infusion Rate (Lig/min/kg) 
Figure 5.38 Plasna AUCs for GTN resulting from continuous 
intravenous infusions of GIN in sheep. (0) fernorafartery; 
(ID) femoral vein. Each point represents the mean + se of 
the results for 3 sheep. 
4 - 
8 
= 
12- 
l'o 0s 	1 510 	100 	200 
16- 
Steady State Plasma GIN Concentration 	(ng I ml 
Figure 5.39 Relationship between the log of the apparent steady state 
arterial (0) and venous (I) plasma GTN concentrations and the percent 
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GTN across the leg and liver is observed at the higher doses whereas 
the availability and clearance of GTN in the lung is increased and 
decreased, respectively, at the middle GTN dose (Table 5.16). Mean 
residence times of GTN in leg, lung and liver all decrease with 
increasing doses of GTN (Table 5.16). Systemic clearances calculated 
using arterial plasma GTN concentrations were much less than those 
calculated for venous plasma data (Table 5.18). 
Figures 5.39 and 5.40 show the relationship between log peak GTN 
plasma concentrations and % reduction in MABP, and log GTN plasma AUC 
and % reduction in MABP for continuous GTN infusions. Figure 5.41 and 
Table A52 show that increasing the dose (or rate of administration) of 
GTN results in a greater reduction in MABP and a greater increase in 
cardiac output. 
5.6.2 Effect of Glyceryl Dinitrates on Nitroglycerin Pharmacokinetics  
Bolus doses of GDNs (5 mg total of 1,3-GDN and 1,2-GDN) had a 
marked effect on the pharmacokinetics of GTN in two sheep receiving 
continuous IV infusions of GTN at a rate of 5.7 ig/min/kg (Figures 
5.42 and 5.43 and Tables A18 and A19). It can be seen that the venous 
plasma GTN concentrations are greater than the arterial plasma GTN 
concentrations after administration of 5 mg GDNs in the post-infusion 
stage. In sheep receiving the same dose of GTN without a bolus dose 
of GDNs being administered (Figure 5.35) the profile of venous plasma 
GTN concentrations is always less than or equal to the arterial pro-
file after termination of the GTN infusion. Figures 5.42 and 5.43 
also show that the terminal phases of GTN kinetics is extended after 
GDN dosing (Table 5.17) (6-10 min after GDNs compared to about 3 min 
without GDNs). 
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tigure 5.42 The effects of a bolus dose of GDNs ( 5 mg total of 
l,3-GDN and 1,2-GDN ) on the pharmacokinetics of GTN in Sheep 29 
receiving a continuous intravenous infusion of cu. (A) pulmonary 
artery; (A) left ventricle; (CD) femoral artery; (•) left femoral 
vein; (0) portal vein; (II) hepatic vein. 
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Figure 5.43 The effects of a bolus dose of GDNs ( 5 mg total of 
1,3-GDN and 1,2-GDN ) on the pharmacokinetics of GTN in Sheep 30 
receiving a continuous intravenous infusion of GTN. (A) pulmonary 
artery; (A) left ventricle; (0) femoral artery; (•) left femoral 
vein; (0) portal vein; (II) hepatic vein. 
Table 5.17 	Effect of glyceryl dinitrates (GIR) on the pharmacokinetics of 
nitroglycerin mo after continuous intravenous infusions of GTN in sheep., 
GTN Infusion 
. Rate 
(pg/min/kg) 
Availability Intrinsic Clearance 	Mean Residence Time 
(1/min) - 
Terminal a 
Half-life 
(mm) 
5.7 0.20 2.55 3.65 2.65 
0.14 3.31 0.47 3.10 
0.16 3.67 0.93 3.30 
5.7 + 5 mg GDN 0.26 1.61 11.90 10.00 
0.28 1.54 7.21 6.25 
aCalculated from the terminal phase of log GIN venous plasma concentration-time profiles. 
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Table 5.18 Individual systemic clearances (calculated as 
dose/AUC) of nitroglycerin (GTN) after continu-
ous intravenous infusions in sheep. 
 
GTN Infusion rate 	Systemic arterial 	Systemic venous 
clearance clearance 
(pg/min/kg) (1/min) (1/min) 
0.4 	 3.2 	21.0 
	
7.0 71.8 
4.7 32.6 
5.7 	 2.7 	13.3 
2.3 16.2 
2.9 20.7 
5.7 + 5 mg GDN Bolus 	2.1 	10.5 
2.5 8.8 
22.1 	 5.4 21.2 
5.5 	15.0 
4.0 16.3 
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Table 5.17 shows that the availability of GTN in the leg in-
creases after the administration of GDNs (average availability without 
GDNs is 0.17, average availability after, GDNs is 0.27) and the 
intrinsic clearance of GTN in the leg is concomitantly reduced 
(average without GDNs is 3.2 1/min, average after GDNs is 1.6 1/min). 
The mean residence time of GTN in the leg is also markedly changed 
after GDN dosing (average 1.7 min without GDNs, average 9.5 min after 
GDNs). 
The average systemic arterial clearance of GTN is only marginally 
reduced after GDNs (2.6 1/min without GDNs, 2.3 1/min after GDNs) how-
ever, the average systemic venous clearance of GTN was greatly reduced 
after treatment with GDNs (16.7 1/min without GDNs, 9.6 1/min after 
GDNs) (Table 5.18). 
5.6.3. Glyceryl Di- and Mononitrate Pharmacokinetics  
In two of the GTN infusions at 0.4 pg/min/kg, 3H-GTN was employed 
to enable monitoring of the plasma concentration time profiles of GDNs 
and GMNs. Figure 5.44 and Tables A20 and A21 show that the ratio of 
formed 1,2-GDN to 1,3-GDN is approximately 2:1 in both femoral ar-
terial and venous plasma samples. As found for GTN, an arterial-
venous difference in plasma GDN concentrations was apparent. However, 
the difference is smaller than found for GTN (Figure 5.34). The 
arterial concentrations of GDN were greater than the venous con-
centrations during the infusion of GTN. On cessation of infusion, the 
arterial concentrations of GDN fell below the venous concentrations 
(Figure 5.44 and Tables A20 and A21). The average availabilities for 
1,3-GDN and 1,2-GDN were 0.895 and 0.89, respectively (Table 5.19). 
The intrinsic clearance of the 1,3-GDN and 1,2-GDN (calculated using 
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Figure 5.46 Time course of plasma 1,3-GDN ( L A) and 1,2-GDN ( 0 II) 
concentrations in the pulmonary artery (open symbols) and left ventricle 
(closed symbols) of Sheep 16 (a) and Sheep 17 (b) receiving continuous 
intravenous infusions of radio-labelled GTN. 
Table 5.19 	Pharmacokinetic parameters of glyceryl dinitrates (a2) formed during 
nitroglycerin infusions (0.4 pg/min/kg) in 2 sheep. 
Drug Availability 	Intrinsic Clearance 	Mean Residence Time 	Terminal a 
(1/min) (mial) 	Half-life 
leg 	lung 	liver 	leg 	lung 	liver 	leg 	lung liver 	(min) 
1,3-GDN 0.09 1.20 0.83 0.024 0.109 12.9 43.5 
0.89 1.33 0.86 0.034 0.117 11.3 5.2 39.7 
1,2-GDN 0.91 1.15 0.88 0.024 0.084 8.0 35.0 
0.87 1.29 0.87 0.048 0.123 9.2 0 34.5 
aCalculated from the terminal phase of log GDN venous plasma concentration-time profiles. 
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Figure 5.47 Time course of plasma GMN concentrations in a femoral 
artery (open symbols) and the left ventricle (closed symbols) of 
Sheep 16 ( 	and Sheep 17 (C) •) receiving continuous intra- 
venous infusions of radio-labelled GTN. 
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Figure 5.48 Time course of plasma GMN concentrations in blood entering 
and leaving (a) the liver (open symbols, portal vein; closed symbols, 
hepatic vein) and m the lungs (open symbols, pulmonary artery; closed 
symbols, left ventricle) of Sheep 16 (A 	) and Sheep 17 (0 •) 
receiving continuous intravenous infusions of radio-labelled GTN. 
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fu values of 0.89 and 0.77 respectively) averaged 0.029 and 0.036 
1/min respectively. Mean residence times in the leg for 1,3-GDN and 
1,2-GDN are 12.1 min and 8.6 min, respectively (Table 5.19). The 
half-lives of the terminal phase of the decay of plasma 1,3-GDN and 
1,2-GDN plasma concentrations are about 35 min and 39 min respectively 
(Figure 5.44). 
Figures 5.45 and 5.46 and Tables A20 and A21 show plasma GDN con-
centrations in blood entering and leaving the liver and lungs. The 
concentrations of GDN in blood leaving the lungs (left ventricle) 
exceed that in the pulmonary artery (Figure 5.46) giving availabi-
lities for the GDNs across the lungs greater than unity (Table 5.19). 
As GMNs continued to be formed at the conclusion of each study, it was 
not possible to obtain AUCs and therefore availabilities for those 
compounds. Figure 5.47 and Tables A22 and A23 show that an arteral-
venous difference in plasma CNN concentrations exists across the leg 
during the infusion of GTN. This difference gradually decreases as 
the plasma concentrations of GMNs increase and eventually at about 
80-120 min the concentration of GMNs in venous plasma exceeds that in 
the arterial plasma (Figure 5.47). Across the liver, the portal vein 
GMN concentrations exceeded the hepatic vein CNN concentrations at all 
times studied (Figure 5.48 (a)). The concentrations of GMNs in the 
pulmonary artery and left ventricle fluctuated but were similar over 
the time of blood sampling (Figure 5.48 (b)). 
The total radioactivity recovered in the fractions of the HPLC 
effluent corresponding to GTN, GDNs and GMNs accounted for more than 
96% of the total radioactivity in plasma injected into the HPLC 
column, indicating that little, if any, of the label was present as 
glycerol or a conjugated metabolite. 
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5.7. SALICYLATE PHARMACOKINETICS AFTER ASPIRIN INFUSIONS IN SHEEP 
5.7.1. Aspirin, Salicylic Acid and Salicyluric Acid Pharmacokinetics  
Plasma concentrations of total ASA and SA in arterial and venous 
samples from four sheep receiving 485 pg ASA/min/kg are shown in 
Figure 5.49 and Tables A24 to A27. An arterio-venous difference 
exists for both ASA and SA during the ASA infusion but is more pro-
nounced for ASA than for SA. At later times after the termination of 
the infusion the venous levels of ASA and SA are slightly greater than 
the arterial levels (Figure 5.49). Figure 5.50 and Tables A28 to A31 
show corresponding free ASA and SA concentrations and f u in two of the 
same four sheep. It can be seen that the fu of ASA is 0.55-0.75 while 
that of SA is about 0.3. Total and free SU levels for the same two 
sheep are shown in Figure 5.51 a, b and Table A32. The unbound frac-
tion of SU in venous and arterial plasma is plotted against time in 
Figure 5.52 (a,b) and is seen to be 0.30-0.35 for the two sheep 
studied. 
Plasma total ASA and SA concentrations in blood samples taken 
from portal and hepatic veins (i.e., across the liver) for the four 
sheep receiving 485 pg ASA/min/kg are presented in Figure 5.53 and 
Tables A24 to A27. At all times studied the ASA and SA concentrations 
in the portal blood exceeded that in the hepatic vein (Figure 5.53). 
In contrast, SU concentrations (Figure 5.54 (a) and (b) and Table A33) 
were always greater in the hepatic vein blood than in the portal vein 
blood. 
Figure 5.55 (and Tables A24 to A27) shows that the concentrations 
of ASA and SA across the lungs were often greater in venous blood than 
in arterial blood both during and after infusion of ASA. 
100 (b) (a) 
[ASA 485ug/min/kg1 !ASA 485ug/min/kg1 
(d) (c) 
1 
IASA 485ug/minikg1 IASA 485ug/min/kg1 
1 
50 
5 
10 
5 
0. 	  0 20 40 6.0 8'0 160 10 1'40 160 160 	0 20 40 do do 160 120 140 160 180 
Time (min) 
Figure 5.49 Femoral arterial (open symbols) and venous (closed 
symbols) plasma ASA (() •) and SA (11 	total concentration- 
time profiles for Sheep 23,(a); Sheep 24, (p); Sheep 25, (c); 
Sheep 28, (d) receiving continuous intravenous infusions of ASA. 
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Figure 5.50 Femoral arterial (open symbols) and venous (closed symbols) 
plasma ASA ( 0 •) and SA (A 	) free concentration-time profiles 
and free fraction-time profiles in 2 sheep receiving continuous intra-
venous ASA infusions. Sheep 25,(a) (b); Sheep 28, (c) (d). 
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Figure 5.51  FiErnoral arterial (open symbols) and venous (closed symbols) 
plasma total ( 0 • ) and free 0 • ) SU concentration-time profiles 
in sheep receiving continuous intravenous ASA infusions. 
Sheep 25, (a); Sheep 28, (b); Sheep 29, (c); Sheep 30, (d). 
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Figure 5.52 The time course of the free fraction of SU in femoral 
arterial (open symbols) and venous (closed symbols) plasma during 
continuous intravenous infusions of ASA in Sheep 25, (a); Sheep 28,(b) 
and Sheep 29, (c). 
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Figure 5.53 Portal vein (open symbols) and hepatic vein (closed 
symbols) plasma ASA ( C) • ) and SA ( 	) total concentration-time 
profiles for Sheep 23, (a); Sheep 24, (b); Sheep 25, (c); Sheep 28, (d) 
receiving continuous intravenous infusions of ASA. 
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Figure 5.54 Portal vein (open symbols) and hepatic vein (closed symbols) 
plasma SU concentration-time profiles for Sheep 25, (a); Sheep 28, (b); 
Sheep 29, (c) and Sheep 30, (d) receiving continuous intravenous infusions 
of ASA. 
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Figure 5.55 Pulmonary artery (open symbols) and left ventricle (closed 
symbols) plasma ASA (C) •) and SA ( i A) concentration-time profiles 
for Sheep 23, (a); Sheep 24, (b); Sheep 25, (c) and Sheep 28, (d) 
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5.7.2. Effect of Salicylic Acid on Aspirin Pharmacokinetics  
Figures 5.56 and 5.57 and Tables A34 to A45 show plasma levels of 
total and free ASA and SA in the arterial and venous blood of four 
sheep receiving 61 ug ASA/min/kg. In three of the sheep (Figures 5.56 
and 5.57 (b), (c), (d)), bolus doses (1 per sheep) of 30, 300 and 1200 
mg SA were given at the 50th minute of ASA infusion. Addition of SA 
appeared to have no effect on the magnitude of the arterial-venous 
differences in total and free ASA concentrations in any of the 
animals. However, the rate of elimination of ASA on termination of 
the ASA infusion was faster in the sheep receiving the 1200 mg SA 
bolus dose (half-life of elimination approximately 17 min for total 
ASA concentrations) than in the other sheep (half-lives of elimination 
approximately 22 to 32 min for total ASA concentrations). In the 
sheep receiving 1200 mg SA the plasma protein binding of ASA changed 
on administration of the SA (Figure 5.58 (d)), whereas the fraction of 
salicylate unbound in the other sheep was not noticeably affected by 
the administration of smaller bolus doses of SA (Figure 5.58 (b), 
(c)). 
The elimination of SA in the sheep that received the 1200 mg 
bolus dose of SA was slower than in the other three sheep (Figures 
5.56 and 5.57 (a), (b), (c), (d)). 
Total and free SU concentrations across the hind-leg of two sheep 
receiving ASA infusions at 61 ug/min/kg are shown in Figure 5.51 (c), 
(d) and Table A32. An apparent initial arterial-venous difference in 
SU plasma concentrations was diminished with time. Figure 5.52 (c) 
shows that a 1200 mg bolus dose of SA probably increased the unbound 
fraction of SU temporarily, however, this interpretation is made 
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Figure 5.58 The tine course of the free fraction of AS A ( 0 • ) 
and SA ( A • ) in fenoral arterial (open symbols) and venous (closed 
symbols) plasma of Sheep 30, (a); Sheep 27, (b); Sheep 26, (c) and 
Sheep 29, (d) receiving continuous intravenous infusions of ASA with 
and without a bolus dose of SA. 
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Table 	5.20 	Comparison of aspirin pharmacokinetic parameters using total and free 
aspirin plasma concentrations. 
Total 	ASA Free 	ASA 
Infusion Bolus Availability Intrinsic Mean Availability Intrinsic Mean 
Rate Dose across clearance Residence across Clearance Residence 
SA leg across leg Time leg across leg Time 
(pg/min/kg) (mg) (1/min) (min) (1/min) (min) 
61 0 0.79 0.135 4.4 0.88 0.072 4.2 
61 • 	30 0.69 0.257 9.6 0.73 0.214 8.7 
61 300 0.92 0.054 2.9 0.95 0.032 7.5 
61 1200 0.82 0.050 3.0 0.86 0.037 4.1 
485 0 0.91 0.027 3.1 0.81 0.063 5.8 
485 0 0.85 0.053 5.2 0.81 0.070 9.7 
Table 	5.21 	Pharmacokinetic parameters of aspirin (ASA) after continuous intravenous 
infusions in sheep. (Mean + SE, n=4). 
	
ASA Infusion 	Availability 	 Intrinsic 	 Mean Residence 
Rate Clearance Time 
(pg/min/kg) 	 (1/min) 	 (min) 
leg lung liver leg lung liver leg lung liver 
0.80 0.96 0.77 0.12 0.16 0.35 4.97 0.72 1.32 
61 + 0.06 + 0.03 + 0.01 + 0.06 + 0.06 + 0.08 + 1.86 + 0.85 + 0.90 
485 0.86 1.00 0.72 0.05 0.02 0.28 3.71 0.37 1.83 
+ 0.06 + 0.01 + 0.03 + 0.02 + 0.02 + 0.04 + 1.01 + 0.20 + 1.29 
- Table 5.22 	Individual systemic clearances ( calculated as dose/AUC) and terminal 
. half-lives of aspirin ( ASA ) after continuous intravenous infusions in sheep. 
ASA Infusion Salicylic Acid Systemic Arterial Systemic Venous Terminal a 
Rate Bolus Dose Clearance Clearance Half-life 
(pg/min/kg) (mg) . 	(1/min) (1/min) (min) 
61 0 0.32 0.41 27.2 
30 0.18 0.26 31.5 
300 0.22 0.24 22.5 
1200 0.44 0.54 16.8 
485 0 0.30 0.42 28.5 
0 0.23 0.24 22.5 
0 0.20 0.22 26.2 
0 0.25 0.29 32.5 
a Calculated from the terminal phase of log total ASA venous plasma concentration-time profiles. 
Table 	5.23 	Pharmacokinetic parameters of salicylic acid (SA) formed during aspirin (ASA) 
infusions at 61 pg/min/kg in 3 a sheep. (Mean ± S.E.) 
	
ASA Infusion 	Availability 	Intrinsic 	 Mean Residence 
Rate Clearance Time 
(pg/min/kg) (1/min) (min) 
leg 	lung 	liver 	leg 	lung 	liver 	leg 	lung 	liver.  
1.19 	1.05 	0.91 0.25 	0.73 	0.17 	0.30 
61 	+ 0.02 	+ 0.02 	+ 0.01 	 +0.04 + 0.76 	+0.17 	±0.30 
aAUCs for SA in the sheep receiving a bolus dose of 1200 mg SA were not 
calculated because of the non-linear elimination kinetics of SA at the 
plasma concentrations found in this study. 
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Figure 5.61 Apparent steady state femoral arterial (open symbols) 
and venous (closed symbols) plasma total ASA concentrations result- 
ing from continuous intravenous infusions of ASA in sheep. 
Each point represents the mean + se of the results for 4 sheep. 
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difficult by the fact that preceding the SA bolus dose, free SU 
concentrations were undetectable. 
Figure 5.59 (a) shows that the plasma concentrations of ASA and 
SA in the hepatic vein were less than those in the portal vein during 
and after ASA infusions. This difference was maintained after bolus 
doses of SA (Figure 5.59 (b), (c), (d) and Tables A37, A40 and A43). 
In contrast, Figure 5.60 and Tables A34, A37, A40 and A43 show no 
differences in ASA plasma concentrations in the pulmonary artery and 
left ventricle before or after bolus doses of SA. However, following 
SA bolus doses there was a consistent difference in plasma SA con-
centrations, those in the left ventricle being greater than those in 
the pulmonary artery. 
Plasma SU concentrations were always greater in the hepatic vein 
than in the portal vein during ASA infusions of 61 pg/min/kg and this 
difference was unaffected by a 1200 mg bolus dose of SA (Figure 
5.54 (c), (d) and Table A33). 
5.7.3. Salicylate Kinetics in Relation to Dose  
For the two ASA infusion rates studied, apparent steady-state 
plasma ASA concentrations were generally achieved within 60 min of the 
commencement of ASA infusion. A linear relationship appears to exist 
between the rate of infusion of ASA and its apparent steady-state 
concentration in femoral venous and arterial plasma (Figure 5.61). 
Tables 5.20, 5.21 and 5.22 show that the total clearance and other 
pharmacokinetic data derived for ASA appear to be independent of ASA 
dose or presence of added SA. Some pharmacokinetic parameters derived 
for SA are presented in Table 5.23. These data were derived only for 
ASA infusions of 61 pg/min/kg because the SA formed upon ASA infusions 
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at a rate of 485 pg/min/kg had only just reached a plateau by the end 
of the blood sampling times. 
5.8 PHARMACOKINETICS AND PHARMACODYNAMICS OF SALICYLATES IN MAN  
5.8.1. Single Dose Study  
Plasma ASA and SA Concentrations  
Figures 5.62 (a) and 5.63 (a) show the mean ASA and SA concen-
trations after ingestion of the soluble and the slow-release ASA. 
Figure 5.64 (a) shows the mean SA concentrations after ingestion of an 
equivalent dose of sodium salicylate. ASA was absorbed much more 
slowly from the slow-release formulation than from the soluble product 
which is evident from the longer peak concentration times and lower 
plasma ASA concentrations for the slow-release product. The times to 
reach peak ASA and SA concentrations were 3.33 ± 0.55 and 4.38 ± 0.29 
hr for the slow-release formulation and 0.38 ± 0.04 and 0.91 ± 0.16 hr 
for the soluble formulation, respectively. The mean peak ASA concen-
tration for the slow-release product (0.61 ± 0.22 pg/ml) was one-sixth 
that achieved for the soluble form (3.65 ± 0.81 pg/ml). In two sub-
jects taking the slow-release preparation, no ASA was detectable (<0.1 
pg/ml) in the plasma. 
The area under the plasma ASA concentration-time curve was less 
for the slow-release formulation (0.79 ± 0.26 pg.hr/m1) than for the 
soluble product (2.84 ± 0.40 pg.hr/m1). However, the differences in 
area do not result from differences in absorption as the area under 
the metabolite (salicylate) concentration-time curve was similar for 
the slow-release (39.45 ± 4.0 pg.hr/m1) and soluble (33.37 ± 
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Figure - 5:62 Plasma salicylate concentrations (a), extent of 
inhibition of MDA synthesis (b), and extent of inhibition of 
platelet aggregation .(c) following ingestion of a single 300 mg 
dose of soluble ASA by human volunteers. 
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(c)inhibition of platelet aggregation induced by adrenalin (0) 
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5.13 pg.hr/m1) dose forms (Figures 5.62 (a) and 5.63 (a)). A similar 
area (32.3 t 2.9 pg.hr/m1) under the plasma SA concentration-time 
curve was found after ingestion of the sodium salicylate mixture 
(Figure 5.64 (a)). 
Platelet Aggregation and MDA Production  
The maximum inhibition by ASA of platelet aggregation induced by 
collagen and adrenalin was 407. and 70% respectively. Figures 5.62 (b) 
and 5.63 (b) show mean inhibition of MDA production, and Figure 5.62 
(c) and 5.63 (c) show platelet aggregability after soluble and slow-
release ASA respectively. The inhibition of platelet aggregability 
and MDA production was not significantly different for each of the 
formulations. Both forms of ASA produced a prolonged inhibition of 
platelet function. Full recovery of platelet function occurred at 
5-10 days in all subjects (Figures 5.62 (b), (c); 5.63 (b)). An 
equimolar dose of sodium salicylate had no inhibitory effect either on 
MDA production or on platelet aggregation (Figures 5.64 (b), (c)). 
Figure 5.65 shows plots for the inhibition of MDA production in 
individual subjects and the corresponding peak ASA concentrations and 
ACUs. It is apparent that the peak ASA concentrations and AUCs vary 
considerably between subjects for both the soluble and slow-release 
formulations, and, in fact, no relationships are apparent. 
5.8.2. Continuous Dose Study 
Plasma ASA and SA Concentrations  
Plasma ASA concentrations were not detectable in any blood 
samples taken immediately before the last of any of the ASA doses 
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(trough sample) (Tables A46 to A51). Corresponding plasma (trough) SA 
concentrations were only detectable in one subject taking 650 mg ASA 
daily and in four subjects taking 1300 mg ASA, the maximum SA concen-
tration being 0.4 jig/mi. Table 5.24 shows the mean plasma ASA and SA 
concentrations in samples taken 3 hr after (peak) the last ASA dose. 
ASA was not detectable in any subject after the ingestion of the 20 mg 
dose and in only two subjects given the 50 mg dose. Only one subject 
(taking 20 mg ASA) had undetectable levels of plasma SA. The detect-
able plasma concentrations of ASA appeared to be directly related to 
the dose of the slow-release ASA formulation for doses between 100 and 
1300 mg (Table 5.24). 
Platelet Aggregation and MBA Production  
Figure 5.66 shows the log ASA dose-response curves for platelet 
aggregation in samples taken 3 hr after ingestion of the final slow-
release ASA dose. With collagen as the inducing agent the maximal 
inhibition of platelet aggregation by ASA was 40%. With adrenalin as 
the inducing agent, ASA inhibited only the second phase of aggrega-
tion. The maximum inhibition of AA-induced aggregation (of 100%) was 
achieved with all the doses of ASA used. However, to achieve a maxi-
mal inhibition of collagen or adrenalin-induced aggregation, doses of 
about 100-200 mg ASA were required. 
Figure 5.67 shows the log ASA dose-response curves for AA and NEM 
induced MBA production by platelets in samples taken 3 hr after inges-
tion of the final slow-release ASA dose. AA induced MBA production 
appeared to be maximally inhibited by 50 mg and above of the slow-
release ASA product. Doses of about 200 mg and above of the slow-
release product were required for maximal inhibition of NEM induced 
MBA production. The extent of inhibition of MBA production and 
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Figure 5.66 Dose-response curves for the effects of a slow-release 
ASA formulation on platelet aggregation induced by adrenalin (II), 
collagen (411) or arachidonic acid (A) after daily doses of ASA for 
7 days. Each point represents the mean + se of the results for 3-8 
volunteers. 
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Figure 5.67 Dose-response curves for the effects of a slow-release 
ASA formulation on platelet MDT production induced by N-ethylmaleimide 
(40) or arachidonic acid (II) after daily doses of ASA for 7 days. 
Each point represents the mean + se of the results for 3-8 volunteers. 
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Table 5 - 24 	Plasma concentrations of aspirin (ASA) and 
salicylate (SA) 3 hr after ingestion of the seventh daily 
dose of Astrix (Mean + SE, n=8). 
ASA 	 SA 
Dose 	Concentration 	Concentration 
(mg) (Pg/m1) (pg/m1) 
	
20 	< 0.1 	0.37 ± 0.09 
50 < 0.1 0.56 + 0.21 _ 
100 	0.15 + 0.07 	1.06 + 0.45 _ _ 
200 0.21 + 0.06 2.37 + 0.86 _ _
650 	0.68 + 0.26 	4.00 + 1.28 _
17.56 + 1300 1.51 + 0.50 4.81 _ _ 
Table 	5.25 Platelet function in blood samples taken immediately before the last dose 
(trough sample, T) and 3 hr after the last dose (peak sample, P) in subjects 
ingesting a slow release ASA formulation (Astrix) daily for one week. 
 
Dose 
(mg) 
% 	Inhibition 	of 	control 	(Mean + SE) 
Collagen induced 	MDA synthesis 
aggregation aggregation 
Adrenalin induced 
	
T 	P 	T 	P 	T 
20 	10.3 + 	3.6 11.2 + 3.8 6.7 + 2.5 5.6 + 1.9 41.5 4.8 23.0 + 6.0 
 
- _ - _ _ 
50 63.5 + 8.9 70.2 + 5.2 14.9 + 5.0 14.7 4.1 51.4 + 8.4 89.6 + 4.4 _ _ _ _ _
100 49.3 _ + 10.6 54.7 _ + 5.4 24.4 _ + 8.6 28.4 _ + 6.3 78.4 + _ 3.2 91.1 ± 3.2 
200 77.2 + _ 3.4 78.0 _ + 3.7 37.6 ± 3.7 43.4 _ + 5.1 83.4 ± 5.5 89.4 _ + 1.2 
650 53.2 _ + 4.8 56.7 _ + 8.0 29.0 ± 7.9 39.2 _ + 8.1 86.1 ± '1.7 97.2 _ + 0.8 
1300 65.7 + 4.4 66.7 + 3.4 37.5 + 7.1 47.9 + 7.8 87.8 + 2.0 95.0 + 1.7 _ _ _ _ _ _
Table 5.26 Platelet function in males (M) and females (F) for the blood samples taken 3 hr 
after the final daily dose of a slow release ASA formulation (Astrix) taken for 
one week. 
 
.Dose 	 % 	Inhibition 	of 	control 	(Mean + SE) 
(mg) 
Adrenalin induced 
aggregation Collagen induced aggregation MDA synthesis 
20 11.0 + 1.0 6.5 + 3.7 3.2 + 	2.2 8.0 + 3.0 28.3 + 	12.3 16.0 + 	9.9 
50 74.5 + 6.3 61.5 + 7.5 9.7 + 	4.3 21.3 + 6.3 86.0 + 6.7 94.7 + 	4.8 
100 43.0 + 	24.8 63.5 + 1.5 33.5 + 	12.2 23.3 + 4.0 86.0 + 4.9 96.2 + 	2.5 
200 76.7 + 4.0 79.3 + 6.9 41.0 + 	7.2 45.2 + 7.9 84.5 + 3.7 91.0 + 	0.91 
650 58.0 + 9.0 52.5 + 	14.6 46.0 + 	12.4 32.5 + 	10.8 97.0 + 0.8 97.5 + 	1.5 
/300 62.0 + _ 7.0 69.5 + 	6.6 50.5 + 	9.9 45.2 13.2 97.0 + 1.4 92.0 + 	4.0 
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platelet aggregation was similar in blood samples taken immediately 
before the last dose and 3 hr after the last dose (Table 5.25). No 
significant differences in platelet function between male and females 
were found for any of the slow-release doses used (Table 5.26). 
CHAPTER 
DISCUSSION 
6.1. ANALYTICAL TECHNIQUES  
6.1.1. Organic Nitrates  
Specificity  
Quantitation of GTN and its metabolites in biological fluids was 
found to be difficult. A high performance liquid chromatographic 
procedure based on the chromatographic conditions described by 
Crouthamel and Dorsch (1979) was suitable for high (supra-therapeutic) 
concentrations of GTN and its metabolites. Whilst gas chromatography 
assays of GTN are particularly sensitive for that compound (Yap et 
al., 1978; McNiff et al., 1981), the response of the electron capture 
detector to the GDNs is only about one half the response to GTN 
(Sokoloski et al., 1983). Moreover, a satisfactory method for re-
solving the GDNs on GC packings was not available when the current 
work was begun. The major problem in quantifying the di- and mono-
nitrates by GC- electron capture is to obtain high and selective 
recoveries. The gas chromatograms using the hexane procedure of Yap 
et al. (1978) or the method used in this work (4.2.4.) display few 
interfering peaks to either GDNs or to GTN. However, only about 207. 
of the dinitrates are extracted into hexane using this procedure (Yap 
et al., 1978). Noonan and Benet (1982) and Needleman et al. (1972) 
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used the low extraction of the GDNs and the GMNs into petroleum ether, 
which is, in polarity, similar to hexane, as the method of quantifying 
labelled GTN. Ethyl acetate and diethyl ether also extract GTN and 
its metabolites from plasma (Needleman and Hunter, 1965; Crew and 
DiCarlo, 1968) but the gas chromatograms obtained by injecting con-
centrated extracts of ethyl acetate show a number of large interfering 
peaks (Rosseel and Bogaert, 1973). It is unlikely that the GMNs, if 
extracted from plasma by hexane, could be quantitated by such methods 
because of interfering peaks. It is even more unlikely if ethyl 
acetate were used because of the serious problem of interfering peaks 
extracted from plasma by that organic solvent (Rosseel and Bogaert, 
1973). An attempt was also made to quantify GTN and GDNs simultane-
ously by GC-MS using negative ion chemical ionization methodology 
(Bignall et al., 1981). This method offered specific detection 
potential due to the unique -ONO M/Z 62 ion. Although a great deal 
of time and effort was spent in trying to obtain a reproducible and 
reliable assay with this system, our attempts proved to be futile. 
The difficulty was due to variable and extensive adsorption of GTN to 
the column packing at the low carrier gas flow rates used for GC-MS. 
More recent work appears to have overcome these difficulties (Gerardin 
et al., 1982). Another problem was not having continuous access to a 
GC-MS and this method therefore was eventually assessed as being un-
suitable for the studies reported in this thesis. The thermal energy 
analyzer has also been employed for organic nitrate analysis 
(Spanggord and Keck, 1980). It proved unsuitable due to cost con-
siderations. 
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Sensitivity  
The high performance liquid chromatographic procedure developed 
in this work (4.2.2) enables the separation of all organic nitrates 
studied with excellent recovery. Unfortunately, this analytical 
procedure proved to be unsatisfactory for the analysis of plasma 
samples containing small GTN concentrations. Concentrations of GTN in 
plasma ranged from 0.2 to 10 ng/ml in samples collected from subjects 
given therapeutic doses of GTN (Armstrong et al., 1980a; McNiff et 
al., 1981), i.e., using 0.2 ml plasma, a minimum detectability of 
about 40 pg GTN was required. Using a fixed wavelength detector at 
214 nm, the limit of detectability was about 10 ng GTN on column. 
Adequate specificity and sensitivity was achieved only by ana-
lyzing radiolabelled ( 3H) GTN after separation by HPLC. Earlier work 
on GTN metabolism used thin layer chromatography (TLC) with or without 
a 14C- labelled GTN (Needleman and Hunter, 1965; Lee, 1973). In 
those studies the GTN concentrations were very high (pg/m1) and 
greatly exceeded the usual therapeutic levels reported for GTN 
(Armstrong et al., 1980a; McNiff et al., 1981). The use of TLC to 
separate pg amounts of GTN for quantitation is likely to be unsatis-
factory due to the volatility of GTN (Urbanski, 1965). In the current 
work, the recoveries of pg amounts of GTN and its metabolites from a 
C 18 HPLC column were found to be incomplete and variable. The 
recovery for 3H-GTN and its metabolites was markedly improved by 
adding large ng amounts of each unlabelled compound in samples to be 
injected. 
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Plasma GTN Concentrations  
The GC assay of plasma GTN concentrations used in the current 
work was a modification of the method of Yap et al. (1978). As the 
recovery of GTN reported by Yap et al. (1978) could not be reproduced 
(5.1.1.), a simpler but less sensitive method was adopted (4.2.4.). 
The adopted technique provided the same recovery of GTN as reported by 
Yap et al. (1978) (i.e., 90%) and a similar precision (5.1.1.). Yap 
et al. (1978) reported a lower limit of detectability of 0.1 ng GTN/ml 
plasma using an injection technique for extracting GTN from plasma. 
This limit is about half that obtained with the present extraction 
procedure (5.1.1.). The present extraction procedure uses a more 
vigorous agitation technique. Injection of the resultant hexane con-
centrate gives a GC chromatogram not quite as 'clean' as that reported 
by Yap et al. (1978). 
6.1.2. Salicylates  
The HPLC assay of salicylates used in the current work (and 
originally developed in this laboratory) showed similar precision and 
reproducibility to that reported by Rumble et al. (1981). 
6.1.3. Tests of Platelet Function 
Platelet Aggregation 
Variability of aggregation tests. The variability in aggregation 
results (5.1.3.) may be caused by variations in the endogenous concen-
trations of the inducing agents in samples collected from patients. 
It is recognized that tests of platelet aggregation using AA and 
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collagen as inducers are generally subject to less variability than 
those in which adrenalin is used. A large day-to-day variation in 
adrenalin induced response can occur in the same subject or in the 
same group of subjects (Table A2). 
The large scatter of results observed for adrenalin induced 
aggregation is consistent with a reported coefficient of variation of 
52% in one subject tested monthly for 6 months (Siess et al., 1981). 
Reasons for the day-to-day variability in adrenalin-induced aggre-
gation are poorly defined. Stress is believed to be one determinant 
of the variability . One study (Arkel et al., 1976) showed that about 
half of the subjects delivering addresses to a conference had greatly 
diminished second phase responses to adrenalin-induced platelet 
aggregation immediately after delivering the address but 7-11 days 
later most had normal adrenalin-induced responses. In the present 
study the stress and trauma associated with blood sampling may also 
have contributed to the variable responses observed for adrenalin. 
The published coefficients of variation of AA and collagen-
induced platelet aggregation, reported by Siess et al. (1981) to be 
less than 15%, are in agreement with the intra- and inter-subject 
coefficients of variation found in the current study (Table A2). 
Platelet MDA Production  
Although the production of .MDA by stimulating platelets with NEM 
has been widely used to assess platelet cyclooxygenase activity, NEM 
is a platelet stimulus of unclear physiological significance. 
Therefore, platelets were also stimulated with AA, the substrate for 
cyclooxygenase. The observed coefficients of variation for both 
inducers are in agreement with those of Stuart et al. (1975). 
109 
6.1.4. Plasma Protein Binding  
As GTN and ASA are both susceptible to in vitro degradation by 
plasma enzymes (Maier et al., 1979; Rowland and Riegelman, 1967), it 
is essential to use a rapid plasma protein binding technique. Of the 
two commonly used techniques, equilibrium dialysis and ultrafiltra-
tion, ultrafiltration is quicker and hence this latter method was 
employed in this work. 
Sorption of ASA and GTN by components of the ultrafiltration 
apparatus was evaluated as we had previously reported the high 
affinity of GTN for some plastics (Cossum et al., 1978; Roberts et 
al., 1980). Sorption of drugs by the filtration membrane for cello-
phane and other types of ultrafilters was reported by Moran and Walker 
(1968) and Spector et al. (1972). More recently Whitlam and Brown 
(1981) evaluated the ultrafiltration technique (using pressure, not 
centrifugation) for SA and other drugs and showed that SA was not 
bound by the membrane filter during control experiments using SA in 
buffer. In the current work SA, ASA, GTN, 1,3-GDN and 1,2-GDN were 
not sorbed by the ultrafiltration membranes (Amicon, YMT) tested or by 
the plastic apparatus. 
6.2. DISPOSITION OF NITROGLYCERIN IN BLOOD  
6.2.1. Metabolism by Erythrocytes  
The present results confirm the results of Lee (1973) who 
reported that GTN was enzymatically degraded in erythrocytes to form 
the GDN metabolites. Noonan and Benet (1982) have also shown that the 
GDNs and GMNs are produced upon incubation of GTN and resuspended 
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erythrocytes in blood. All of these reports are at variance with 
results presented by Wu et al. (1981) and Sokoloski et al. (1983) who 
could not detect GDN metabolites following the loss of GTN from solu-
tions incubated with resuspended erythrocytes and blood. It is not 
clear why those workers could not detect the GDNs even though they 
used an assay reportedly able to detect them. They concluded that GTN 
is degraded by some unknown physical process when in contact with 
blood components. 
Despite those latter studies* current evidence suggests that the 
denitration of GTN in erythrocytes is enzymatic in nature. Evidence 
for a novel mechanism of GTN denitration comes from the recent work of 
Bennett et al. (1984). This interesting study showed that GTN deni-
tration to GDNs in erythrocytes is due, at least in part, to the 
interaction of GTN with haemoglobin. When GTN was incubated with 
haemoglobin (ferrous), GDNs were detected, but pretreatment of the 
haemoglobin with carbon monoxide almost completely inhibited the 
metabolism of GTN to the GDNs. In incubations of GTN with erythrocyte 
lysate supernatant, pretreatment with carbon monoxide only partially 
inhibited GTN denitration. It is likely, therefore, that at least one 
mechanism other than interaction with haemoglobin is involved in the 
overall elimination of GTN in erythrocytes. Although there are at 
least two species of glutathione transferase present in erythrocytes 
(Marcus et al., 1978; Awasthi and Singh, 1984) one has been shown to 
have little, if any, activity towards GTN and the other has not been 
* More recent work with an improved assay technique has shown the pre-
sence of the GDNs resulting from incubation of erythrocytes and GTN (T. 
Sokoloski, personal communication). 
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tested for activity towards GTN. Therefore, it is not presently known 
what other mechanism is responsible for GTN metabolism in erythro-
cytes. 
GDNs were also lost from solutions incubated with resuspended 
erythrocytes. Initial studies using large concentrations of 
unlabelled GDNs showed that the larger GDN concentrations were lost at 
a slower rate than the smaller concentrations. These results are 
consistent with the report of Sokoloski et al. (1983) who showed that 
the half-lives of 1,3-GDN at concentrations of 10, 60, 180 and 480 
ng/ml were 33, 40, 141 and 282 mm,  
The GMN metabolites of the unlabelled GDNs were not detected in 
the current study because of interfering peaks on the chromatograms. 
When the labelled GDNs were used in metabolic studies the GMNs were 
detected. This is best illustrated in Figure 5.13 which shows the 
generation of 3H-GMNs. Noonan and Benet (1982) also showed that 
3H-GTN is metabolized by erythrocytes with the ultimate formation of 
the 3H-GMNs. Unfortunately, Bennett et al. (1984) did not assay for 
GMNs during incubations of haemoglobin and GTN. Although the deni-
tration of GDNs to form the GMNs is likely to occur in such incu-
bations, this step awaits verification. 
6.2.2. Metabolism by Plasma  
The metabolism of GTN in human and sheep plasma occurs at a much 
slower rate than in erythrocytes. The half-lives of GTN at initial 
plasma concentrations of 10 and 50 ng/ml were about 50 min while half-
lives of GTN at initial concentrations of 10 and 50 ng/ml blood or 
erythrocyte suspension were about 3.6 and 6 min, respectively. This 
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difference in the rate of GTN metabolism between plasma and erythro-
cytes had also been observed by Armstrong et al. (1980c), Noonan and 
Benet (1982), and Sokoloski et al. (1983). 
6.2.3. Concentration Dependent Nature of Metabolism  
It is clear from Figure 5.14 and Tables 5.7 and 5.8 that the rate 
of metabolism of GTN by erythrocytes is concentration dependent, the 
large GTN concentrations being metabolized at a slower rate than the 
smaller GTN concentrations. Similar findings have been reported by 
Noonan and Benet (1982) and Sokoloski et al. (1983). The smallest GTN 
concentration studied by those groups was 17 ng/ml and 10 ng/ml, 
respectively, with the half-lives of disappearance of GTN being 15 min 
and 4 min, respectively. In the current work initial GTN concentra-
tions of 2 and 0.8 ng/ml suspension or blood, which are near the lower 
end of the therapeutic range in man, were found to be metabolized with 
half-lives being about 3 min. An explanation of the concentration 
dependent nature of the in vitro rate of metabolism of GTN in blood is 
not readily forthcoming. If Michaelis-Menten kinetics were operative 
then the slope of the plots of % GTN remaining versus should have 
increased with time. Even for extended incubation times when the 
limits of GTN detectability were reached the plots remained linear 
(results not shown). This unusual kinetic behaviour could be a result 
of the use of intact cells. When homogenates of other tissues were 
used no such concentration dependent metabolism of GTN was observed. 
This could suggest that the endogenous co-factors of the erythrocyte 
were depleted at different rates for larger GTN concentrations. 
Finally, Bennett et al. (1984) suggest that at least two mechanisms 
are responsible for denitration of GTN in erythrocytes. The unusual 
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kinetics of GTN denitration observed in erythrocytes may be a result•
of simultaneous denitration processes. 
6.2.4. Concentration Independent Nature of Distribution  
The distribution of a drug within blood is a function of plasma 
protein binding, partitioning into erythrocytes and the haematocrit 
(Rowland and Tozer, 1980). The initial study in the current work 
(Figure 5.14) showed that although the rate of GTN metabolism was con-
centration dependent, the rapid initial uptake of GTN by erythrocytes 
was relatively constant (a drop in GTN concentration of about 20-30%). 
In the study designed to accurately quantitate that initial drop the 
haematocrit was set at 0.45 and the plasma protein binding of GTN and 
the affinity of GTN for the erythrocytes were found to be constant 
over a wide GTN concentration range. Thus it would be expected that 
the blood/plasma (B/P) concentration ratio of GTN would be constant 
over a wide GTN concentration in any one subject. Noonan and Benet 
(1982) found that the B/P ratio of GTN was about 0.65 for an initial 
GTN concentration of 136 ng/ml blood and throughout the time course of 
degradation. The B/P ratio can be calculated using the equation 
(Rowland and Tozer, 1980); 
Cb = 1 + H (Fu .a - 1) 
where 	Cb = blood concentration of the drug, 
c = plasma concentration of the drug, 
H = haematocrit, 
fu = fraction of drug unbound in plasma and 
a = affinity of the erythrocyte for the drug. 
(6.1) 
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Calculations using the erythrocyte/plasma partition coefficient as an 
index of the erythrocyte affinity for GTN give a B/P ratio of 0.91. 
Experimental data (Figure 5.18) give a B/P ratio of 0.75 (calculated 
from the dpm found in the plasma when separated from the erythro-
cytes). These results are consistent with those of Noonan and Benet 
(1982) and show that GTN is not concentrated in the erythrocyte. 
Furthermore, the B/P ratio for GTN metabolites of 0.9 - 1.2 reported 
by the above workers is consistent with reduced plasma protein binding 
of 1,2-GDN and 1,3-GDN when compared to GTN (Tables 5.7 and 5.8). 
6.2.5. Pharmacokinetic Implications of Nitroglycerin 
Denitration In Blood  
The limited information available on the pharmacokinetics of GTN 
in man suggest that the contribution of GTN clearance by blood to the 
overall body clearance is probably small. McNiff et al. (1981) using 
an estimated half-life of metabolism of 3 min for GTN in blood con-
cluded that this route of clearance could only account for < 3% of the 
overall body clearance. Thus, GTN metabolism by blood is probably of 
major importance in the estimation of plasma GTN concentrations as 
significant amounts of GTN may be degraded prior to analysis. This 
will be particularly important in bioavailability studies of GTN from 
ointment and transdermal delivery systems when plasma GTN concentra-
tions will be invariably less than 1 ng/ml (Black, 1982). Figure 5.18 
shows that if an enzyme inhibitor is not added to the blood imme-
diately on sampling from a patient and if there is delay in centri-
fuging the blood, degradation of GTN will occur despite the blood 
being placed in a container precooled to 2 °C. A delay of only 3 min 
between sampling and centrifuging could result in a loss of 30% of the 
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GTN present if no iodoacetamide ( or other effective agent) is added 
to the blood immediately on sampling. 
A recent study by Rey et al. (1983) highlights the ramifications 
of not taking sufficient care to ensure the in vitro stability of GTN. 
The method employed by those workers involved blood sampling, after 
administration of GTN, and storing the blood samples for 10 min at 4°C 
before centrifugation to obtain plasma for GTN analysis. No mention 
was made of using an enzyme inhibitor to prevent the in vitro degrada-
tion of GTN in blood. Figure 5.18 shows that the metabolism of GTN 
(initially 1.5 ng/ml blood) by blood proceeds at 2 °C, albeit slowly, 
but at a sufficient rate to result in an underestimation of GTN plasma 
concentrations by about 25% after 10 min storage. Rey et al. (1983) 
comment that the GTN plasma concentrations obtained from their study 
were lower than expected based on the results of Armstrong et al. 
(1979) for similar GTN doses. Armstrong et al. (1979), although not 
using an enzyme inhibitor, immediately centrifuged blood samples to 
obtain plasma for GTN analysis. 
GTN is also degraded in plasma. Silver nitrate is used exten-
sively to reduce the degradation of GTN by plasma during work-up for 
assay or during storage at -20 ° C (Yap et al., 1978; Maier et al., 
1979); however, it is not used to prevent GTN degradation by blood 
because it causes gelling of the blood sample. The efficiency of 
iodoacetamide in inhibiting degradation of GTN by plasma on storage at 
-20 ° C has not been evaluated although Taylor et al. (1981) found that 
iodoacetamide (final concentration of 4 mM) prevented the degradation 
of GTN in plasma for up to 5 hr at room temperature. They also 
reported that iodoacetamide did not interfere with the determination 
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of plasma concentrations of GTN using the assay of Yap et al. (1978). 
This aspect was confirmed for sheep plasma in the current work. 
• GTN is not the only drug to undergo in vitro metabolism-in blood. 
Rowland and Riegelman (1967) showed that aspirin is hydrolyzed to 
salicylic acid in vitro. More recently, Chen et al. (1983) have shown 
that procainamide is metabolized to N-acetylprocainamide when stored 
in blood at 5 ° C and 25 ° C. It appears then that drug stability needs 
to be ascertained not only in formulations intended for administration 
to patients but also in blood and plasma samples taken from those 
patients in order to ensure proper dosage regimen adjustments based on 
correct pharmacokinetic calculations. 
6.3. PHARMACOKINETICS OF NITROGLYCERIN IN SHEEP 
6.3.1. Continuous and Bolus IV Doses  
Delivery System 
During IV infusions, steady state plasma drug concentrations 
(C) are dependent upon the rate of administration of the drug and ss 
the clearance of the drug (Rowland and Tozer, 1980). The rate of 
administration is usually well defined. However, if the drug being 
infused interacts with the infusion system, the actual rate of 
administration is less than anticipated. GTN interacts with the 
plastics of standard delivery systems made of polyvinyl chloride and 
cellulose propionate (Cossum et al., 1978; Roberts et al., 1980; 
Baaske et al., 1980). However, GTN has little affinity for poly-
olefins such as polyethylene (Cossum et al, 1978; Baaske et al., 
1982) and so these plastics must be used for GTN infusions to prevent 
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the loss of the drug during infusions. Other drugs known to interact 
with the plastics of conventional administration sets are isosorbide 
dinitrate (Cossum and Roberts, 1981), diazepam (Parker and MacCara, 
1980) and chlormethiazole (Tsuei et al., 1980). These drugs are, 
however, compatible with polyolefin systems (Cossum and Roberts, 
1981). 
Sampling  
A further potential problem in using GTN in this work was an in-
teraction of GTN and the plastic catheters used for blood sampling. 
Table 5.13 shows that losses due to such an interaction were minimal, 
probably because: 
(i) the catheters were made of a polyolefin substance; and 
(ii) the flow rate used in this validation was high (40 ml/min). 
High flow rates were used to mimic the experimental situation where 
blood samples are withdrawn rapidly. Jacobi et al. (1983) reported a 
transient loss of GTN to central venous pressure catheters using a 
very slow flow rate of drug solution of 30 ml/hr. Table 5.13 also 
shows that when the flow rate of GTN drug solution being drawn through 
the plastic catheters was reduced to 5 ml/min (as would happen during 
partial blockage of blood sampling lines) the loss of GTN was still 
less than 2%. The GDNs and GMNs showed no losses during contact with 
plastic catheters. 
Plasma Concentrations After Bolus Injections  
GTN disappeared from arterial venous plasma in a bi-exponential 
manner after administration of bolus injections over 1 min. Needleman 
et al. (1972) found that the blood clearance of 14C-GTN in rats was 
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bi-phasic following IV bolus doses. In contrast, no distribution 
phase was reported for GTN given intracardially (700 pg/kg) to rats 
(Yap and Fung, 1978). Idzu et al. (1982) and Miyazaki et al. (1982) 
both reported bi-phasic decay profiles of GTN venous plasma concen-
trations after bolus intravenous doses of GTN to humans and dogs, 
respectively. 
The half-lives of the two phases of GTN plasma concentration 
decay were approximately 0.8 min and 2.0 min, respectively, for all 
but the largest bolus dose of GTN in arterial and venous plasma. The 
half-lives of the a and a phases of decay after administration of the 
largest bolus dose were about 1.0 and 3.0 min, respectively. These 
times are similar to 0.45 min and 4.25 min after a dose of 7 pg/kg in 
conscious dogs (Miyazaki et al., 1982), 0.37 min and 4.95 min after a 
dose of 4 pg/kg in anaesthetized humans (Idzu et al., 1982) and the 
phase half-life of 4.2 min in rats that received an intra-cardial 
bolus dose of 700 pg/kg (Yap and Fung, 1978). 
Plasma Concentrations After Infusions  
Steady-state GTN venous and arterial plasma concentrations were 
generally achieved within 20 min after beginning an infusion. McNiff 
et al. (1981) reported that steady-state or near steady-state GTN 
concentrations in venous plasma were reached within 30 min after 
starting a GTN infusion at the rate of 0.23 pg/min/kg in 3 of 9 normal 
human subjects. The average venous C ss found by McNiff et al. (1981) 
was about 0.4 ng/ml. The average C ss of about 0.5 ng/ml in venous 
plasma of sheep receiving GTN infusions at the rate of 0.4 pg/min/kg 
(Figure 5.33) is of this order. Armstrong et al. (1982) found that 
GTN infusions at a rate of about 0.28 pg/min/kg resulted in average 
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venous C of 0.90 ng/ml and average arterial C of 2.6 ng/ml in four ss 	 ss 
patients with congestive heart failure. 
Considerable inter-individual differences in GTN plasma levels 
were observed in human patients or volunteers receiving continuous IV 
GTN infusions (Armstrong et al., 1980a; Imhof et al., 1982; McNiff et 
al., 1981; Wei and Reid, 1979). It has been pointed out by McNiff et 
al. (1981) that the amount of GTN in the plasma compartment probably 
accounts for about 17. of the total amount of GTN in the body. Minor 
fluctuations in the amount of GTN in the tissues may cause major fluc-
tuations in the plasma GTN concentrations. In this respect, changes 
in posture may contribute to fluctuations in GTN plasma concentrations' 
(Curry and Kwon, 1985). Sheep used in this work were anaesthetized 
and so completely immobilized. This factor may have contributed to 
the small variations observed in apparent steady-state GTN plasma 
concentrations of blood sampled from each of the six sampling sites in 
sheep. Moreover, stabilization of GTN in blood by iodoacetamide after 
sampling may also have contributed to the small inter-individual vari-
ations in apparent steady-state GTN concentrations. 
The decay in plasma GTN concentrations after termination of GTN 
infusions in sheep was found to be monoexponential for a GTN dose of 
0.4 pg/min/kg but biexponential for the two larger doses. The second 
phase of the GTN decay curve after infusions of 0.4pg/min/kg was not 
observed due to the lack of sensitivity of the GC assay used to ana-
lyze plasma GTN concentrations (0.2 ng/ml). McNiff et al. (1981) also 
reported a monoexponential decay of GTN after infusions in humans 
using a GC assay with a detection limit of 0.05 ng/ml. A half-life of 
about 3 min was reported by those workers. The half-lives for the two 
phases of GTN disappearance from venous plasma were about 0.75 min and 
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3-4 min, respectively. It could be inferred that the half-life calcu-
lated by NcNiff et al. (1981) comprises components of the distribution 
and elimination phases. Miyazaki et al. (1982) reported the half-
lives of the a and a phases of decay in venous plasma GTN concen-
trations in anaesthetized dogs to be 0.50 and 4.95 min, respectively. 
6.3.2. Arterial-Venous Plasma Nitroglycerin Gradients  
A pronounced difference in GTN plasma concentrations exists at 
the different sampling sites of sheep given GTN by infusion. These 
results are consistent with the report of Armstrong et al. (1982) that 
a substantial gradient in GTN plasma concentrations existed between 
the radial artery and a peripheral vein in humans receiving continuous 
infusions of GTN. Calculations of systemic venous plasma clearance in 
the current work give values which greatly exceed normal cardiac 
output in sheep (about 2.5 1/min). Blood clearance is even greater 
than plasma clearance and is obtained by multiplying plasma clearance 
by 1/0.83 (0.83 is the average blood/plasma ratio of the two values 
calculated in this work, 0.75 and 0.91, Section 6.2.4.). Systemic 
arterial plasma clearance values were also greater than cardiac venous 
clearance. These results suggest that a substantial proportion of GTN 
is cleared by extra-hepatic routes. 
Extraction Across the Leg  
The results from the tissue homogenate experiments show that the 
observed arterial-venous GTN concentration gradient is likely to be a 
result of GTN metabolism in the leg tissues. Metabolism of GTN across 
the hind leg has not been reported previously although Runciman et al. 
(1982) have reported that lignocaine, pethidine and chlormethiazole 
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were all substantially extracted across the hind limb of sheep. Kreye 
and Reske (1981) reported an arterial-venous gradient for nitroprus-
side across the hind limb of the anaesthetized rat and suggested that 
this site was partially responsible for the rapid in vivo inactivation 
of nitroprusside. 
The mean availability of GTN across the hind leg of the sheep was 
between 0.12 and 0.29 for increasing GTN doses delivered as continuous 
IV infusions, and 0.21 and 1.04 for GTN doses delivered as bolus 
injections. These values for availability were associated with de-
creased MRTs; however, the decrease in MRT at the largest GTN doses 
delivered by either continuous infusion or bolus injection did not 
reach statistical significance, owing at least in part to the vari-
ability of individual MRTs (Tables 5.14 and 5.16). 
The contributions of haemodynamic (Section 6.4) and metabolic 
changes to the observed dose-dependent increases in GTN availability 
may not be easily separated. However, some separation may be gauged 
by assuming the disposition of a drug in an organ is described by a 
particular pharmacokinetic model. If the disposition of a drug is 
described by a well stirred model, availability (F) and mean residence 
times (MRT) can be related to the volume of distribution of the drug 
(V) in the organ, the-organ blood flow (Q), the fraction of the drug 
unbound in blood (f u) and the intrinsic clearance (Clint)  by the organ 
using equations described by Weiss (1982): 
(6.2) 
Q + fu Clint 
and 
MRT = 	V (6.3) 
Q + fu Clint 
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On re-arrangement of these two equations it is seen in equation 
6.4 that the MRT of a solute in an organ is inversely proportional to 
the blood flow in that organ: 
MRT = 	FV 	 (6.4) 
The decreases in MRT of GTN at higher GTN doses corresponds to 
increases in cardiac output (and therefore hind leg blood flow) for 
GTN doses administered by continuous infusion. Increased blood flow 
in the leg does not, however, account completely for the observed 
decreases in MRT and associated increases in availability of GTN with 
larger GTN doses since larger GTN doses delivered by bolus injection 
reduced the cardiac output, and supposedly hind leg blood flow. In 
addition, the cardiac output never increased to any appreciable degree 
after baseline levels had been re-established following the fall in 
cardiac output induced by larger GTN bolus doses. 
Results from the in vitro experiments showed that muscle tissue 
is capable of metabolizing GTN to the GDNs and GMNs. Moreover, the 
rate of GTN metabolism is reduced in the presence of GDNs in vitro and 
the clearance of GTN is reduced by the co-administration of GDNs in 
vivo (see below). These results suggest that it is most unlikely that 
only haemodynamic parameters influence the disposition of GTN in vivo. 
They further suggest that the well-stirred model does not completely 
describe the disposition of GTN. 
Extraction Across the Lungs  
The lungs were found to be a site of GTN clearance in the sheep. 
During continuous GTN infusions, the mean GTN availability across the 
lungs ranged from 0.53 to 0.72, indicating that substantial amounts of 
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GTN were being lost in that tissue. Armstrong et al. (1982) have 
shown that in humans receiving continuous infusions of GTN there was 
an extraction of about 16% of GTN during passage through the lungs. 
While the concentrations of GDNs in blood leaving the lungs were 
greater than in blood entering the lung for all times studied, this may 
have been due to a distribution phenomenon whereby the lung could 
"trap" GDNs produced at other body sites early during the infusion, 
releasing them back into the plasma at subsequent times. 
In vitro experiments verified that lung tissue is capable of 
metabolizing GTN to GDNs and GMNs. Those results are consistent with 
results presented by Heinzow and Ziegler (1981) who showed that 10% of 
GTN was lost from solutions being perfused through isolated rat lungs 
with the concomitant formation of GDNs. Another organic nitrate drug, 
isosorbide dinitrate, has recently been shown to be metabolized by 
rabbit lung homogenates and in perfusion experiments (Mayer et al., 
1983). 
The variation in the availability of GTN across the lung with 
infusion rate may be related to changes in pulmonary blood flow 
brought about by reductions in the systemic venous return. Since 
pulmonary blood flow is, in part, determined by the systemic venous 
return, alterations in GTN availability at the highest GTN dose may 
reflect a reduction in pulmonary blood flow (as opposed to pulmonary 
artery flow or cardiac output). 
Extraction Across the Liver  
It has been known for many years that GTN is metabolized in the 
liver (Oberst and Snyder, 1948; Heppel and Hilmoe, 1950) to form the 
GDNs and GMNs (Needleman and Krantz, 1965). The results of the 
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current work are consistent with those reports. Based on those early 
reports and more recent work showing that the bioavailability of GTN 
given orally is very small due to extensive first-pass metabolism 
(Needleman et al., 1972; Needleman, 1973; Yap and Fung, 1978), GTN is 
not routinely administered in oral preparations. 
The current results show substantial amounts of GTN in blood 
leaving the liver via the hepatic vein. This finding is contrary to 
what was expected based on the reports of Needleman and co-workers. 
Needleman (1973) wrote, "Orally administered organic nitrates are ab-
sorbed into the portal circulation and are rapidly and completely de-
graded by a liver enzyme before reaching the systemic circulation and 
therefore can have little chance of producing vasodilation." In an 
editorial, Krantz and Leake (1975) questioned Needleman's assertion 
that orally administered GTN is completely metabolized in the first-
pass through the liver. They raised the point that if Needleman was 
correct then William Murrell's anginal patients would have failed to 
benefit by taking GTN orally, a route which was known to alleviate 
anginal pain. It may be that for larger GTN doses, the hepatic meta-
bolism of GTN is reduced by co-factor depletion or by metabolite 
inhibition (see Section 6.3.4.). The concentration dependence of GTN 
clearance by the liver in vivo was not reflected by the in vitro  
findings. Table 5.11 shows that the metabolism of GTN by liver 
homogenates was independent of GTN concentration. The results imply 
that in vitro metabolism of GTN by sheep tissue homogenates was not 
limited by co-factor depletion. 
Extraction of GTN by the liver increased as the dose of GTN in-
creased so that at the larger GTN infusion rate the availability of 
GTN was about 0.5 when comparing its concentration in the portal and 
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hepatic veins. This availability calculation assumed no contribution 
by the hepatic artery. The estimate is likely to be larger in reality 
due to the 30% contribution of the hepatic artery flow to the blood 
flow in the hepatic vein (Zakim, 1981) and assuming that GTN delivered 
to the liver via arterial and venous bloods is subjected to the same 
metabolizing systems. 
It is uncertain if the apparent concentration-dependent clearance 
of GTN by the liver could be explained by changes in liver blood flow 
induced by GTN. Firstly, Colley and Sivarajan (1984) showed that 
liver blood flow of dogs was unaffected by GTN infusions during 
halothane anaesthesia. Dumont et al. (1982), however, reported that 
GTN infused to reduce the blood pressure of conscious dogs by 20 mm Hg 
decreased the liver blood flow by about 20%, but those workers 
measured the blood flow of the hepatic artery only. Secondly, Blei et 
al. (1984) found that portal vein ligation, which reduced the liver 
blood flow by up to 40%, had no effect on the apparent systemic 
clearance of GTN in pentobarbitone-anaesthetized rats. It is not 
known what the effects of pentobarbitone anaesthesia, surgery and GIN 
• infusions are on liver blood flow of sheep as such measurements were 
not made during the experiments. Therefore, even if there is a GIN 
dose-dependent increase in liver blood flow it is unlikely that it 
would explain completely the observed increase in availability of GTN 
with increasing GIN doses. A more likely explanation is that the 
metabolism of GTN is reduced at larger GTN doses by either depleting 
co-factor stores or by inhibition by the GDNs (see below). Fung et 
al. (1984a) have suggested that the presence of at least two enzyme 
systems each having different affinities and/or capacities for GTN may 
explain the dose-dependent increase in oral bioavailability of GTN in 
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the rat. Such a proposal may also help to explain the dose-dependent 
availability of GTN across the liver of sheep. 
Extraction by Blood Vessels  
Although no specific studies were performed to assess the 
relative uptake of GTN by arteries and veins, studies did show that 
sheep arteries and veins are capable of metabolizing GTN to the GDNs•
(Table 5.11). These results are in accord with the recent findings of 
Fung et al. (1984b) that rat blood vessel segments metabolize GTN to 
the GDNs, and ISDN to the isosorbide mononitrate metabolites. Those 
workers demonstrated a substantial "first-pass" uptake of GTN by blood 
vessels after administration of GTN into various vascular sites: the 
segments of blood vessel nearest the site of administration of GTN had 
larger GTN concentrations than segments further "downstream" of the 
site of administration. Their results also suggested a lower affinity 
of GTN for aorta but it was unclear whether this should be interpreted 
as meaning that arterial tissue is generally responsible for less GTN 
uptake than venous tissue. 
The current results and those of Fung et al. (1984b) are in 
conflict with those of Armstrong et al. (1980b) who, despite using 
sensitive assay, did not detect GDNs in the perfusate of isolated dog 
blood vessels. This may have been because the GDN metabolites distri-
buted into the blood vessels upon formation, or alternatively the seg-
ments of blood vessels may have been too small to produce detectable 
amounts of GDNs. 
Metabolism of GTN in an individual organ is dependent on the 
enzyme activity within the cells of the organ and in the blood vessels 
perfusing the organ. In some organs, e.g. capillary beds, blood 
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vessels are numerous and may play a major role in GTN metabolism. 
What the contribution of the blood vessels is to the overall meta-
bolism of GTN remains to be investigated. An increase in the blood 
flow in a vessel would, however, be expected to be associated with a 
reduced extraction of GTN by that vessel. An analogy is the finding 
of a reduced extraction of GTN by polyvinyl chloride infusion tubing 
at faster GTN solution flow rates (Cossum et al., 1978). 
The metabolism of GTN by blood vessels may also be of importance 
in the present hypotheses of the mechanisms by which GTN causes vaso-
dilation. Several hypotheses have been proposed to explain the mech-
anism by which GTN and other organic nitrate drugs relax vascular 
smooth muscle (Bennett and Marks, 1984). According to the theory of 
Needleman and Johnson (1973) and Needleman et al. (1973), GTN reacts 
with sulphydryl groups of receptors in the vascular smooth muscle. 
The reaction converts the nitrate receptor to the disulphide form, at 
the same time reducing GTN to a denitrated (GDN) form with the release 
of a nitrite ion. 
Ignarro et al. (1981) have suggested a scheme in which GTN is 
reduced to one of the GDNs with the release of a nitrite ion, which by 
a series of reactions forms a reactive intermediate. The formation of 
cGMP is enhanced by the reactive metabolite and it is this increased 
level of cGMP which causes relaxation. The results of the current 
work are consistent with both of these hypotheses since both hypotheses 
require the formation of the GDN metabolites. However, Fung et al. 
(1984b) point out that the rapid onset of action of GTN in intact 
animals requires that there be a similarly rapid denitration of GTN in 
the blood vessels. Those workers recommend further studies to examine 
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whether denitration of GTN completely accounts for its vasodilator 
action. 
6.3.3. Arterial-Venous Glyceryl Di- and Mononitrate Gradients  
Because of the difficulty in measuring plasma GDN concentrations 
there is a scarcity of literature on the topic of GDN pharmaco-
kinetics. Most workers have used large doses of radio-labelled GTN 
( 14C-GTN) in experiments with rats, giving high blood GTN concen-
trations (pg/ml) (DiCarlo et al., 1968; Johnson et al., 1972). In 
those studies either the GDNs were measured as a single substance in 
plasma (Johnson et al., 1972) or as separate substances in urine and 
the results used to give an indirect measure for plasma (DiCarlo et 
al., 1968). In the latter study, both GDN isomers were present in all 
urine samples, the concentration of the 1,2-GDN always being greater 
than that of the 1,3-GDN. 
By using HPLC and 3H-GTN in the current work, it was possible to 
measure separate plasma GDN concentrations and combined GMN concentra-
tions following the infusion of a GTN dose (0.4 pg/min/kg) commonly 
used clinically in humans. The bi-exponential decay profile for the 
1,3-GDN and 1,2-GDN had a terminal half-life of about 40 and 35 min, 
respectively, which compare to the terminal half-lives in dogs of 48.5 
and 40.6 min reported by Miyazaki et al. (1982). Those workers 
infused GTN into dogs at a rate of 6 pg/min/kg and measured plasma GDN 
concentrations by gas chromatography-mass spectrometry. They also 
found that plasma concentrations of 1,2-GDN were about 3- fold that of 
the 1,3-GDN, a result similar to that found in the current work. 
Estimates of the half-lives of the a phase of plasma GDN decay 
profiles varied with the site of sampling; however, the half-lives in 
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venous plasma were about 10 min and 15 min for the 1,2-GDN and 
1,3-GDN, respectively. Corresponding values reported by Miyazaki et 
al. (1982) for venous plasma were 8.1 min and 8.5 min. 
The analytical procedure used for this work did not fully resolve 
the GMNs and so they were measured as one peak. Moreover, the plasma 
GMN concentrations had not decreased at the end of blood sampling and 
so their pharmacokinetic parameters could not be estimated. Spanggord 
and Keck (1980) using a HPLC with thermal energy analyzer method for 
quantifying organic nitrates found that the predominant plasma GMN was 
2-GMN in dogs given GTN orally. No estimate of the pharmacokinetic 
parameters of the GMNs could be made in that study because of the in-
complete metabolism of the GDNs. 
Metabolite Gradients Across the Leg  
The arterial-venous gradient in plasma GDN concentrations was re-
versed after the termination of the GTN infusion. This resulted in 
plasma AUCs for the GDNs which were only slightly less in the venous 
plasma than in the arterial plasma. The calculated values for avail-
ability were about 0.9 for the GDNs (Table 5.19) indicating that they 
were metabolized in the leg. Confirmation that muscle could degrade 
GDNs to GMNs was obtained from in vitro experiments (Table 5.11). 
Thus, muscle appears to contain the necessary enzymes for the deni-
tration of GTN to the GMNs. 
An arterial-venous gradient exists for plasma CNN concentrations 
(Figure 5.47). This gradient was diminished during the GTN infusion 
so that by about 60 min after the GTN infusion ceased there existed a 
venous-arterial plasma GMN gradient. The earlier arterial-venous gra-
dient most probably represents distribution of GMNs into the muscle 
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tissue while the later venous-arterial gradient represents distribu-
tion of GMNs back from the tissues into the plasma. Unfortunately, 
the experiments were not conducted over a long enough time period for 
quantitating the availability of GMNs across the leg. As the muscle 
probably lacks conjugating enzymes (Gram, 1980) it is most probable 
that the availability of GMNs would have been unity. 
A very small portion of GTN is excreted in rat urine as the glu-
curonic acid conjugate of CNN (DiCarlo et al., 1968). It is possible 
that very small amounts of GMNs are metabolized also to glycerol since 
DiCarlo et al. (1968) measured 14C- glycerol in the urine of rats 
dosed with 14  C-GTN but the percentage of GTN converted to glycerol was 
about 6% after 4 hr. The GMNs are probably water-soluble enough to be 
excreted faster than they can be metabolized further to glycerol. 
This suggestion is supported by the work of Needleman and Hunter 
(1965) who showed that CNN was practically unaltered by liver homo-
genates in vitro. 
Metabolite Gradients Across the Lungs  
The lungs were found to be sites of GDN metabolism in vivo and in 
vitro. Table 5.11 shows that lung homogenates were capable of meta-
bolizing GTN to GDNs and then to GMNs. The work of Heinzow and 
Zeigler (1981) in which GDNs were detected in the non-recirculating 
effluent of lung perfusions containing GTN supports the contention 
that GTN is metabolized in the lung. 
• Plasma GMN profiles across the lung are variable showing no con-
sistent trend in respect of their uptake or release (Figure 5.48(b)). 
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Metabolite Gradients Across the Liver  
Portal vein - hepatic vein plasma GDN and GMN gradients show a 
consistent uptake of these compounds by the liver. This is in 
contrast to the gradients of GDNs and GMNs across the leg and lung 
which were sometimes an A-V gradient and other times a V-A gradient. 
This might suggest that the liver is the primary site of GDN and GMN 
metabolism while extra-hepatic tissues are the primary sites of GTN 
metabolism. 
6.3.4. Effects of Glyceryl Dinitrates on Nitroglycerin  
Pharmacokinetics  
In vitro experiments showed that the rate of metabolism of GTN in 
human erythrocytes and homogenates of sheep liver, lung, muscle, vena 
cava and aorta was reduced by the addition of GDNs. It was therefore 
decided to investigate whether GDNs were able to reduce the clearance 
of GTN in vivo. Bolus doses of GDNs administered during infusions of 
GTN had a slight effect on the arterial GTN plasma concentrations but 
a marked effect on the venous plasma GTN concentrations. Pharmaco-
kinetic parameters of GTN in sheep administered GDNs were different to 
those of sheep not administered GDNs during the GTN infusion. GTN 
availability across the leg was increased by GDN administration and 
this was associated with a decrease in intrinsic clearance by the leg. 
The mean residence time of GTN in the leg was clearly increased by the 
administration of GDNs. 
A more pronounced effect of GDNs on the pharmacokinetics of GTN 
is seen by plotting cumulative venous AUC/cumulative arterial AUC for 
GTN versus time (Figure 6.1). In Figure 6.1 it is seen that shortly 
after the administration of GDNs during GTN infusion the value of the 
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Figure 6.1 Effect of a bolus dose of GDNs on the ratio of cumul-
ative venous and arterial AUCs in sheep receiving continuous intra-
venous infusions of GTN. Sheep 10, (R); Sheep 11, (0); Sheep 12, 
(A); Sheep 29, (II) and Sheep 30, ("). 
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ratio of cumulative AUCs begins to increase showing that the GDNs have 
a rapid onset of action in reducing the clearance of GTN. When the 
GTN infusion was stopped the cumulative AUCs ratio continued to 
increase at all times sampled thereafter. In sheep that did not 
receive a bolus dose of GDNs, the ratio of cumulative venous 
AUC/cumulative arterial AUC remained constant or increased only mar-
ginally (Figure 6.1). 
These results are consistent with GDNs inhibiting the metabolism 
of GTN in the muscle and blood vessels of the leg. They also appear 
to account, at least in part, for the increase in availability of GTN 
across the leg and liver and the decreasing intrinsic clearances ob-
served during infusions of increasing doses of GTN. Moreover, the in-
crease in the half-lives of GTN elimination from arterial and venous 
plasma and the decrease in venous systemic clearance after serial 
bolus doses of GTN could be explained, in part, by the inhibition of 
GTN clearance by increasing amounts of GDNs formed from preceding 
bolus injections. 
The finding that the arterial-venous gradient in GTN plasma con-
centrations was reduced at larger GTN infusion rates (as illustrated 
by the increased availability) is also consistent with the results of 
Armstrong-Moffat et al. (1981). Those workers found that after 
continuous administration of GTN to dogs for 5 days, the arterial-
venous GTN gradient was abolished. They suggested that the disap-
pearance of the gradient was possibly due to saturation at sites of 
GTN uptake. No mention was made of the rate of GTN administration 
used in that study but it is tempting to suggest that it was a rela-
tively small rate (i.e., < 1 pg/min/kg). In that event, the larger 
doses of GTN administered in the present work might have resulted in 
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the abolition of the arterial-venous GTN gradient in much less time 
than 5 days of continuous infusion. Indeed, the A-V gradient in sheep 
was abolished by serial bolus GTN doses •(Figure 5.28) which were 
administered over a total of about 4 hr. 
The abolition of the GTN concentration gradient at larger GTN in-
fusion doses could be facilitated by the clearance of GDNs being re-
duced at larger GDN concentrations. It was seen that the half-lives 
of elimination of plasma GDN concentrations, formed during infusions 
of 0.4 pg GTN/min/kg (Figure 5.44) were 35 to 40 min (Table 5.19). It 
is possible that these half-lives could be considerably extended 
during chronic infusions of GTN, leading to accumulation of GDNs. 
Evidence for the concentration-dependent metabolism of GDNs comes from 
the data describing GDN metabolism in human erythrocytes (Table 5.10). 
Moreover, Table 5.9 shows that in blood, larger GDN concentrations 
inhibit GTN metabolism to a greater extent than smaller GDN concen-
trations. If these effects can be extrapolated to the muscle and 
other sites of tissue metabolism of GDNs then it is likely that the 
reason for the abolition of the arterial-venous GTN gradient on 
chronic GTN infusions (Armstrong-Moffat et al., 1981) is the inhibi-
tion of GTN metabolism in the leg by GDNs. 
It has been shown very recently that the clearance of another or-
ganic nitrate drug,ISDN, in rats was reduced in the presence of the 5- 
and 2- mononitrate metabolites (Sutton and Fung, 1984). Those workers 
postulated that this interaction arose as a result of the mononitrates 
inhibiting the metabolism of the parent compound. A similar pheno-
menon has been reported for diazepam and desmethyldiazepam in humans 
(Klotz et al., 1976) and for lignocaine and its mono-N-deethylated 
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metabolite, monoethylglycinexylidide, in the isolated perfused rat 
liver (Pang and Rowland, 1977; Lennard et al., 1983). 
6.4. PHARMACODYNAMICS OF NITROGLYCERIN IN SHEEP  
Bolus GTN doses were found to reduce the MABP and MLVP in a 
dose-dependent manner. Bogaert and Rosseel (1972b) have previously 
reported similar effects (i.e., changes in hind-leg perfusion pres-
sure) in the dog but did not quantify plasma GTN concentrations. In 
the current work, when plasma concentration and the AUCs for the both 
arterial and venous plasma were related to the reduction in MABP and 
MLVP, different slopes were obtained for the arterial and venous data. 
One explanation for the different slopes may be the A-V gradient in 
plasma GTN concentrations. 
The dose dependency of duration of effect and the association of 
the larger GTN effects with a reduced cardiac output are consistent 
with the results of O'Rourke et al. (1971) with conscious dogs and 
De Maria et al. (1974) with humans. The reduction in cardiac output 
results from a reduction in left ventricular work as reflected by the 
MLVP. This reduction in cardiac output should be avoided when com-
mencing GTN infusions in patients suffering acute myocardial infarc-
tion. In clinical practice GTN is often administered as a small IV 
bolus dose followed by a continuous infusion (Hill et al., 1981). If 
the bolus is delivered too quickly, the cardiac output may fall and 
exacerbate an already ischaemic myocardium (Parratt 1974; 1979). 
Blood pressure responses to bolus doses of GTN in dogs and 
rabbits (Bogaert et al., 1970) were reported not to parallel the 
plasma levels of GTN. However, those workers used an indirect ana-
lytical method for plasma GTN levels which measured total organic 
Figure 6.2 The temporal relationships of the reduction in mean 
arterial blood pressure MBP03nd arterial (A) and venous (A) 
plasma GTN concentrations elicited by a bolus dose of 54.5 pg 
GTN/kg in Sheep 13. 
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•nitrate since no appropriate method to measure parent drug or 
separated metabolites was available at the time. Therefore, it is 
likely that Bogaert et al. (1970) were also measuring GDNs and GMNs. 
In the current work blood pressure appeared to return to baseline 
values in parallel with falling GTN plasma levels. An example of this 
is presented in Figure 6.2 which shows MABP returning to the baseline 
value at about the same rate as the detectable GTN venous and arterial 
plasma concentrations decay following a bolus GTN dose of 54.4 ug/kg 
into sheep No. 13. 
Continuous IV infusions of GTN were associated with much less 
drastic hypotensive effects than the bolus doses provided. The rates 
at which GTN was administered in this study caused a modest dose-
dependent decrease in MABP and a small dose-dependent increase in 
cardiac output, both effects of which are consistent with some pre-
vious studies (O'Rourke et al., 1971; Kovick et al., 1976). Moreover, 
the reduction in MABP was related to peak plasma GTN concentrations 
and AUCs in a dose-dependent manner. In the current work blood pres-
sure fell as the GTN infusion commenced and a plateau was reached 
which coincided with steady-state plasma GTN levels. On termination 
of the infusion, blood pressure returned to baseline values in unison 
with the detectable plasma GTN concentrations. An example of this is 
presented in Figure 6.3. The results presented in this figure were 
obtained in experiments using a GTN infusion rate of 0.4 ug/min/kg. 
This rate of GTN administration is similar to that used by Armstrong 
et al. (1983) in congestive cardiac failure patients to study the 
relationship of arterial plasma GTN concentrations and the haemo-
dynamic responses elicited by GTN (21 pg/min). Their results showed 
that as the plasma GTN concentrations increased to a steady-state 
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Figure 6.3 The temporal relationships of the reduction in 
mean arterial blood pressure (MABP)(and arterial OM and venous 
(A) plasma GTN concentrations elicited by a continuous intra-
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value of about 4 ng/ml, the pulmonary capillary wedge pressure 
gradually fell to a plateau which was 20% below baseline and which was 
maintained throughout the course of the infusion. Armstrong et al. 
(1983) reported very small changes in systolic blood pressure in their 
patients. The small changes in blood pressure are consistent with 
results obtained in the anaesthetized sheep. In summary, the results 
obtained in the anaesthetized sheep are in accord with the results of 
Armstrong et al. (1983) using cardiac failure patients, in that a 
maximal haemodynamic response occurred in parallel with maximal plasma 
concentrations. 
A comparison of the effects of GTN administered by IV bolus and 
continuous IV infusion is seen in Figure 6.4. It is clear that a dose 
of GTN delivered by bolus will have a much greater hypotensive effect 
than the equivalent dose administered as a continuous infusion. 
Bogaert et al. (1970) also showed that the absolute amount of GTN 
administered was less important than a rapid change in the plasma GTN 
concentrations in eliciting a haemodynamic response to GTN. 
The depression of arterial pressure by GTN is augmented in anaes-
thetized open chest preparations (Vatner and Heyndrickx, 1975). 
Therefore, the degree and duration of MABP reduction induced by bolus 
and continuous doses of GTN in the current work may have been greater 
than would have been recorded in conscious animals. This is because in 
the open chest anaesthetized animal the reflex control of the circula-
tion is attenuated (Vatner and Heyndrickx, 1975). Added to this is 
the hypotensive effect of pentobarbitone, the anaesthetic agent used 
in this work. 
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6.5. CLINICAL IMPLICATIONS OF NITROGLYCERIN STUDIES 
6.5.1. Therapeutic Monitoring  
The results from the present work show that the interpretation of 
plasma GTN concentration datamust be in relation to: (i) possible 
degradation of GTN after blood sample collection; (ii) the site of 
blood sample collection; and (iii) the effect of metabolites of GDN. 
A previous study (Cossum et al., 1978) has shown the potential for 
intravenous administration systems to influence the plasma GTN con-
centrations due to reduced availability of GTN. 
The current studies have also pointed out a potential for 
incorrect GTN dosage adjustments to be made. When GTN infusions are 
administered over extended periods of time the possibility exists that 
venous plasma GTN concentrations will slowly increase, possibly due to 
GDN-induced reduction in GTN metabolism. Thus, a reduction in GTN 
dosage may be instituted. The oral bioavailability of GTN is markedly 
enhanced in patients with certain liver diseases (Porchet and Bircher, 
1982). Nevertheless, the current results show that the liver is 
probably not the major site of GTN clearance. Thus, reduced dosing of 
GTN to patients with liver disease may not be necessary. 
When GTN is administered intravenously it is mandatory to monitor 
haemodynamic responses. The present results adequately display the 
rapid changes in blood pressure and cardiac output which can accompany 
the rapid IV administration of GTN. It is therefore likely that 
clinicians would rely mostly on haemodynamic responses to GTN rather 
than in plasma GTN concentration data. The present results serve to 
reinforce that practice. 
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6.5.2. Tolerance  
Two of the current •hypotheses put forward 	explain the 
mechanism of action of organic nitrates in relaxing vascular smooth 
muscle require the GDNs to be formed prior to or subsequent to acti-
vation of the smooth muscle receptor by GTN. The present work has 
shown that GTN transformation to GDN can be inhibited by GDN itself. 
This suggests that the relaxation elicited by GTN may be reduced or 
prevented by GDNs. 
Tolerance to the haemodynamic effects of organic nitrates, 
according to the hypothesis of Needleman and Johnson (1973), results 
from there being less sulphydryl groups on receptors available to 
interact with the parent organic nitrate. Alternatively, the hypo-
thesis of Ignarro et al. (1981) suggests that organic nitrates are 
reduced within vascular smooth muscle and the nitrite ion so formed 
elicits a response by reacting through an active intermediate, S-
nitrosothiol. Tolerance may be associated with a reduced formation of 
the active intermediate. 
The results obtained in the current work may provide an important 
link between tolerance development to organic nitrates and altered 
pharmacokinetics during long-term administration of those drugs. The 
development of tolerance to GTN may be as a result of the reduced 
availability of sulphydryls (Needleman and Johnson, 1973) or an active 
intermediate, or by inhibiting the reaction of the active metabolite 
with the receptor (Ignarro et al., 1981). The former possibility may 
be caused by the accumulation of GDNs in the smooth muscle cells, 
interfering with the reaction of GTN and sulphydryls. It is known 
that the GDNs have only 1/15 - 1/20 of the vasodepressive potency of 
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GTN (Needleman et al., 1969; Bogaert et al., 1968). When they are in 
abundance in the vascular cell they may prevent the interaction of GTN 
with the receptor either by exclusion or by reacting with the receptor 
at a different site to GTN and which prevents GTN reacting with the 
receptor. It is likely that GDNs are metabolized to GMNs in the vas-
cular tissue (although none was detected in the in vitro experiments 
of the current study, probably because of the small vascular tissue 
masses used). The GMNs may also accumulate upon the eventual degrada-
tion of the GDNs during chronic GTN therapy and prevent GTN from 
reacting with the receptor. GMNs are known to lack vasodilator 
activity (Needleman et al., 1969). 
Increasing metabolite concentrations in the vascular cells may 
also prevent the formation of the active intermediate proposed in the 
hypothesis of Ignarro et al. (1981) by reducing the conversion of the 
pre-cursor, nitrite ion, from GTN. Alternatively, if tolerance 
develops as a result of some interference in the interaction of the 
active intermediate with the receptor, then accumulating metabolite 
levels may be responsible. 
Evidence of tolerance development to the hypotensive effects of 
GTN during long-term low dose GTN therapy in humans is conflicting 
(Abrams, 1980). However, tolerance to GTN has been described in rats, 
rabbits and dogs, with the degree of tolerance directly related to the 
dose of GTN administered (Abrams, 1980). More information is avail-
able on the tolerance developed to ISDN. Tolerance to high dose 
chronic oral ISDN therapy (up to 480 mg ISDN daily) in humans develops 
within 1-2 days (Thadani et al., 1980). The same group of workers 
later reported reduced plasma clearance of ISDN at the larger chronic 
doses used in their initial study (Fung et al., 1981). Fung and 
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Parker (1983) reported the presence of a previously undetected pro-
longed ISDN disappearance phase after 60 mg ISDN orally 4 times a day 
for up to 3 weeks. The terminal half-life of 7.7 hr for ISDN was 
slower than for the terminal half-lives of the 2-ISMN and 5-ISMN 
metabolites which were 3 hr and 6 hr, respectively. These results 
suggested that the metabolites were inhibiting the clearance of ISDN, 
a point which was later verified by Sutton and Fung (1984). Other 
workers have reported that 5-ISMN accumulates on chronic dosing of 
ISDN (Shane et al., 1978; Bruyneel et al., 1982). 
Recent evidence linking increased levels of organic nitrate meta-
bolites with the occurrence of tolerance to the hypotensive effects of 
the parent organic nitrate comes from the studies of Blasini et al. 
(1982) and Kogi et al. (1982), both of which are cited in a recent 
review by Rietbrock and Woodcock (1984). Dosing of patients with ISDN 
40 mg 4 times daily for 7 days resulted in the complete attenuation of 
the hypotensive effects of ISDN (Blasini et al., 1982). However, 36 
hr after the final ISDN dose another dose of 40 mg ISDN had its ori-
ginal maximal hypotensive effect on blood pressure. During the 36 hr 
break from ISDN dosing, 5-ISMN would have almost disappeared from the 
plasma given its half-life of about 5-6 hr (Abshagen and Sporl-Radun, 
1981; Fung and Parker, 1983). 
Kogi et al. (1982) appeared to overcome the problem of tolerance 
development to ISDN in dogs by administering the drug from a trans-
dermal preparation and it was suggested the reason for this was the 
much lower ISMN plasma concentrations arising in the plasm after 
transdermal dosing of ISDN compared to the large ISMN plasma concen-
trations produced following oral administration of the drug. 
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Figure 6.5 Effect of adding a 5 mg bolus dose of GDNs on the 
mean arterial blood pressure in sheep infused with 5.7 pig/min/kg 
GTN. Open symbols represent sheep receiving bolus dose of GDNs 
and closed symbols sheep not receiving bolus. 
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Similar experiments to those just described need to be performed 
using GTN to be able to determine a role for GDNs in the mechanism of 
tolerance development to the hypotensive effects of GTN. A diminution 
of the hypotensive effects of GTN was not observed when bolus doses of 
GDNs were administered during GTN infusions in sheep (Figure 6.5). 
One explanation for this could be that the dose of GDNs administered 
as a bolus (5 mg), although inhibiting GTN metabolism at the vascular 
receptor, was large enough to exert a substantial hypotensive action 
of its own despite the GDNs having only about 1/15 of the vasode-
pressive action of GTN. Experiments designed to elucidate the role of 
the GTN/GDN interaction in the development of tolerance to GTN will 
need to incorporate relatively small GDN doses. 
In summary, pharmacokinetic analysis of the organic nitrates may 
have given some insight into the cause of tolerance to the hypotensive 
effects of these drugs. Perhaps the most important and most difficult 
aspect to elucidate is whether organic nitrate metabolites can be 
proven to interfere with the interaction of the parent organic nitrate 
and its (possible) receptor in the vascular smooth muscle. 
6.6. PHARMACOKINETICS OF ASPIRIN IN SHEEP  
There are very few reports in the literature concerning IV dosing 
of ASA. Bolus ASA intravenous doses have been administered to dogs 
(Leonards, 1962) and humans (Rowland and Riegelman, 1968; Loo and 
Riegelman, 1968), and continuous IV infusions of ASA have been 
delivered to humans (Loo and Riegelman, 1968; Harris and Riegelman, 
1969). These studies demonstrated that the delivery of ASA to the 
systemic circulation was dependent on the route of administration. 
Harris and Riegelman (1969) infused ASA into the portal vein and vena 
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cava of dogs and compared the resulting ASA AUCs based on aortic 
plasma concentration profiles with AUCs obtained in aortic plasma 
after an equivalent oral dose of ASA. This work demonstrated signi-
ficant ASA extraction across the liver and gut wall. The present work 
extends these findings to demonstrate significant extra-hepatic 
metabolism of ASA and an in vivo interaction of ASA and SA. 
6.6.1. Plasma Protein Binding  
Plasma protein binding studies in vitro showed that the fraction 
of ASA unbound in normal sheep plasma for ASA concentrations of 10 and 
50 pg/ml was about 0.35 - 0.37. Given that ASA binding is dependent 
on the ASA concentration and the plasma protein concentration (Aarons 
et al., 1980) the values of fu for ASA at ASA concentrations of 10 and 
50 pg/ml are consistent with the results of Aarons et al. (1980). 
Those workers reported a f u for ASA of 0.32 (in the absence of SA) at 
an ASA concentration of 0.2 pg/ml and a protein concentration of 40 
mg/l. 
The presence of SA at a concentration of 50 pg/ml increased the 
free fraction of ASA to about 0.49 and this is consistent with the 
displacement of ASA from human and bovine albumin by SA as reported 
previously by Aarons et al. (1980). The free fraction of SA in normal 
sheep plasma was 0.15 - 0.22 for SA concentrations of 10 and 50 pg/ml 
(Table 5.6). These values are close to the values of fu for similar 
SA concentrations in dog and horse plasma (Sturman and Smith, 1967). 
During anaesthesia and surgery, the plasma albumin concentrations 
of all sheep fell. This decrease during surgery is probably a result 
of an increased catabolism of albumin and/or a greater distribution of 
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albumin into the extravascular space (Davies, 1976). The ramification 
is that the protein binding of ASA and SA would be altered. 
In in vitro studies on the binding of ASA and SA, diluted plasma 
(1:1) increased the f u of ASA with and without added SA relative to 
normal plasma whereas potassium fluoride and pentobarbitone had a neg-
ligible effect on the binding of ASA. The results of ASA and SA 
protein binding determinations in samples taken during ASA infusions 
are consistent with the in vitro findings and results reported in 
other studies (Moran and Walker, 1968; Spector et al., 1972; Aarons et 
al., 1980). Thus, the major determinants of ASA binding in sheep 
plasma were: 
(i) albumin concentration, and 
(ii) SA concentration. 
6.6.2. Arterial-Venous Plasma Aspirin Gradients  
Extraction Across the Leg  
The mean availability of total and free ASA across the hind leg 
of the sheep during ASA infusions at 485 pg/min/kg was 0.86 and about 
0.81, respectively. Results from the in vitro experiments showed that 
ASA is hydrolyzed to SA when in contact with muscle tissue homogenates 
and so the observed arterial-venous ASA concentration gradient is prob-
ably a result of ASA hydrolysis in the leg tissues. The rate of ASA 
hydrolysis by muscle homogenates was not dependent on the initial ASA 
concentration nor was SA able to inhibit the metabolism of ASA. 
These results suggest that muscle tissue could be a site of ASA 
clearance which contributes to the relatively short half-life of ASA 
in vivo. Although it has been recorded that ASA is hydrolyzed to SA 
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•in the gastro-intestinal tract (Rowland et al., 1972), blood (Rowland 
and Riegelman, 1967), liver (Harris and Riegelman, 1969), kidney and 
other organs (Rainsford, 1984) by the so-called "aspirin esterases," 
it has not previously been reported that muscle tissue has aspirin 
esterase activity. ASA may acetylate the proteins of muscle since 
Rainsford et al. (1983) and Rainsford (1984) report that ASA is 
capable of acetylating a variety of proteins. 
Extraction Across the Lungs  
Despite the in vitro experiments showing that lung tissue homo-
genates can hydrolyze ASA to SA, the mean availability of ASA across 
the lungs during in vivo experiments was close to unity (Table 5.20). 
The apparent lack of extraction may arise from either: 
(i) ASA not being distributed into the lung cells where the 
esterases are likely to reside; or 
(ii) as a consequence of the enormous flow rate of blood (the 
lungs receive the entire cardiac output). 
According to the negligible well stirred model, the availability (F) 
is given by the equation: 
1 	 (6.2) 
1 + fu Clint  /Q 
where fu is the fraction unbound, Clint is the intrinsic clearance, 
and Q the blood flow. If the flow rate Q is very much greater than f u 
• Clint (as is likely in the lung), the availability will appear to be 
unity. 
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Extraction Across the Liver 
The results of the current study are consistent with earlier 
reports which showed that the liver is responsible for substantial 
degradation of ASA. Harris and Riegelman (1969) showed that the mean 
availability of ASA infused into the portal vein was only 0.64 of the 
availability of ASA infused into the vena cava of conscious dogs. 
Results for the anaesthetized sheep preparation show that the mean 
availability of ASA across the liver during infusions was 0.72 - 0.77. 
6.6.3. Arterial-Venous Salicylic Acid and Salicyluric Acid Gradients  
Metabolite Gradients Across the Leg  
The arterial-venous gradient in total and free plasma SA concen-
trations was reversed after the termination of the ASA infusion at 485 
pg/min/kg. Because SA was still being formed at the end of the blood 
sampling after the infusion of ASA at 485 pg/min/kg no plasma AUCs 
could be calculated and therefore no estimate of availability was 
possible. However, the mean SA availability across the leg could be 
calculated from the data obtained for the infusion of ASA at 61 
pg/min/kg and was found to be 1.19 (Table 5.23) indicating that SA was 
not being further metabolized in the leg muscle. An availability 
greater than unity would arise from the production of SA in the leg on 
ASA metabolism. 
The above conclusions are consistent with the in vitro findings. 
In the in vitro incubations of ASA with muscle homogenates, ASA was 
metabolized and could be totally accounted for by the production of 
SA. Metabolism of SA involves hydroxylation or conjugation with 
glycine or glucuronic acid. As there is no evidence for these path- 
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ways in skeletal muscle (Gram, 1980), it is not surprising that SA is 
not metabolized during its passage across the leg. 
Bolus doses of SA delivered into the aorta resulted in a venous-
arterial gradient in SA concentrations. The rate of elimination of SA 
was considerably slower after the bolus dose of 1200 mg SA than after 
the lesser SA doses. This finding is consistent with previously 
published results which show the elimination of SA to be non-linear in 
nature as a result of saturation of its major metabolic pathway (Levy, 
1965; Tsuchiya and Levy, 1972). 
Total and free SU concentrations were typically slightly greater 
in the arterial plasma than venous plasma during the early stages of 
their formation but the gradient had been abolished or reversed by the 
time the ASA infusion was terminated. Administration of the 1200 mg 
bolus SA dose temporarily resulted in the formation of an arterial-
venous gradient in SU concentrations. 
Metabolite Gradients Across the Lungs  
The mean availability of SA across the lungs was close to unity 
and therefore comparable with the values for ASA for the two ASA 
infusion rates. Glucuronide conjugation occurs in mammalian lung 
tissue but glycine conjugation does not (Gram, 1980) and so it is 
possible that SA could be further metabolized to salicyl acyl 
glucuronide or salicyl phenolic glucuronide. However, as suggested 
earlier for ASA (6.6.2.), distribution of SA in the lung and the high 
pulmonary blood flow may be such to result in an availability close to 
unity. 
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Metabolite Gradients Across the Liver  
SA has a moderately low hepatic extraction ratio (Rowland and 
Tozer, 1980). In the sheep, the availability of SA across the liver 
was calculated to be 0.91, i.e., an extraction ratio of 0.09. The 
very low extraction ratio results in part from SA generated in the 
liver during ASA metabolism. Leonards (1962) reported that after oral 
administration of ASA to dogs, plasma ASA concentrations in the 
hepatic vein were less than those in the portal vein, a result con-
sistent with the findings of the current work. Leonards (1962) also 
reported that plasma salicylate concentrations in the hepatic vein 
were larger than in the portal vein. The large extraction ratio for 
ASA and its conversion to SA would lead to an availability of SA 
greater than unity. An availability exceeding unity may also be due 
in part to the analytical method used by Leonards (1962) who used the 
method of Brodie et al. (1944). This method measures total sali-
cylate, (i.e., salicylate, salicylurate and salicylate glucuronides) 
after vigorous hydrolysis. 
The present results show that SU concentrations in the hepatic 
vein were greater than in the portal vein which is consistent with its 
formation in the liver. In humans SU production is mainly via hepatic 
metabolism and renal metabolism is a minor pathway (Schachter and 
Manis, 1958; Lowenthal et al., 1974). The proportions of renal and 
hepatic production of SU in sheep are unknown. 
6.6.4. Effect of Salicy^  lic Acid on Aspirin Pharmacokinetics  
In order to investigate whether SA administration during ASA 
infusion had any effects on ASA pharmacokinetics ASA infusions at 
61 pg/min/kg were used. This was because SA formed during ASA 
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infusions at 485 pg/min/kg achieved plasma concentrations of the order 
of 50 pg/ml. It was intended to infuse SA as bolus doses into sheep 
which had easily detectable ASA plasma concentrations yet which had 
only small SA plasma concentrations. This was necessary to monitor 
the effects of a dose of SA on the clearance of ASA. 
SA had no discernible effects on the elimination of ASA except 
for the 1200 mg bolus dose of SA when the half-life of elimination of 
ASA was approximately two-thirds that obtained for lower SA doses. 
This effect was observed for both total and free ASA plasma concentra-
tions and was probably due to the displacement of ASA from plasma 
proteins by SA. In vitro protein binding studies of the interaction 
of ASA and SA showed that SA could displace ASA from protein binding 
sites, a result which is consistent with the in vitro findings of 
Aarons et al. (1980). ASA has been classified as a drug of inter-
mediate hepatic extraction ratio (Rowland and Tozer, 1980). Since 
hepatic clearance is a function of intrinsic clearance and fu , the 
change in the total clearance of ASA is affected by a change in f u . 
It is unlikely that SA affected the hepatic intrinsic clearance of ASA 
as in vitro experiments failed to show any inhibition of ASA meta-
bolism in liver (or muscle or lung) homogenates by SA. As bolus 
dosing of SA had no effect on cardiac output the increased elimination 
of ASA after the 1200 mg SA dose appears to be due solely to the 
effects of SA on ASA binding. 
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6.7. PHARMACOKINETICS AND PHARMACODYNAMICS OF ASPIRIN IN MAN  
6.7.1. Plasma Aspirin Levels  
The peak ASA levels following ingestion of 300 mg soluble or 
micro-encapsulated ASA in the current study were generally in agree-
ment with other workers' reports. Rowland et al. (1972) and Rance et 
al. (1975) reported peak plasma ASA levels after 650 mg soluble ASA as 
10-23 jig/ml and a mean of about 10 jig/ml, respectively. The mean peak 
plasma ASA concentrations after 300 mg soluble ASA in the current work 
were about 3.5 jig/mi. 
The slow-release ASA used in the current work was in the form of 
micro-encapsulated granules and is a relatively new product. The dif-
ferences in bioavailability of ASA from single doses of the soluble 
and similar slow release formulations are consistent with results pre-
sented by Brantmark et al. (1982), and Ross-Lee et al. (1982). 
The approximate direct relationship for (detectable) peak ASA 
concentrations and doses of the slow release ASA formulation (Table 
5.24) is consistent with the direct relationship between steady-state 
plasma ASA concentrations and dose after IV infusions in sheep (Figure 
5.61), and with the lack of dose dependency of ASA kinetics reported 
by Pedersen and Fitzgerald (1984) after oral doses of ASA in man. 
6.7.2. Aspirin Bioavailability and Platelet Function  
The degree of inhibition of platelet function was similar for the 
soluble and slow-release ASA formulations despite marked differences 
in plasma ASA concentrations. The magnitude of platelet function 
inhibition is unrelated to the peak ASA concentrations or to the area 
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under the plasma ASA concentration-time curve. A possible explanation 
for this lack of correlation is the irreversible and saturable ace-
tylation of platelets (Roth et al., 1975). From the slow-release 
formulation the plasma ASA concentrations were very low, and in MO 
subjects were undetectable ( < 0.1 pg/m1). However, there was a 
corresponding marked inhibition of platelet function. It is apparent, 
therefore, that platelets may be acetylated when plasma ASA concen-
trations are very low. The lack of correlation between inhibition of 
platelet function and plasma ASA concentrations shows that plasma ASA 
concentrations cannot be used as an index of platelet inhibition 
produced by ASA. 
The present study shows that low doses of either a soluble or a 
slow-release formulation are adequate for the inhibition of platelet 
function as assessed in these experiments. The dose of the slow-•
release formulation required to produce 50% of maximal inhibition of 
platelet aggregation/MDA production was less than 50 mg for AA and 
adrenalin, and less than 100 mg for collagen. This dose is comparable 
with doses reported for faster releasing ASA formulations. Burch 
et al. (1978) found that repeated daily administration of 20, 80 and 
325 mg ASA for 5-7 days produced 61, 86 and > 95% inactivation of 
cyclooxygenase, respectively. Lorenz et al. (1981) found that 
repeated daily administration of 100 mg ASA almost totally inhibited 
aggregation and TXB 2 formation after induction by AA, adenosine 
diphosphate and low collagen concentrations. Larger collagen con-
centrations (of the order used in this study and in that of Masotti et 
al., 1979) resulted in reduced platelet aggregation for doses of 100 
mg ASA per day but with complete suppression of TXB2 formation 
(Patrano et al., 1980). The incomplete inhibition by ASA of platelet 
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aggregation induced by larger collagen concentrations probably results 
from collagen inducing aggregation by other mechanisms independent of 
TXA2 synthesis (Emms et al., 1982). Relatively high doses (1,200 - 
1,300 mg) of soluble ASA were employed in the initial clinical trials 
evaluating the efficacy of ASA for transient ischaemic attacks (Fields 
et al., 1977; The Canadian Co-operative Study Group, 1978). More 
recent studies have suggested that lower doses of soluble ASA may be 
preferred to the higher doses because the lower doses of ASA may 
inhibit platelet TXA 2 production and platelet aggregation without 
markedly interfering with PGI 2  production by vessel wall cyclo-
oxygenase (Masotti et al., 1979; Preston et al., 1981; Hanley et al., 
1981; Patrignani et al., 1982; Fitzgerald et al., 1983). This aspect 
discussed in Section 6.8. 
The effects of ASA on the in vivo endothelial cell wall pro-
duction of PGI 2 per se are difficult to estimate because PGI 2 is a 
local hormone present only in very low concentrations in systemic 
plasma (Haslam and McGlenaghan, 1981; Blair et al., 1982). The meta-
bolites of PGI2 have been quantified (particularly 6-oxo-PGF 1a) in the 
urine of subjects taking soluble ASA (Fitzgerald et al., 1983; 
Patrignani et al., 1982). Patrignani et al. (1982) suggested that 
0.45 mg ASA/kg (i.e., about 30 mg) may be a suitable dose since 
platelet activity was impaired while renal production of PGI 2  was not 
during one month of therapy in healthy subjects. However, Fitzgerald 
et al. (1983) using urine levels of metabolites of TXA2 and PGI2 as 
indices of platelet and vessel wall cyclooxygenase activity found that 
even doses as low as 20 mg per day for 8 days had a marginal effect on 
PGI2 production, the degree of selectivity decreasing with increasing 
dose. 
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Other workers have evaluated the effects of ASA on PGI 2 produc-
tion by different techniques. Masotti et al. (1979) suggested that a 
single dose of approximately 175 mg (2.5 mg/kg body weight) had no 
effect on PGI 2 synthesis induced by forearm ischaemia, whereas larger 
doses (3.5 to 10 mg/kg body weight) significantly inhibited PGI 2 
synthesis with full recovery by 48 hr. Preston et al. (1981) found 
that 150 and 300 mg ASA substantially depressed the production of 
6-oxo-PGF 1a  from autologous human venous biopsies. Hanley et al. 
(1981) found 81 mg ASA taken 14 hr preoperatively resulted in approxi-
mately 60% depression of the release of PGI 2-like material from 
autologous postoperative venous biopsies. However, a single dose of 
40 mg had not effect on PGI 2 synthesis by venous tissue. 
6.8. CLINICAL IMPLICATIONS OF ASPIRIN STUDIES  
As the ASA dose-platelet function response curves appear to be 
similar for the slow-release formulation examined in this study and a 
conventional soluble ASA formulation, the relative extent to which 
these formulations may affect vessel wall cyclooxygenase may be of 
clinical significance. The slow-release preparation in doses in 
excess of 100 mg produced maximum inhibition of platelet function via 
platelet cyclooxygenase as measured by in vitro methods. The extent 
to which the vessel wall cyclooxygenase was inhibited and the relation-
ship of dose of ASA and inhibition of vessel wall cyclooxygenase was 
not determined in these studies. However, it is possible that the•
lower plasma ASA concentrations found for the slow-release formulation 
could be associated with a lesser inhibition of vessel wall cyclo-
oxygenase than of platelet cyclooxygenase. A slow-release formulation 
may result in selective inhibition of platelet cyclooxygenase in the 
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portal circulation with only very small amounts of ASA being available 
systemically due to the significant hepatic first-pass effect for ASA. 
Thus, production of the anti-aggregating and vasodilator PGI 2 may be 
relatively unaffected. 
Recent studies by Weksler et al. (1985a,b) have suggested that 
doses of ASA in the range 20-40 mg daily may be beneficial for 
patients with recent cerebral ischaemia and patients with athero-
sclerosis. The basis of this claim is that low ASA doses have a 
similar anti-platelet effect to high doses but they also have a 
cumulative anti-platelet effect. Moreover, Weksler et al. (1985b) 
found that those low doses of ASA produced marked inhibition of 
platelet aggregation and thromboxane synthesis in patients with 
coronary artery disease but only a partial depression of vascular PGI 2 
production, as measured in vessel segments removed during surgery. 
Pedersen and Fitzgerald (1984) are others who have shown that oral 
doses of 20-40 mg ASA produce marked inhibition of thromboxane for-
mation and they have also suggested that pre-systemic acetylation of 
platelet cyclooxygenase can be achieved by small doses of a 
conventional ASA formulation, but that slow administration of very low 
doses of ASA may offer an even better means of selective platelet 
cyclooxygenase inhibition. 
One factor which may make the attainment of a selective pre-
systemic acetylation of platelet cyclooxygenase more difficult than 
currently envisaged involves the significant extra-hepatic metabolism 
of ASA. As shown in the sheep experiments, extraction of ASA occurred 
across the leg of the sheep and this results from metabolism of ASA to 
SA. These results indicate that metabolism of ASA by the liver after 
oral administration only partly accounts for the observed availability 
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in man (Rowland et al., 1972; Pedersen and Fitzgerald, 1984). This 
availability is obtained when the availabilities of the liver, lung 
and leg are multiplied as is customary for organs in series (Gibaldi 
and Perrier, 1982). This suggests that the trans-hepatic gradient of 
ASA would not be as pronounced after an oral dose compared to not 
taking the extra-hepatic metabolism of ASA into consideration. It is 
possible that after very small oral doses of ASA the extraction of ASA 
by the liver would leave insufficient amounts of ASA to be available 
to the cyclooxygenase of the systemic vessel walls, regardless of 
extra-hepatic ASA metabolism. Nevertheless, this aspect of ASA 
metabolism needs to be borne in mind when designing low dose ASA 
protocols to try to achieve selective effects of ASA on cyclo-
oxygenase. 
Cerletti et al. (1981) have suggested that ASA and SA compete for 
binding sites on cyclooxygenase and that SA may protect the vessel 
wall cyclooxygenase more than platelet cyclooxygenase from the effects 
of ASA. Following administration of 300 mg slow-release ASA formula-
tion, the peak plasma ASA/SA concentration ratio was about 0.1. In 
contrast, the ratio following administration of the 300 mg soluble 
formulation was about 0.3 which is similar to the value of 0.5 found 
by Rowland et al. (1972). SA had no effect on extraction or mean 
residence time of ASA in sheep but did displace ASA from plasma pro-
teins at high concentrations of SA. It is possible that SA could also 
displace ASA from vascular cyclooxygenase yielding an apparent pro-
tective effect for SA in relation to the inhibition of PGI 2 production 
induced by ASA. In this respect a slow-release ASA formulation may be 
more beneficial because of the relative ASA and SA systemic blood 
concentrations arising from this preparation. Only when PGI2 
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production is measured after administration of the slow-release ASA 
preparation can this aspect be elucidated. 
The full clinical implications of this work await the reports of 
large-scale, international studies currently underway which are inves-
tigating the most appropriate dose, dosing interval and formulation of 
ASA to reduce the incidence of cerebro/cardiovascular disease. 
Judging by the results presented in this thesis and a survey of the 
current literature, it would be anticipated that ASA from a slow-
release preparation would have, at least, an equivalent effect to an 
equivalent dose of ASA from a faster releasing preparation if, indeed, 
chronic ASA therapy is found to reduce the incidence of cerebro/ 
cardiovascular disease. 
6.9. CONCLUSIONS  
This thesis has presented results which show that GTN and ASA are 
subject to significant extra-hepatic metabolism in sheep. Moreover, 
the disposition of both drugs in sheep is affected, to various degrees 
and in different manners, by their major metabolites. The full 
clinical ramifications of these findings await further investigations 
in man. 
One aspect not covered in this thesis is the possibility of an 
interaction between ASA and GTN. Preliminary reports from some inves-
tigators suggest that the haemodynamic responses to GTN are attenuated 
by co-administration of ASA. Other reports suggest that ASA augments 
the haemodynamic responses to GTN. This is potentially a very impor-
tant interaction considering the probable large numbers of patients 
dependent on sufficient haemodynamic response to GTN who use ASA 
either chronically or intermittently. 
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Despite the widespread use of GTN and ASA over many years, it is 
apparent that many avenues of research remain to be followed to more 
fully understand the pharmacokinetics and pharmacodynamics of these 
two important and interesting drugs. 
APPENDIX 
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Table 91 Intra- and 	Inter-Subject Variability in Control 	Platelet AegrPpation Rpsoonses 	to 
X Liyht Transmission 
Adrenalin 
Subject Day 1 2 3 5 WAN S.D. 	S.E. 	S 	C.V. 
KS 15 16 14 65 21 26.2 21.8 	9.7 	83.4 
EM 94 80 72 81.3 II.) 6.5 13.9 
DK 15 36 12 82 15 32.2 29.7 	13.3 	92.2 
SS 79 86 77 80.0 4.5 2.6 5.6 
DR 83 86 90 82 84 85.2 3.1 	1.4 	3.6 
HE 82 62 82 75.2 11.7 6.6 14.0 
SC 76 87 86 82 79 82.0 4.8 	1.7 	5.8 
MW 87 86 51 74.7 20.6 12.1 27.6 
RH 83 85 82 82 16 69.9 29.8 	10.6 	42.7 
AU 83 87 83 84.5 2.6 1.5 3.1 
MS 81 82 84 85 83.7 1.5 	0.9 	1.9 
SJ 12 87 15 38.0 42.9 25.2 113.0 
WM 24 76 80 77 80 67.2 24.4 	8.7 	36.0 
EN 77 85 85 82.3 4.6 2.7 5.6 
JC 72 80 80 80 19 67.2 26.9 	9.6 	40.2 
NW 12 30 21 21.3 8.7 5.2 41.0 
MEAN 59.9 72.1 63.4 79.3 49.9 
S.D. 32.8 23.3 29.7 6.1 34.3 Total Population 	variability 
S.E. 8.5 5.8 7.4 2.2 12.2 
X C.V. 54.8 32.4 46.9 7.7 68.8 Mean 	• 	63.4 
S.D. 29.3 
S.E. 	3.4 
X C.V. 	• 	46.0 
Table 92 Intra- and 	Inter-Subject Variability 	in Control 	Platelet Aegreyation 
% Light Transmission 
Responses to Collagen 
Subject Day 2 3 4 5 MEAN 	S.D. 	S.E. 	X C.V. 
KS 86 82 80 82 83 82.6 	2.2 	1.0 	2.7 
EM 90 85 82 85.7 4.0 1.9 4.7 
DK 90 91 87 82 82 86.8 	4.1 	1.9 	4.8 
SS 86 90 82 86.3 3.7 2.2 4.3 
DR 90 90 85 84 85 86.8 	2.9 	1.3 	3.4 
HE 92 82 83 86.0 5.6 3.3 6.6 
SG 81 86 77 78 80 80.8 	4.0 	1.8 	4.9 
MW 91 92 87 90.3 2.5 1.5 2.8 
RH 80 86 80 81 83 82.3 	2.7 	1.2 	3.3 
AU 92 90 82 88.1 5.1 3.0 5.8 
MS - 87 85 85 82 84.7 	2.5 	1.2 	2.9 
SJ 90 87 84 87.1 3.0 1.7 3.4 
WM 83 77 85 82 82 81.7 	3.1 	1.5 	3.9 
EN 84 92 85 87.0 4.3 2.5 5.0 
JC 78 82 85 82 84 83.3 	4.2 	1.9 	5.1 
HW 85 86 90 87.0 2.6 1.5 3.4 
MEAN 86.6 86.8 83.8 82.0 82.7 
S.D. 4.6 4.3 3.1 2.0 1.5 Total Population Variability 
S.E. 1.2 1.0 0.8 0.7 0.5 
% C.V. 5.3 5.0 3.7 2.5 1.9 	 Mean 	84.7 
S.D. 3.4 
S.E. 	0.4 
C.V. 	• 	4.0 
Table 	93 Intra- and Inter-Subject Variability in Control Platelet Aygregation Responses 
to Arachidonic Acid 
SUBJECT 
KS 
EM 
DK 
SS 
DR 
HE 
SC 
MW 
RH 
AU 
MS 
Si 
WM 
EN 
JC 
HW 
DAY 1 2 3 4 5 MEAN S.D. S.E. 	%C.V. 
80 
80 
83 
86 
86 
83 
82 
82 
85 
83 
82 
75 
82 
90 
82 
82 
82 
87 
80 
80 
82 
85 
79 
80 
83 
85 
80 
87 
82 
82 
82.1 
85.3 
83.2 
80.5 
83.7 
84.8 
80.5 
81.5 
2.0 
2.0 
0.8 
2.2 
1.3 
1.3 
Total 
1.1 	2.4 
1.1 	2.3 
0.5 	1.0 
1.3 	2.6 
0.7 	1.6 
0.7 	1.6 
Pooulation 	Variabili:y MEAN 
S.D. 
S. K. 
X C.V. 
83.7 
3.3 
0.8 
4.0 
82.0 
2.9 
1.0 
3.6 
83.3 
2.5 
0.9 
3.0 
'an 	• 	82.6 
Sar 	W 
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Table A4 Nitroglycerin (GTN) plasma concentrations (ng/nl) after intravenous bolus doses 
of nitroglycerin injected into a femoral vein of sheep No. 13. (FA = femoral 
artery, FV • femoral vein) 
 
Dose of GTN (1.g/kg) 
	
TIME 	 2.7 	 5.4 	 13.6 	 27.2 	 54.4 	 108.8 
(min) FA 	FV FA 	FV FA 	FV 	FA 	FV 	FA 	Fl.' 	FA 	FV  
0 	15.2 	0.23 	38.4 	3.4 	72.3 	3.5 	145.6 	1.9 	304.8 	302.4 	496.3 	211.1; 
1 0.82 	a ND 	3.5 	2.2 	7.0 . 7.4 	27.2 	16.8 	81.6 	36.8 	172.1 	46.0 
2 	0.24 	ND 	1.1 	0.83 	1.8 	1.5 7.5 	2.2 	11.2 	13.0 	55.5 	50.2 
3 ND 	ND 	0.22 0.21 	1.1 	0.83 	1.2 	1.2 3.5 	4.2 10.9 	41.6 
4 	ND 	ND ND 	ND 	0.68 	0.57 	0.97 	0.98 	2.7 	4.0 	9.8 	10.3 
5 ND 	ND 	ND 	ND 	0.32 	0.25 	0.72 	0.43 	2.0 	3.5 9.2 	8.: 
6 	ND 	ND ND 	ND ND 	ND 	0.53 	0.39 	1.3 	1.3 	6.3 	8.6 
8 ND 	ND 	ND 	ND 	ND 	ND 	0.34 	ND 	0.50 	0.63 3.5 	3.0 
10 	ND 	ND ND 	ND ND 	ND 	0.20 	ND 	0.38 	0.51 	2.1 	3.0 
12 ND 	ND 	ND 	ND 	ND 	ND ND 	ND 	0.24 	0.27 	1.3 	1.6 
15 	ND 	ND ND 	ND ND 	ND 	ND 	ND ND 	ND 	0.72 	1.2 
AUS _.,,. . 	8.6 24.4 	5.2 	47.7 	12.8 	113.1 	23.9 	258.1 	218.0 	533.2 	300.2 
AUMS ....?..., 	2 : 1 	 9.0 	7.3 	23.6 	20.3 	72.7 	40.1 	167.3 	160.6 	663.6 	728.6 
KRT 	0.24 0.37 1.41 	0.49 	1.58 	0.64 	1.68 	0.65 	0.74 	1.24 	2.4•., 
°not detectable 
Table Ac Nitroglycerin (CTN) plasma concentrations (ng/ml) after intravenous bolus doses 
of nitroglycerin injected into a femoral vein of sheep No. 14. (FA • femoral 
artery, FV 	femoral vein). 
 
Dose of GTN (g/k) 
Time 	 2.7 	 5.4 	 13.6 	 27.2 	 54.4 	 108.8 
(min) FA 	FV 	FA 	FV 	FA 	FV 	FA 	FV 	FA 	FV 	FA 	Fl.'  
0 	9.8 	0.33 	38.0 	2.1 	45.2 	2.9 	97.3 	3.7 	311.0 	110.0 	420.0 	410.F . 
1 1.1 	5ND 	3.8 	1.1 	9.2 	4.7 	15.3 	10.5 78.2 	114.0 151.8 	130.1 
2 	0.38 	ND 	1.3 	0.74 	1.1 	1.1 	2.8 	2.3 	10.8 	8.7 	38.3 	53.: 
3 0.21 	ND 	0.43 	b_ 0.67 	0.54 	0.98 	1.1 4.3 	b_ 10.0 	12.1 
4 	ND 	ND 	0.25 	ND 	0.53 	0.41 	0.71 	0.77 	3.6 	3.9 	8.3 	10.4 
5 ND 	ND ND 	ND 	0.41 	0.37 	0.61 	b. 2.9 	2.7 7.8 7.8 
6 	ND 	ND 	ND 	ND 	0.27 	0.24 	0.41 	b. 	1.5 	1.6 	5.9 	8.5 
8 ND 	ND ND 	ND 	• ND 	ND 	0.27 	0.22 	0.84 	0.62 2.9 6.2 
10 	ND 	ND 	ND 	ND ND 	ND ND 	ND 0.45 	0.38 	2.3 	5.1 
12 ND 	ND ND . ND 	ND 	ND 	ND 	ND 	0.33 	0.41 1.9 3.9 
15 	ND 	ND 	ND 	ND ND 	ND ND 	ND 0.22 	0.38 	0.97 	2.4 
AUS _..„.. 6.6 25.1 	4.0 	35.6 	9.4 	70.8 	18.6 	262.0 	198.3 457.5 	485.5. 
AUMS..).. 	2.4 	 11.3 	7.9 	25.4 	19.0 	45.6 	37.9 	211.0 	263.5 	682.4 	1184.5 
HRT 	0.36 0.45 1.97 	0.71 	2.02 	0.64 	2.04 	0.80 	1.33 	1.49 	2.4- 
C0 detectable 
bsampling line blocked 
Table AN Nitroglycerin (GTN) plasma concentrations (ng/ml) after intravenous bolus doses 
of nitroglycerin injected into a femoral vein of sheep No. 15. (FA • femoral 
artery, FV • femoral vein). 
 
Dose of GTN (uq/k) 
Time 	2.7 	 5.4 	 13.6 	 27.2 	 54.4 	 108.8 
fmin) 	FA 	El/ 	FA 	FV 	FA 	FV 	FA 	FV 	FA 	FV 	FA 	 FV  
0 	13.8 	0.45 	34.7 	3.1 	68.1 	6.8 	118.2 	59.7 	288.8 	60.9 	387.2 	488.7 
1 	2.1 	0.26 	5.9 	2.9 	17.9 	10.0 5.0 	6.1 	78.3 	69.3 205.1 	300.8 
2 	0.42 	°ND 	2.1 	1.4 	4.0 	3.0 • 	1.1 	1.4 	28.7 	14.0 	131.8 	140.7 
3 	0.26 	ND 	1.4 	0.68 	2.2 	1.6 0.73 	0.99 	8.3 	7.3 46.3 	121.7 
4 	ND 	ND 	0.94 0.44 	1.9 	1.1 	0.67 	0.84 	6.1 	7.0 	18.9 	50.8 
5 	ND 	ND 	0.59 0.23 	1.2 	0.81 	0.53 	0.58 3.7 	3.1 7.4 	28.7 
6 	ND 	ND ND 	ND 	0.64 	0.57 	0.29 	0.31 	2.4 	2.1 	6.0 	12.7 
8 	ND 	ND 	ND 	ND 	0.47 	0.24 ND 	0.26 1.2 	0.88 4.2 6.3 
10 	ND 	ND NO 	ND ND 	ND 	ND 	ND 	0.54 	0.58 	3.7 	6.0 
12 	ND 	ND 	ND 	ND 	NO 	ND ND 	ND 	0.22 	0.22 2.4 4.8 
15 	ND 	ND ND 	ND ND 	ND 	ND 	ND ND 	0.28 	1.0 	1.9 
9.9 29.8 	7.6 	64.0 	21.7 68.0 	39.3 	277.4 	138.4 639.7 	957.0 
AUMR.4„. 3.9 	 31.1 14.9 	70.1 	43.6 	22.9 	29.6 	266.6 	236.1 	1098.6 	2022.0 
MST 	0.39 	- 	1.05 	1.96 	1.09 	2.01 	0.34 	0.75 	0.96 	1.71 1.71 	2.11 
' , Iot dr•toct 1h 1.• 
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Table A7 	Reduction in mean arterial blood pressure 
(MABP) and mean left ventricular pressure (MLVP) induced by 
bolus doses of nitroglycerin (GTN) administered into a 
femoral vein of Sheep Nos. 13 a , 14b and 15c • 
Dose GTN 
(14/kg) a 
% Reduction 
  
MABP MLVP MABP MLVP MABP MLVP 
2.7 12.3 10.5 9.1 6.6 17.7 11.1 
5.4 16.1 11.8 14.6 13.2 19.4 16.7 
13.6 29.0 29.4 18.6 17.1 31.3 25.3 
27.2 43.3 42.9 33.3 34.1 50.0 33.3 
54.4 64.3 50.0 42.9 42.5 71.9 60.5 
108.8 70.2 60.5 55.6 53.4 77.1 73.7 
Table AR The effect of bolus doses of nitroglycerin 
(GTN) on the duration of reduction in mean 
arterial blood pressure and their effects on 
cardiac output in sheep Nos. 13 a , 14b , 15 c . 
 
Dose GTN 	Duration of blood 	Maximum % change in 
pressure reduction cardiac output 
(pg/kg) (min) 
a 	b 	c 	a 
2.7 1.4 1.2 1.3 + 	11.0 + 	6.1 + 	10.2 
5.4 2.2 1.9 2.0 0 - 	2.8 + 	6.3 
13.6 3.0 3.6 4.2 - 	2.0 - 	4.1 0.3 
27.2 8.0 8.4 9.4 - 	2.7 - 	4.8 - 	1.2 
54.4 20.0 24.0 22.0 - 	6.5 - 	8.0 - 	4.8 
108.8 28.0 29.1 25.5 - 	17.5 - 20.1 - 	13.9 
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Table A9 • Nitroglycerin plasma concentrations (ng/ml) after an intravenous infusion of 
nitroglycerin (0.4 ug/min/kg) into a femoral vein of sheep No. 9. 
 
I 	Time 
N 	(min) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery 
Left 
ventricle 
Femoral 	Femoral 
artery vein 
0 
10 
20 
30 
40 
41 
42 
43 
44 
45 
46 
48 
50 
52 
55 
60 
65 
1.4 
1.5 
1.5 
1.4 
a ND 
0.32 
0.34 
0.39 
6.7 
8.2 
7.9 
8.1 
4.7 
4.1 
4.7 
5.0 
4.2 
4.1 
4.6 
4.5 
1.6 
0.90 
0.37 
NO 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
0.42 
0.71 
0.63 
0.66 
0.23 
ND 
ND 
ND 
ND 
ND 
NO 
ND 
ND 
ND 
NO 
ND 
AUC 	 59 	10 	 316 	 189 	 156 	 21 vim 
AUHS ...). .. 	 1547 	349 	 8485 	 5045 	 3820 	 570 
WIT 	 26.22 	32.34 	 26.85 	 26.63 	 24.42 	26.52 
anot detectable 
Table A10 	Nitroglycerin plasma concentrations (ng/m1) after an intravenous infusion of 
nitroglycerin (0.4 ug/min/kg) into a femoral vein of sheep No. 16. 
	
Time 	 Portal 	Hepatic 	 Pulmonary 	Left 	 Femoral 	Femoral 
F1 (min) vein vein artery ventricle artery vein   10 1.0 aND 5.5 2.5 2.2 ND U 20 1.2 ND 6.0 2.6 2.4 0.22 S I 	30 	 1.2 	 ND 	 6.0 	 2.8 . 	 2.8 	 0.24 0 	40 1.2 0.26. 5.8 2.8 2.7 0.28 N 41 	 0.65, 	 ND 
42 0.26 ND 
43 	 ND 	 ND 
44 ND ND 
45 	 ND 	 ND 
46 ND ND 
48 	 ND 	 ND 
50 ND ND 
52 	 ND 	 ND 
55 ND ND 
60 	 ND 	 ND 
65 ND ND 
AUL,. 	47 	 3 	 238 	 109 	 91 	 8 
AUML). 	1263 125 .6275 2926 2239 253 
HRT 	 26.89 	44.7 	 26.32 	 26.72 	 24.58 	32.46 
'not detectable 
Table 	All Nitroglycerin plasma concentrations (ns/m1) after an intravenous infusion of 
nitroglycerin (0.4 ug/min/kg) into a femoral vein of sheep No. 17. 
 
 
Time 
(min) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery ventricle 
Femoral 
artery 
Femoral 
vein 
 
         
I 
N 
F 10 	 1.7 	 'ND 	 6.1 	 3.9 	 3.7 	 0.41 U 
S 20 1.8 0.28 	 6.2 3.9 3.8 0.52 
I 30 	 1.8 	 0.35 . 5.8 	 3.9 	 3.7 	 0.48 0 ..V._ 40 1.8 0.42 	 6.0 3.9 3.8 0.64 
41 	 1.3 	 0.31 
42 0.78 0.20 
43 	 0.34 	 ND 
44 ND ND 
45 	 ND 	 ND 
46 ND ND 
48 	 ND 	 NO 
50 ND ND 
52 	 ND 	 NO 
55 ND ND 
60 	 ND 	 ND 
65 ND ND 
72 	 II 	 246 	 159 	 137 	 19 
Alltig, 	1915 358 6410 4163 3267 502 
HRT 	 26.39 	 32.54 	 26.02 	 26.10 	 23.74 	 26.42 
'not detectable 
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Table 	412 Nitroglycerin plasma concentrations (ng/ml) after an intravenous 	infusion of 
nitroglycerin (5.7 ug/min/kg) 	into a 	femoral vein of sheep No. 	10. 
Time 
Smin) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery 
Left 
ventricle 
Femoral 
artery F7:1,11 
F 
U 
S 10 10.3 3.4 92.7 67.1 65.2 12.3 
1 20 12.5 4.3 	• 94.1 73.5 73.0 13.8 
0 30 11.7 3.8 105.3 70.2 68.9 13.3 
111_ 40 13.4 4.4 103.2 71.8 71.4 15.4 
41 40.8 8.8 
42 4.8 4.2 
43 2.2 2.0 
44 1.6 1.8 
45 1.2 1.2 
46 0.91 0.82 
48 0.63 0.60 
50 0.37 0.43 
52 0.22 0.20 
55 aND ND 
60 NO ND 
65 NO ND 
AUL,.. 	466 	 154 	 3849 	 2746 	 2517 	 505 
AUMS_+5o 	12078 3994 98483 69296 59811 12485 
MIT 	 25.92 	25.84 	 25.58 	 25.22 	 23.76 	24.72 
°not detectable 
Table 413 	Nitroglycerin plasma concentrations (mg/ml) after an intravenous infusion of 
nitroglycerin (5.7 ug/min/kg) into a femoral vein of sheep No. 11. 
Time 
Smin) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery 
Left 
ventricle 
Femoral 
artery 
Femoral 
vein 
I 
N 
F 
U 
S 	10 13.4 4.3 115.3 79.1 76.0 10.0 
1 	20 14.6 8.2 112.0 81.2 78.1 12.2 
0 	30 22.4 8.5 122.4 82.2 85.2 11.0 
!I_ 40 20.2 5.0 122.0 84.1 85.0 9.8 
41 62.0 6.7 
42 8.4 5.2 
43 3.7 3.2 
44 3.0 3.1 
45 2.1 2.0 
46 1.8 1.5 
48 1.2 1.2 
50 0.88 0.80 
52 0.64 0.71 
55 0.30 0.30 
60 ND ND 
65 ND ND 
717 262 4781 3298 2947 414 
20132 6885 125806 86513 71276 10269 
NRT 	 28.07 	26.18 	 26.31 	26.23 	 24.18 	24.77 
°not detectable 
Table 	ma 	Nitroglycerin plasma concentrations (mg/ml) after an intravenous infusion of 
nitroglycerin (5.7 pg/min/kg) into a femoral vein of sheep No. 12. 
Time 
Smin) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery 
Left 
ventricle 
Femoral 
artery 
Femoral 
vein 
I 	10 10.1 2.3 121.1 90.2 89.2 10.0 
0 	20 14.3 4.7 123.8 92.9 92.8 13.4 
N 	30 18.7 3.2 126.0 96.5 93.7 12.6 
-- 40 18.1 4.8 127.3 99.2 97.1 12.1 
41 57.3 7.5 
42 8.9 	. 5.4 
43 4.1 4.0 
44 2.9 3.4 
45 1.9 2.0 
46 1.6 1.4 
48 1.0 0.96 
50 0.77 0.77 
52 0.51 0.54 
55 0.26 ND 
60 aND ND 
65 ND NO 
620 	152 	 5051 	3841 	 3371 	 545 
AUMS 	 17648 4454 132337 101476 80502 12372 
MRT -1" 	 28.46 	29.30 	 26.20 	26.42 	 23.88 	22.7 
°not detectable 
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Table All Nitroglycerin plasma concentrations (mg/ml) after an intravenous infusion of nitroglycerin (22.1 mg/min/kg) into a femoral vein of sheep No. 18. 
 
Portal 
vein 
Hepatic 
vein 
Pulmonary artery 
Left 
ventricle 
Femoral 
artery 
Feoral 
50.8 
72.2 
83.1 
83.5 
34.6 40.1 
55.4 
56.7 
252.7 
288.7 
283.8 
296.1 
161.2 
173.1 170.5 
170.0 
143.2 
160.0 
163.7 
170.2 
68.7 
2 0 .4 
1:.4 
12.9 
9.0 
6.0 
3.8 2.8 
1.6 
34.5 41.8 
37.5 
35.5 24.8 
19.1 
16.8 
12.2 8.5 
6.5 
3.9 
2.7 
1.5 
60 	 0.40 	0.32 aND ND 
2895 1867 11260 6740 5791 1464 
79887 52185 294100 173950 141231 36846 
MAT 	27.59 	27.95 	26.12 	25.80 	24.39 	25.17 
°not detectable 
Nitroglycerin plasma concentrations (ng/m1) after an intravenous infusion of 
nitroglycerin (22.1 IA/min/kg) into afeozL ein of sheep No. 19. 
11 10 
N 
F 
U 
0 30 
S 
N 40 
I 20 
41 
42 
43 
44 
46 
48 
50 
• 52 55 
Time 
(min) 
65 AUS_,.. 
AUMS . .. 
'Table 	0.16 
S 10 
I 20 
O 30 
D, 40 
41 42 
43 
44 
46 
48 
50 
52 
55 
60 
65 
AUC 	2218 o -ask° 
AIRS". 	60718 
MRT 27.31 	27.5 
•°not detectable 
Femoral vein 
42.3 51.8 
57.6 
55.9 33.9 
24.7 
19.3 
13.2 
8.0 
6.9 
4.2 
3.0 
1.6 0.70 
0.40 
2110 	974 	12983 	6165 	5505 . 	1982 
AUMS ....,... 	57153 	26559 352949 	169545 137338 	51384 
MRT 	27.09 27.27 	27.83 	27.50 	24.95 	25.92 
Table Al7 	Nitroglycerin plasma concentrations (ng/m1) after an intravenous infusion of nitroglycerin (22.1 mg/min/kg) into a femoral vein of sheep No. 20. 
Time 	Portal Smin vein  
Hepatic 
vein ' 
Pulmonary 
artery 
Left 
ventricle 
Femoral 	Femoral 
artery vein 
    
Time 
(min) 
:I 
N 
F 
U . 
S 10 
I 20 
0 30 40 
41 
42 
43 
44 
46 
48 
50 
52 
55 
60 
65 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery ventricle 
Fe.ar:1 
artery 
43.2 
50.9 
57.6 
57.9 
18.1 
25.2 
27.3 26.4 
258.6 313.2 
360.5 
357.1 
133.0 141.0 
168.0 169.9 
131.5 
140.2 
166.2 167.8 
83.2 31.4 20.0 
13.7 
8.3 
6.7 4.0 
3.0 
1.7 0.72 
0.44 
	
45.7 	17.3 	285.1 	171.0 	170.2 	39.2 
50.3 15.5 321.8 173.2 171.8 40.8 60.7 	21.3 343.7 	181.4 181.0 	40.0 
61.8 22.1 	341.9 181.0 	180.2 41.5 72.8 	23.2 
25.9 18.7 
15.9 	13.3 
12.3 10.8 
8.7 8.3 
6.0 	6.0 
4.0 3.9 
2.9 3.0 1.8 	2.3 
0.79 0.70 
0.26 aND 
771 	13120 	7155 	6405 	1552 
21203 351055 	188008 153813 38981 
26.76 	26.28 . 	24.01 	25.12 
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Table Al8 Nitroglycerin plasma concentrations (ng/ml) after an intravenous infusion of 
nitroglycerin (5.7 pg/min/kg) into a femoral vein of sheep No. 29. A bolus 
dose of glyceryl dinitrates (5mg) was injected into the aorta at the 30th 
minute of nitroglycerin infusion. 
 
Time 
(min) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
' 	artery 
Left 
ventricle 
Femoral 
artery 
Femoral 
vein 
I 
N 
F 10 14.2 6.3 107.8 82.3 80.7 12.5 U 
S 20 15.0 7.0 110.3 83.8 81.3 12.6 
I 30 15.1 7.3 112.1 83.4 83.2 14.4 0 
A- 40 15.3 6.8 113.4 84.1 83.8 19.0 41 29.4 16.2 
42 10.8 14.1 
43 4.7 12.9 
44 4.0 14.0 
45 3.7 13.8 
46 3.5 12.8 
48 S 3.0 11.1 
50 2.6 10.9 
52 2.3 10.0 
55 2.1 7.2 
60 1.5 6.0 
65 1.0 3.8 
AUC04.0 
AVMS.. 
MIC 
598 
16120 
26.96 
285 
7695 
27.00 
4621 
124280 
26.89 
3470 
92864 
26.76 
3004 
72002 
23.97 
782 
28036 
35.8 
Table Al9 Nitroglycerin plasma concentrations (ng/ml) after an intravenous infusion of 
nitroglycerin (5.7 ug/min/kg) into a femoral vein of sheep No. 30. A bolus of 
glyceryl dinitrates (5mg) was injected into the aorta at the 30th minute of 
nitroglycerin infusion. 
 
Time 
(min) 
Portal 
vein 
Hepatic 
vein 
Pulmonary 
artery 
Left 
ventricle 
Femoral 
artery 
Femoral 
vein 
U 
S 10 10.0 3.4 98.7 74.2 73.8 13.7 
I 20 12.9 3.8 ... 99.3 74.5 74.5 13.8 
0 30 12.3 3.9 101.2 75.3 74.9 14.0 
N 35 15.6 4.7 97.6 77.6 77.3 20.9 
36 16.9 21.3 
37 6.2 19.7 
38 4.1 16.3 
39 3.2 15.7 
40 2.3 15.0 
41 2.0 12.1 
43 1.7 10.5 
45 5 1.5 10.0 
47 5 1.2 7.2 
50 S 1.0 4.9 
55 0.93 2.8 
60 0.75 1.8 AUC u-0.03 
AUM F 	co 
MRT 
439 
10465 
23.84 
157 
4149 
26.43 
3966 
99070 
24.98 
3016 
75940 
25.18 
2324 
49655 
21.37 
654 
18692 
28.58 
Table 020 Glyceryl dinitrate (1, 3-CON, 1, 2-GDN) plasma concentrations (mg/m11 after an Intravenous infusion of nitroglycerin (0.4 09/min/kg) into a femoral vein of 
sheep No. 16. 
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Time 
(min) 
Portal vein Hepatic vein Pulmonary artery 
Left ventricle Femoral artery 
Femoral vein 
I, 3-CON 1,2-CON 1,3-GDN 1,2-CON 1.3-CON 1,2-CON 1,3-CON 1.2-GUN 1.3-GIN 1, 2-GIN 1.3-CON 1,2-C21 
II 
IF 	10 0.67 1.0 0.48 0.82 0.84 1.2 1.1 1.5 1.2 1.8 0.98 1.4 
li 	20 1.5 3.0 1.3 2.7 1.6 3.0 2.0 3.5 2.0 3.2 1.3 2.2 
.t, 	30 2.4 3.9 2.1 3.6 2.4 4.0 2.9 4.7 2.7 4.6 1.7 3.4 
N 	40 2.4 4.7 2.1 4.4 2.1 4.8 2.9 5.5 2.8 5.4 1.9 4.3 
45 2.4 5.0 1.7 3.8 
50 1.4 3.0 1.2 2.6 1.4 3.0 1.6 3.2 1.6 3.0 1.3 2.6 
60 0.98 1.7 1.2 1.9 
70 0.62 1.1 0.48 0.92 0.70 1.2 0.79 1.4 0.78 1.4 1.0 1.8 
85 0.66 1.2 0.72 1.3 
100 0.51 0.92 0.62 1.2 
130 °ND 0.49 NO 0.55 
AUS_o. 	141 243 117 214 147 253 177 292 173 292 156 267 
AUMS,w.,9794 14443 7863 12473 10575 15301 12274 17605 12049 17921 12877 18534 
MST 	69.5 	59.4 	67.2 	58.3 	71.9 	100.0 	69.3 	60.3 	69.6 	61.4 	82.5 	69.4 
a not detectable 
Table 0.21 Glyceryl dinitrate (1, 3-CON, 1, 2-CON) plasma concentrations (mg/m1) after an 
intravenous infusion of nitroglycerin (0.4 sg/min/kg) into a femoral vein of sheep No. 17. 
 
Time 	Portal vein 	' Hepatic vein 	Pulmonary 	Left ventricle 	Femoral 	Femoral vein (min) lrtAry  
1,3.0.0N 	1,2-CO4 1,3-coN 1,2-008 	1,37060(N 1,2-CO0 	1,3-GON 1,2-GO4 	1,3-I 	1,2-4271 1,3-011 	1,2,301 
	
-21 
10 	0.58 	1.0 	0.43 	0.81 	0.63 	' 1.0 	0.92 	1.9 	1.1 	1.9 	0.87 	1.3 
S 	20 	1.0 	2.1 	0.67 	2.0 1.0 	2.3 	2.0 	3.9  
0 30 	1.3 	3.0 	0.94 	2.7 	2.3 	4.1 	2.9 	5.0 	2.8 	4.9 	1.7 	3.6 
N 40 	1.6 	4.3 	1.3 	3.8 2.0 	4.8 	2.9 	5.6 3.0 	5.8 	1.9 	4.4 
45 2.5 	5.1 	1.6 	3.7 
50 	1.1 	2.8 	0.92 	2.4 	1.3 	2.0 	1.5 	3.0 	1.3 	3.0 	1.4 	2.7 
60 1.0 	1.8 	1.2 	2.0 
70 	0.90 	1.2 	0.86 	1.0 	0.8 	1.4 	1.0 	1.6 	0.78 	1.4 	0.98 	1.7 
85 0.65 	1.1 	0.76 	1.4 
100 	 0.50 	0.78 	0.60 	0.93 
130 at:0 	0.47 	12) 	0.55 
123 	221 	106 	192 	134 	240 	178 	309 	166 	304 	148 	265 ALS -we 
ALIS.4. 9563 	13825 	8788 	11765 9350 	15248 	11925 	18407 	10457 	17592 	10993 	17778 
MRT 	77.7 	62.6 	82.9 	61.3 	69.8 	63.5 	67.0 	59.6 63.0 	57.9 	74.3 	67.1 
°not detectable 
Time 
min) 
Femoral 
artery 
Fen, : 1 1 ,1 Pulmonary 
artery 
Left 
ventricle 
Portal 	Hepatic 
vein vein 
166 
Table 	A22 	Clyceryl mononitrate plasma concentrations (mg/m1) after an intravenous infusion of 
nitroglycerin (0.4 ug/min/kg) into a femoral vein of sheep No. 16. 
Time 
	
Portal 
	
Hepatic 
	
Pulmonary 
	
Left 
	
Femoral 
	
Femoral 
vein vein artery ventricle artery vein 
10 
	
0.52 
	
0.47 
	
0.60 
	
0.87 
	
0.83 
	
0.41 
0 
	
20 1.3 0.94 2.1 1.8 1.7 1.2 
30 1.6 
	
1.2 3.4 3.1 3.0 1.5 
40 
	
3.0 2.6 
	
4.9 
	
5.0 
	
5.0 
	
3.4 
45 6.0 4.3 
50 5.1 
	
4.4 8.1 8.6 8.4 5.2 
60 
	
9.4 
	
5.7 
70 6.3 	5.9 
	
8.3 	 8.1 
	
8.0 6.0 
85 8.2 6.5 
100 
	
8.0 
	
7.1 
130 7.4 7.9 
Table 	A23 	Clyceryl mononitrate plasma concentrations (mg/m1) after an intravenous infusion of 
nitroglycerin (0.4 ag/min/kg) into a femoral vein of sheep No. 17. 
F 
11 
S 
	
10 	 0.63 	0.47 	 1.2 	1.2 	 1.0 	0.43 I n 20 1.0 0.82 2.0 2.1 2.0 1.3 
; 30 	 2.3 	2.0 3.5 4.3 4.3 	2.8 
-.40 4.3 4.0 	 5.7 	6.1 	 6.2 4.6 
45 7.4 	5.0 
50 	 5.4 	4.9 7.6 7.4 7.4 5.3 
60 7.0 	6.3 
70 6.3 	5.9 	 6.7 	7.0 	 7.0 6.4 
85 	 6.9 	7.4 
100 6.6 7.6 
130 6.2 	7.6 
Table 	624 Aspirin (ASA) and salicylic acid (SA) plasma concentrations (,g/m1) after an 
intravenous infusion of aspirin (485 Vg/min/kg) into a femoral vein of 
sheep No. 23. 
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Time 	Portal Vein 	Hepatic Vein 	Pulmonary 	Left 	 Femoral 	Femoral 
	
artery ventricle artery vein 
(min) 	ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 
80 29.2 43.2 23.5 44.8 
85 20.0 45.9 17.3 46.3 
95 12.3 46.8 10.8 46.4 11.2 45.3 11.1 47.0 11.4 46.3 9.4 47.1 
105 8.8 45.0 7.2 46.8 
120 5.2 44.3 5.0 45.2 
135 3.7 45.7 4.0 45.0 
150 2.4 44.1 2.6 44.3 
165 1.5 43.2 1.7 41.8 
AUL )... 	4061 	- 	2652 	 4075 	- 	3982 	- 	3857 	- 	2768 
AUMS . 	226793 	- 158782 - 	226248 	- 222885 216746 	- 168653 
MRT 	 55.8 	- 	59.9 	- 55.5 	- 	56.0 	- 	56.2 	- 	60.9 
Table A25 Aspirin (ASA) and salicylic acid (SA) plasma concentrations (Lain') after an 
intravenous infusion of aspirin (485 ug/min/kg) into a femoral vein of 
sheep No. 24. 
 
Time 
fain) 
Portal Vein 
ASA 	SA 
Hepatic Vein 
ASA 	SA 
Pulmonary 
artery 
ASA 	SA 
Left 
ventricle 
ASA 	SA 
Femoral 
artery 
ASA 	SA 
Femoral 
vein 
ASA 	SA 
NI 	15 e 14.2 14.5 27.0 14.4 34.0 12.0 34.3 14.0 31.3 14.7 27.5 13.0 
U 	30 36.0 26.0 24.6 19.3 41.6 25.3 40.6 27.1 38.6 27.3 31.6 28.8 
1- 
S 	45 39.4 30.4 31.3 28.4 41.6 37.8 40.4 43.2 41.6 43.0 32.8 37.6 I 
0 	60 38.8 39.1 30.9 38.0 41.5 49.3 41.3 54.1 40.9 53.2 31.3 53.8 N 	75 39.8 48.3 30.5 47.8 41.6 53.2 40.7 59.0 40.5 57.3 30.6 58.7 
80 27.1 58.7 23.8 59.8 
85 18.0 58.0 18.8 58.0 
95 16.3 58.3 16.0 58.4 
105 14.6 57.6 12.8 56.2 12.6 55.2 12.8 58.1 12.0 57.8 12.5 57.0 
120 7.9 58.0 7.5 57.3 
135 5.5 55.3 5.4 56.8 
150 2.9 52.4 3.2 53.7 
165 2.2 50.6 1.9 50.6 
AUSio. 3951 - 3042 3955 - 3915 3704 - 	3134 
AUMC o-a..to 249180 - 202037 245166 - 243662 • 223877 194697 
MRT 63.1 66.4 62.0 - 62.2 60.4 . 	62.1 - 
:I 
N 15 	46.2 	11.6 	27.9 	11.2 	44.0 	11.5 	40.8 	11.5 	40.2 	11.0 	24.5 	6.2 
F 30 47.1 	24.3 	27.3 	20.8 	47.0 	21.7 	46.3 .22.5 	45.6 	20.9 	30.0 	16.4 U 
S 45 	45.3 	32.1 	27.9 	29.8 	46.5 	32.7 	45.1 	33.8 	44.8 	33.2 	31.8 	29.1 
I 60 0 44.0 36.0 28.6 31.3 46.3 38.8 46.9 38.9 46.0 38.9 31.3 36.2 N 75 44.8 42.8 28.3 40.1 46.8 40.1 45.8 41.7 45.8 40.3 32.0 40.1 
Table A26 Aspirin (ASA) and salicylic acid (SA) plasma concentrations ( . 2/m1) after an 
Intravenous infusion of aspirin (485 ug/min/kg) into a femoral vein of sheep No. 25. 
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Time 	 Portal Vein 
(min) 	 ASA 	SA 
Hepatic 	Vein 
ASA 	SA 
Pulmonary 
artery 
ASA 	SA 
Left 
ventricle 
ASA 	SA 
Femoral 
artery 
ASA 	SA 
Femoral 
vein 
ASS 	SA 
15 	 38.7 
U 	30 _a 
45 	 _a 
0 I 60 47.3 
75 	47.4 
80 
85 
95 
105 
120 
135 
150 
165 
AUC 	4690 
AUMC 	325904 o-Pto 
MRT 	 69.5 
	
20.4 	30.1 
- 	32.4 
- 	35.3 
55.2 	32.1 
56.1 	33.4 
- 	3422 
- 230956 
- 	67.5 
18.6 
32.3 
38.4 
53.8 
54.6 
- 
42.0 
44.1 
49.9 
51.5 
53.5 
5194 
361443 
69.6 
18.7 	40.1 
35.6 	44.1 
50.0 	51.0 
58.7 	52.3 
58.9 	53.0 
- 	5170 
- 360032 
- 	69.6 
18.4 
34.6 
50.3 
60.2 
60.0 
- 
40.3 
43.1 
51.5 
52.0 
52.0 
38.2 
23.5 
17.2 
13.8 
9.0 
6.1 
3.5 
2.9 
4438 
275408 
62.1 
17.3 	34.3 
34.8 	38.7 
49.3 	42.1 
58.9 	44.3 
59.5 	45.6 
60.6 	37.1 
62.3 	26.1 
58.7 	18.0 
60.3 	13.9 
60.3 	9.9 
58.9 	6.7 
56.3 	4.4 
55.8 	3.2 
- 	4040 
- 263634 
- 	65.2 
13.8 
30.5 
48.7 
57.1 
57.3 
58.5 
60.9 
61.3 
60.4 
61.3 
60.8 
62.4 
60.1 
- 
a  sampling line blocked 
Table 	A27 	Aspirin (ASA) and salicylic acid (SA) plasma concentrations (e/m1) after an 
intravenous infusion of aspirin (485 vg/min/kg) into a femoral vein of 
sheep No. 28. 
Time 	 Portal Vein 	Hepatic vein 	Pulmonary 
artery 
Left 
ventricle 
Femoral 
• artery 
Femoral 
vein . 
(m n) 	 ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 	ASA 	SA 
1 
l',. 	15 	32.0 	15.5 	23.5 	16.0 	36.2 	19.3 	34.4 	19.9 	34.0 	19.0 	22.2 	14.3 
 
_UI 30 32.8 	30.2 	24.1 	28.7 38.3 	34.8 	39.0 	34.0 	38.5 	24.2 	30.5 	28.0 S 45 	35.6 	35.9 	25.1 	33.2 	42.0 	46.3 	45.0 	49.2 	45.3 	47.2 	36.8 	46.0 I 0 60 37.6 	48.1 	25.2 	47.0 	38.8 	53.1 	42.0 	55.6 	40.8 	54.8 	33.8 	49.4 N 75 	36.4 	49.8 	24.9 	49.0 	39.7 	54.0 	43.0 	54.1 	42.1 	53.8 	35.1 	50.0 
80 25.6 	52.7 	29.5 	52.1 
85 	 16.4 	50.1 	18.0 	24.2 
95 15.1 	51.3 	12.3 	50.6 	14.9 	55.0 	14.9 	55.3 	14.6 	54.3 	15.0 	54.4 
105 	 13.7 	60.0 	11.8 	50.7 
120 7.8 	51.0 	5.3 	49.5 	7.3 	50.2 	7.6 	53.5 	7.6 	52.8 	7.0 	52.9 
135 	 5.2 	58.1 	5.7 	64.4 
150 4.4 	50.9 	4.4 	52.8 
165 	 3.4 	49.8 	3.7 	55.2 
AUS,... 	3483 	- 	2456 	 3764 	- 	3906 	- 	3797 	- 	3225 
Aumg... 	227022 	- 159380 235397 	- 247358 245634 	- 225476 
MRT 	 65.2 	- 	64.9 	 62.5 	- 	63.3 	 64.7, 	. 
/ 
69.9 
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Table 	ils 
0 
!I 
U 
N 
	
F 15 	40.3 
S 
I 
30 
45 
60 	
43.1 
51.5 
52.0 
75 52.0 
80 	38.2 
85 23.5 
95 	17.2 
105 13.8 
120 	9.0 
135 6.1 
150 	3.5 
165 2.9  
Total and free (Ec) aspirin concentrations 
(ug/m1) and fraction unbound (fu) of aspirin 
in arterial and venous plasma of sheep No. 25 
after a continuous intravenous infusion of 
aspirin (485 ug/min/kg). 
0.58 23.4 34.3 0.46 15.7 
0.62 26.7 38.7 0.52 20.1 
0.61 31.4 42.1 0.56 23.4 
0.66 34.3 44.3 0.56 24.7 
0.64 33.3 45.6 0.57 26.0 
0.71 27.1 37.1 0.62 22.9 
0.65 15.3 26.1 0.67 17.6 
0.73 12.5 18.0 0.63 11.3 
0.69 9.5 13.9 0.63 8.8 
0.70 6.3 9.9 0.71 7.0 
0.72 4.4 6.7 0.76 5.1 
0.74 2.6 4.4 0.70 3.1 
0.65 1.9 3.2 0.66 2.1 
Table 	A29 Total and free (fc) salicylic acid concentrat- 
ions (.g/ra1) and fraction unbound (fu) of 
salicylic acid in arterial and venous plasma 
of sheep No. 25 after a continuous intra-
venous infusion of aspirin (485 ug/min/kg). 
Time (min) Total 
Arterial 
fc Total 
Venous 
fc fu fu 
15 17.3 0.33 5.7 13.8 0.35 4.8 
30 I 45 34.8 49.3 0.28 0.29 9.7 14.3 30.5 48.7 0.30 0.34 9.1 16.6 
0 60 58.9 0.33 19.4 57.1 0.29 16.6 
175 59.5 0.34 20.2 57.3 0.31 17.8 
80 60.6 0.35 21.3 58.5 0.36 21.1 
85 62.3 0.34 21.2 60.9 0.34 20.7 
95 58.7 0.38 22.5 61.3 0.32 19.6 
105 60.3 0.38 22.7 60.4 0.38 23.0 
120 60.3 0.35 20.9 61.3 0.35 21.4 
135 58.9 0.36 21.5 60.8 0.37 22.5 
150 56.3 0.36 20.3 62.4 0.37 23.1 
165 55.8 0.36 20.0 60.1 0.34 20.4 
Arterial 	 Venous 
Time Coin) Total 	fu 	fc 	Total 	fu 	fc 
AUC u-ard, 
• AUMC °AK. 
MST  
4438 	2845 
275408 	181288 
62.1 63.7 
4040 	2306 
263634 	160323 
65.2 69.5 
  
Table 	:,11 Total and free (fc) concentrations of 
salicylic acid (ug/m1) and fraction un-
bound of salicylic acid in arterial and 
venous plasma of sheep No. 28 after a 
continuous intravenous infusion of 
aspirin (485 ug/min/kg). 
Table A30 Total and free (ft) aspirin concentrations 
(ug/ml) and fraction unbound (fu) of aspirin 
in arterial and venous plasma of sheep No. 28 
after a continuous intravenous infusion of 
aspirin (485 ug/min/k8). 
 
  
34.0 0.66 22.4 22.2 0.75 16.7 
38.5 0.73 28.0 30.5 0.70 21.5 
45.3 0.76 34.3 36.8 0.65 24.0 
40.8 0.72 29.5 33.8 0.83 28.1 
42.1 0.74 31.0 35.1 0.78 27.5 
25.6 0.80 20.5 29.5 0.76 22.4 
16.4 0.78 12.9 18.0 0.79 14.3 
14.6 0.72 10.5 15.0 0.75 11.2 
13.7 0.67 9.2 11.8 0.78 9.2 
7.6 0.69 5.2 7.0 0.87 6.1 
6.2 0.73 3.8 5.7 0.71 4.0 
4.4 0.68 3.0 4.4 0.66 2.9 
3.4 0.70 2.4 3.7 0.70 2.6 
• 3797 	2932 	3225 	2390 
AUMS.4,..245634 174621 	225476 16550/ 
MRT 	64.7 	59.5 	69.9 	69.2 
Time (min) Total 
Arterial 
fc Total 
Venous 
ft fu fu 
lj 
15 19.0 0.26 • 5.0 14.3 0.26 3.8 ti.4
60 
U 30 
45 
0 
34.2 
47.2 
0.26 
0.32 
8.8 
15.2 
28.0 
46.0 
0.26 
0.29 
7.3 
13.5 
54.8 0.29 15.8 49.4 0.33 16.4 
75 53.8 0.31 16.5 50.0 0.35 11.5 
BO 52.7 0.31 16.5 52.1 0.35 18.0 
85 50.1 •0.33 16.4 54.3 0.33 17.9 
95 54.3 0.31 16.7 54.4 0.33 18.1 
105 60.0 0.29 17.6 50.7 0.35 17.9 
120 52.8 0.31 16.2 52.9 0.36 18.8 
135 58.1 0.28 16.2 64.4 0.26 17.1 
150 50.9 0.31 15.8 52.8 0.30 16.1 
165 49.8 0.31 15.6 55.2 0.29 16.0 
Arterial 	Venous 
Total 	fu 	fc 	Total 	fu 	ft Time (min) 
N 15 
30 
S 45 
60 0 EIS 
80 
85 
95 
105 
120 
135
• 150 
165 
170 
Table 	A32 Total and free salicyluric acid (SU) 	plasma concentrations 	(vg/m1) 	across a hind 
leg after an aspirin (ASA) 	infusion 	in sheep. 	(FA 	= 	femoral 	artery, 
FV 	= 	femoral vein, T 	= total, F 	= 	free). 
ASA ASA A8A ASA 
61 ug/min/kg 
485 ug/min/kg 485 pg/min/kg + SA 1200 mg 61 	ug/min/kg 
Sheep No. 25 Sheep No. 	28 Sheep No. 	29 Sheep No. 	30. 
Time FA FV FA FV FA FV FA FV 
min) T F T F T F T F T F T r* T T 
15 2.1 aND 1.8 ND 4.8 0.8 3.8 0.7 0.7 ND 0.6 ND 1.0 ND 0.9 	ND 
30 4.6 1.1 4.0 1.0 7.3 2.2 6.0 2.0 2.2 NO 1.9 ND 1.4 ND 1.2 	ND 
45 7.6 2.3 7.0 2.2 10.0 3.2 9.2 2.8 2.8 ND 2.6 ND 1.6 ND 1.4 	ND 
60 
0 
9.3 3.2 7.7 2.7 10.0 3.0 8.6 3.2 7.3 2.8 4.7 2.0 2.1 ND 1.7 	ND 
75 9.0 2.9 9.0 2.8 9.8 3.1 9.1 3.1 9.4 3.7 5.8 2.6 2.1 ND 2.2 	ND 
80 8.7 3.0 9.1 3.3 9.9 3.1 9.9 3.3 10.2 3.9 7.7 3.6 2.0 ND 2.2 	ND 
85 8.2 2.7 9.0 3.1 8.6 3.1 10.0 3.1 11.8 3.7 10.4 4.2 2.0 ND 2.1 	ND 
95 10.6 3.4 9.8 3.1 10.2 3.1 , 10.1 3.4 13.2 4.2 11.5 4.0 1.7 ND 1.8 	ND 
105 9.2 3.2 10.2 3.7 12.0 3.7 9.6 3.4 14.9 5.0 13.3 , 4.2 1.4 ND 1.7 	ND 
120 11.0 3.7 10.3 3.3 11.5 3.5 11.5 4.0 14.0 5.1 15.3 5.2 1.6 ND 1.6 	ND 
135 11.1 3.7 11.1 3.8 14.1 4.0 14.7 4.1 16.1 5.4 16.0 5.1 1.4 ND 1.5 	ND 
150 12.3 3.8 13.6 3.8 13.9 4.4 13.5 4.0 17.1 5.8 16.2 5.4 1.1 ND 1.2 	ND 
165 13.0 3.8 13.6 4.3 13.2 3.9 14.0 4.2 18.5 5.8 18.5 6.1 0.91 ND 1.0 	ND 
anot detected 
Table A33 	Time course of salicyluric acid (SO) plasma concentrations (vg/m1) across the 
liver after an aspirin infusion in sheep. 
ASA 
	
ASA 	 ASA 	 ASA 
485 vg/min/kg 
	 485 ug/min/kg 	 61 ug/min/kg 	 61 vg/min/kg 
• SA 1200 mg 
Sheep No. 25 	 Sheep No. 28 	 Sheep No. 29 	 Sheep No. 30 
Hepatic 
vein 
2.8 
6.3 
8.3 
9.8 
9.9 
Time 
[min) II0 N 60 U 15 S 30 F I 45 	2.0 a_ 8.3 
75 	8.3 
85 
95 
105  
	
Portal 	Hepatic 	Portal 	Hepatic 	Portal 	Hepatic 
vein vein vein vein vein vein 
4.0 	5.6 	0.81 	1.0 	0.86 
	
1.3 
5.3 7.0 2.0 2.3 1.4 2.3 
6.8 	8.2 	2.8 	3.6 	1.9 
	
2.7 
7.8 9.4 7.4 11.1 2.1 3.5 
8.8 	10.2 	8.8 	12.4 	2.6 
	
4.0 
10.2 13.8 
10.3 	11.9 	 2.9 
	
4.2 
11.5 12.7 12.7 	15.6 	3.3 4.6 
Portal 
vein 
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Table 	A34 Aspirin (ASA) and salicylic acid (SA) plasma concentrations (,g/m1) after an intravenous infusion of aspirin (61 ug/min/kg) into a femoral vein of 
 
sheep No. 	30 
Time Portal Vein Hepatic Vein Pulmonary artery 
Left 
ventricle 
Femoral 
artery 
Femoral 
vein 
ASA SA ASA SA -ASA SA ASA - SA ASA SA ASP SA (tm n) 
F 3.4 4.2 
2.4 
4.3 
2.7 
3.4 
2.1 
3.8 
3.7 
5.1 
2.5 
4.8 
3.7 
4.8 
2.7 
5.0 
3.7 
4.6 
2.5 
4.9 
2.9 
3.5 
2.2 
4.0 30U
Ni 15 
S 45 4.4 5.4 3.4 4.9 5.8 6.3 5.6 6.0 5.4 5.8 3.6 5.2 
ij 	60 4.8 6.5 3.8 6.0 5.7 6.0 5.7 6.1 5.7 6.2 3.9 6.0 
N 	75 5.2 6.3 3.7 6.2 5.9 5.8 5.8 6.3 5.5 6.1 3.9 6.3 
80 2.7 5.5 2.8 6.1 
85 1.5 4.9 2.0 5.9 
95 0.84 4.3 0.62 4.0 1.2 4.0 1.0 4.0 0.90 4.1 1.2 4.5 
105 0.68 3.2 0.72 3.8 
120 0.45 2.7 0.56 3.1 
135 0.30 2.3 0.33 2.6 
150 0.20 1.9 0.25 2.2 
165 aND 1.6 ND 1.8 
AUS_io„ 
AUMg4w , 
MIT 
381 
21645 
56.8 
806 
102060 
126.6 
293 
16329 
55.7 
748 
88115 
117.8 
463 
26924 
58.1 
783 
86076 
109.9 
445 
25355 
57.0 
795 
87755 
110.4 
408 
22613 
55.4 
651 
81082 
124.5 
322 
19262 
59.8 
779 
88852 
114.0 
anot detectable 
Total and free (fc) aspirin concentrations 
(14/m1) and fraction unbound (fu) of aspirin 
in arterial and venous plasma of sheep No. 30 
after a continuous intravenous infusion of 
Table 	A.36 	Total and free (fc) salicylic acid concent- 
rations (ug/m1) and fraction unbound (fu) of 
salicylic acid in arterial and venous plasma 
of sheep No. 30 after a continuous intraven- 
Table 	A35 
aspirin (61 ug/min/kg). ous infusion of aspirin (61 ug/min/kg). 
Time (mm) Total 
Arterial 
fc Total 
Venous 
fc Time (min) Total 
Arterial 
ft Total 
Venous 
fc fu fu fu fu 
I 
15 3.7 0.38 1.4 2.9 0.40 1.1 N 15 2.5 0.27 0.73 2.2 0.24 0.51 
30 4.6 0.43 2.0 3.5 0.48 1.7 F u 30 4.9 0.25 1.2 4.0 0.25 1.0 
45 5.4 0.44 2.4 3.6 0.52 1.9 $ 45 5.8 0.24 1.4 5.2 0.26 1.3 
60 5.7 0.44 2.5 3.9 0.51 2.0 I 0 60 6.2 0.26 1.6 6.0 0.26 1.6 
A 75 5.5 0.45 2.5 3.9 0.51 2.0 li.,75 6.1 0.28 1.7 6.3 0.30 1.9 
80 2.7 0.44 1.2 2.8 0.48 1.3 80 5.5 0.27 1.5 6.1 0.26 1.6 
85 1.5 0.38 0.57 2.0 0.44 0.88 85 4.9 0.26 1.3 5.9 0.25 1.5 
95 0.90 0.41 0.37 1.2 0.44 0.53 95 4.1 0.24 1.0 4.5 0.26 1.2 
105 0.68 0.35 0.24 0.72 0.41 0.30 105 3.2 0.22 0.70 3.8 0.27 1.0 
120 0.45 aND, 0.56 0.46 0.24 120 2.7 0.24 0.65 3.1 0.23 0.71 
135 0.30 ND 0.33 ND 135 2.3 0.26 0.60 2.6 0.24 0.62 
150 0.20 ND 0.25 ND 150 1.9 0.25 0.47 2.2 0.25 0.55 
165 ND ND ND ND 165 1.6 0.25 0.40 1.8 0.27 0.49 
AUL,. 408 
ALMS... 22613 
MRT 55.4 
172 	322 	153 
9466 	19262 9051 
55.0 	59.8 	59.2 
AU 	188 
AUMS4. 81082 20272 
MRT 	124.5 	107.8 
779 
88852 
114.1 
203 
23466 
115.6 
not detectable 
Time 
(m'n) 
15 
-- 
S 
1 
45 
60 
N 75 
80 
85 
95 
105 
120 
135 
150 
165 
HAT 
724 1333 546 1206 
42811 146319 33839 128782 
59.1 109.8 	62.0 106.8 
2.6 
4.0 
4.3 
4.4 
3.9 
2.6 
1.7 
0.95 
0.57 
0.42 
0.30 
0.22 
'ND 
331 	483 
19082 	33754 
57.6 	69.9 
Time (min) Total 
Arterial 
Total 
Venous 
fc fu fc fu 
N 15 2.7 0.30 0.82 1.8 0.37 0.67 
30 5.2 0.27 1.4 4.0 0.30 1.2 
SI 45 6.1 0.34 2.1 7.1 0.27 1.9 
0 60 15.2 0.25 3.8 18.1 0.24 4.4 
Nj 75 12.0 0.22 2.6 15.2 0.26 4.0 
80, 11.3 0.22 2:4 14.6 0.26 3.8 
85 10.4 0.22 2.2 14.4 0.25 3.6 
95 8.0 0.25 2.0 11.7 0.24 2.8 
105 7.2 0.24 1.7 9.8 0.23 2.2 
120 6.2 0.26 1.6 8.4 0.25 2.1 
135 4.9 0.25 1.2 6.5 0.27 1.8 
150 4.0 0.24 0.96 5.0 0.26 1.3 
165 3.3 0.24 0.8 3.9 0.28 1.1 
AUL,. 1352 333 1668 430 
36321 186163 48935 
MN? 110.1 109.1 112.3 • 113.8 • 
Venous 
Total fu fc 
2.8 0.57 1.6 
5.0 0.44 2.2 
5.2 0.52 2.7 
4.9 0.57 2.8 
5.0 0.60 3.0 
4.4 0.54 2.4 
4.0 0.50 2.0 
2.4 0.48 1.1 
1.8 0.40 0.72 
1.1 0.45 0.49 
1.0 0.34 0.34 
0.8 0.35 0.28 
0.51 ''ND 
241 
15992 
66.3 
Arterial  
	
Time 	(min) Total 	fu 	ft 
1 15 
	5.2 	0.50 
8.2 	0.49 
0 
U 
N 75 
N F 
S 45 	8.8 	0.49 I 60 
30 
8.3 	0.53 
8.2 	0.47 
80 	5.3 	0.49 
85 3.3 	0.51 
95 	2.4 	0.40 
105 1.8 	0.32 
120 	1.2 	0.35 
135 0.82 	0.36 
150 	0.57 	0.38 
165 0.40 	- 
AUL.. 694 
AUlle_1.3 41875 • 
HRT 	60.3 
"not detectable 
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Table A31 Aspirin (ASA) and salicylic acid (SA) plasma concentrations fug/m1) after an intraver- 
ous infusion of aspirin (61 ug/min/kg) into a femoral vein ot sheep No. 27. A bolus 
dose of sodium salicylate equivalent to 30 mg salicylic acid was injected into the 
aorta at the 50th minute of aspirin infusion. 
 
Portal Vein 
ASA 	SA 
Hepatic Vein 
ASA 	SA 
Pulmonary artery 
ASP. SA 
Left 
ventricle 
ASA Si 
Femoral artery 
ASP. SA 
Femoral vein 
ASP. SA 
4.8 2.4 4.0 2.6 6.0 2.1 5.8 2.7 5.2 2.7 2.8 1.8 
7.3 3.8 5.0 3.7 8.5 5.0 8.2 5.4 8.2 5.2 5.0 4.0 
8.0 6.0 6 . 8 5.8 a_ a_ 8.9 6.1 8.8 6.1 5.2 7.1 
8.0 15.8 6.9 14.4 8.8 12.8 8.6 16.0 8.3 15.2 4.9 19.1 
7.9 13.1 6.7 12.8 8.2 10.9 8.2 12.2 8.2 12.0 5.0 15.2 
5.3 11.3 4.4 14.6 
3.3 10.4 4.0 14.4 
2.5 8.3 1.9 7.1 2.4 8.0 2.4 8.2 2.4 8.0 2.4 11.7 
1.8 7.2 1.8 9.8 
1.2 6.2 1.1 8.4 
0.82 4.9 1.0 6.5 
0.57 4.0 0.80 5.0 
0.40 3.3 0.51 3.9 
739 1241 729 1342 694 1352 483 1648 
44262 137234 43521 144860 41875 148895 33754 185153 
59.9 110.6 	59.7 107.9 	60.3 110.1 	69.9 112.3 
'sampling line blocked 
Table g38 Total and free (fc) aspirin concentrations 
(ug/m1) and fraction unbound (fu) of aspirin 
in arterial and venous plasma of sheep No. 27 
after a continuous intravenous infusion of 
aspirin (61 ugimin/kg) and a bolus dose of 
sodium salicylate equivalent to 30 mg 
salicylic acid. 
 
Table A39 • Total and free (fc) salicylic acid concent- 
rations (ug/m1) and fraction unbound (fu) of 
salicylic acid in arterial and venous plasma 
of sheep No. 27 after a continous intravenous 
infusion of aspirin (61 ug/min/kg) and a 
bolus dose of sodium salicylate equivalent 
to 30 mg salicylic acid. 
  
    
Time 
(min) 
] 
L  S 
N 
N 15 
30 
45 
60 
75 
80 
85 
95 
105 
120 
135 
150 
165 
AU ., 
AUMS4.. 
Arterial 
fc Total 
Venous 
ft Total 	fu fu 
4.9 0.47 2.3 3.4 0.47 1.6 
5.6 0.48 2.7 4.8 0.48 2.3 
7.0 0.48 3.4 6.0 0.45 2.7 
7.5 0.49 3.7 6.6 0.51 3.3 
7.6 0.50 3.8 6.5 0.52 3.4 
5.5 0.46 2.5 6.0 0.50 3.0 
4.2 0.47 1.4 4.5 0.46 2.1 
3.0 0.44 0.95 3.0 0.48 1.4 
2.0 0.48 0.65 2.1 0.40 0.85 
1.45 0.47 0.50 - 1.6 0.44 0.73 
1.0 0.48 0.38 1.1 0.45 0.50 
0.71 0.42 0.30 0.77 0.50 0.38 
0.44 'ND 0.44 ND 
Total 
Arterial 
fc Total 
Venous 
ft fu fu 
N 15 1.6 0.30 0.48 1.6 0.29 0.46 
30 2.4 0.33 0.80 3.2 0.34 1.1 
S 45 
ti  60 
4.8 
57.6 
0.29 
0.23 
1.4 
13.5 
5.0 
63.2 
0.27 
0.32 
1.3 
20.2 
E 	75  36.0 0.30 12.0 55.3 0.31 17.3 
80 32.5 0.28 9.0 38.0 0.35 13.3 
85 31.0 0.23 7.1 34.0 0.31 10.4 
95 23.0 0.27 6.1 28.5 0.29 8.2 
105 21.2 0.25 5.3 25.3 0.30 7.6 
120 17.9 0.24 4.3 20.0 0.28 5.5 
135 14.0 0.26 3.7 16.5 0.30 4.9 
150 12.2 0.21 2.6 13.3 0.26 3.5 
165 9.8 0.20 2.0 10.6 0.26 2.8 
Time (min) 
S1N 15 F .... U " 45 0 60 75 
80 
85 
95 
105 
135 
150 
165 
173 
Table 	A40 Aspirin (ASA) and salicylic acid (SA) plasma concentrations (...c/ml) after an 
intravenous infusion of aspirin (61 ..:R/min/kR) into a femoral vein of sheep No. 
A bolus dose of sodium.salicylate equivalent to 300 mg salicylic acid was inject. . into the aorta at the 50th minute of aspirin infusion. 
Portal Vein 
AA SA 
Hepatic Vein 
AsA SA 
Pulmonary 
artery 
AS1 SA 
, 	Left 
ventricle 
',SA SA 
Femoral 
artery 
!SA S1 
Fer=1 
ASA el, 
4.4 1.3 3.7 1.5 5.3 1.0 4.8 1.8 4.9 1.6 3.4 1.6 
5.9 3.7 4.3 3.4 5.7 3.2 5.6 2.4 5.6 2.4 4.8 3.2 
5.3 5.1 4.7 4.9 7.0 5.7 7.2 5.0 7.0 4.8 6.0 5.0 
7.4 68.8 6.3 54.4  7.7 53.4 7.6 58.7 7.5 57.6 6.6 63.2 
7.4 51.3 6.0 49.8 7.8 32.9 7.8 36.1 7.6 36.0 6.5 55.3 
5.5 32.5 6.0 38.0 
4.2 31.0 4.5 34.0 
2.9 26.2 1.8 24.1 3.1 22.7 3.1 23.8 3.0 23.0 3.0 28.5 
2.0 21.2 2.1 25.3 
1.4 17.9 1.6 20.0 
1.0 14.0 1.1 16.5 
0.71 12.2 0.77 13.3 
0.44 9.8 0.44 10.6 
619 4137 480 3726 677 3307 669 3518 632 3652 580 4246 
42010 452932 30915 412268 45335 372517 45222 394197 41445 422832 39723 482663 
MRT 
67.8 109.5 64.4 110.6 67.0 112.6 67.6 112.0 65.6 115.8 68.5 113.7 
Table 	A41 	Total and free (fc) aspirin concentrations 
lug/ml) and fraction unbound (fu) of 
aspirin in arterial and venous plasma of 
sheep No. 26 after a continuous intravenous 
infusion of aspirin (61 ug/min/kg) and a 
bolus dose of sodium salicylate equivalent 
to 300 mg salicylic acid. 
Table 042 	Total and free (Er) salicylic acid concentrat- 
ions (Cg/m1) and fraction unbound (fu) of 
salicylic acid in arterial and venous plasma 
of sheep No. 26 after a continuous intravenous 
infusion of aspirin (61 vg/min/kg) and a bolus 
dose of sodium salicylate equivalent to 
300 mg salicylic acid. 
632 
AUML...41445 
MRT 65.6 
°not. detectable 
287 580 274 3652 899 4246 
18142 39723 19363 AUMS4 . 422832 98984 482663 
63.2 68.5 70.7 HOT 115.4 110.1 113.7 
1261 
138323 
109.7 
Left 
ventricle 
ASS SA ASS SA ASS SA 
Femoral 
artery 
Femoral 
vein 
303 
15057 
49.7 
 
3.3 1.1 
	
3.9 	2.5 
4.1 	3.8 
4.0 212.1 
2.8 	163.2 
1.8 	155.3 
1.2 	148.0 
0.69 	144.7 
0.44 138.5 
aND 	120.8 
ND 	111.6 
ND 	107.5 
293 
14332 
48.9 
2.6 	0.51 
3.0 	2.3 
3.3 
2.8 	240.9 
2.2 	152.3 
1.8 	155.1 
1.5 	157.6 
0.82 	155.3 
0.50 	141.3 
0.29 	132.0 
ND 	123.7 
ND 	119.2 
240 
12448 
51.9 
3.4 
3.8 
4.1 
4.3 
3.0 
1.2 
2.7 
4.0 
214.3 
164.1 
1.2 	149.0 
0.48 140.0 
Arterial  
Total 	fu 
1.1 	0.27 
2.5 	0.26 
3.8 	0.26 
212.1 	0.38 
163.2 	0.37 
155.3 	0.36 
148.0 	0.37 
144.7 	0.37 
138.5 	0.35 
120.8 	0.36 
111.6 	0.36 
107.5 	0.37 
Time (min) 
N 15 
Venous 
fc 	Total 	fu 	fc 
30 
S 45 
60 0 
li 75 
80 
85 
95 
105 
120 
135 
150 
165 . 
0.30 
0.60 
1.0 
80.0 
60.9 
55.9 
55.2 
53.5 
48.4 
43.8 
40.2 
39.8 
0.81 
2.3 
3.9 
240.8 
152.3 
155.7 
157.6 
155.3 
141.3 
132.0 
123.7 
119.2 
0.25 
0.28 
0.25 
0.46 
0.44 
0.45 
0.47 
0.43 
0.40 
0.40 
0.42 
0.42 
0.20 
0.61 
1.0 
112.4 
67.0 
70.0 
74.3 
66.8 
56.0 
52.9 
52.0 
50.1 
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Aspirin (ASS) and salicylic acid (SA) plasma concentrations (ug/ml) after an intra-venous infusion of aspirin (61 9g/min/kg) into a femoral vein of sheep No. 29. A 
bolus dose of sodium salicylate equivalent to 1200 mg salicylic acid was injected 
into the aorta at the 50th minute of aspirin infusion. 
Table 
 543 
Time (min) 
Portal vein 
ASA SA 
Hepatic vein 
ASA SA 
Pulmonary 
artery 
ASA SA 
N 15 3.5 2.0 3.0 1.8 3.5 1.2 
30 3.9 2.7 3.0 2.5 4.0 2.8 
S 45 4.3 3.8 3.3 3.7 4.1 4.6 
1 
0 
60 4.8 232.7 4.0 208.3 4.0 210.1 
.j 75 3.4 164.0 2.7 151.8 3.7 155.9 
80 
85 1.0 153.7 0.72 150.1 1.2 146.3 
95 
105 0.56 136.3 0.42 134.1 0.46 138.6 
120 
135 
150 
165 
AUS 	320 	- 	256 	341 
AU1IS15112 12704 17288 
HRT 	47.2 	49.6 50.7 
'not detected 
Table 	A44 Total and free (fc) aspirin concentrations 
(us/m1) and fraction unbound (fu) of aspirin 
in arterial and venous plasma of sheep No. 29 
after a continuous intravenous infusion of 
aspirin (61 mg/min/kg) and a bolus dose of 
sodium salicylate equivalent to 1200 mg 
salicylic acid. 
 
Table A45 Total and free (fc) salicylic acid concentrat- 
ions (ug/ml) and fraction unbound (fu) of 
salicylic acid in arterial and venous plasma 
of sheep No. 29 after a continuous intraven- 
ous infusion of aspirin (61 ug/min/kg) and 
a bolus dose of sodium salicylate equivalent 
to 1200 mg salicylic acid. 
  
   
     
     
T . me (min) Total 
Arterial 
fc Total 
Venous 
fc fu fu 
N 15 '3.3 0.51 1.7 2.6 0.46 1.2 
30 3.9 0.49 1.9 3.0 0.50 1.5 
S 45 4.1 0.51 2.1 3.3 0.54 1.8 
0 60 4.0 0.88 3.5 2.8 0.96 2.7 
E 75 2.8 1.0 2.8 2.2 1.0 2.2 
80 1.8 1.0 1.8 1.8 1.0 1.8 
85 1.2 1.0 1.2 1.5 1.0 1.5 
95 0.69 0.99 0.70 0.82 0.99 0.84 
105 0.44 1.0 0.43 0.50 1.0 0.49 
120 °ND ND 0.29 1.0 0.30 
135 NO ND 
150 
165 - 
AUg4. 	293 201 240 • 	173 
AU115 .4.,. 14332 11264 12448 10397 
NRT 	, 	48.9 56.0 51.9 60.1 
'not detectable 
Table 	0.46  
'Subject Adrenalin 
T 	e 
Collagen 
T 	e 
Arachidonic 
acid 
T 	P 
Arachidonic 
acid 
T 	e 
NEM 
T P T P 
KS - 0 9 - 	97 - 	46 38 30 < 0.10 	< 0.10 
EN 0 0 0 	. 0 - - - - 47 - < 0.10 	< 0.10 
DK - 0 0 97 - 	41 56 40 < 0.10 	< 0.10 
SS 12 10 13 13 - - - - 36 39 < 0.10 	< 0.10 
' 	DR 23 12 16 4 - - - - 32 11 < 0.10 	< 0.10 
HE 14 28 14 7 - - - 20 3 < 0.10 	< 0.10 
SC 13 10 9 0 - 	100 - 	51 63 32 < 0.10 	< 0.10 
MW 0 7 2 12 - - - - 40 6 < 0.10 	< 0.10 
MEAN 10.3 11.2 6.7 5.6 98.0 46.0 41.5 23.0 < 0.10 	<0.10 
S.D. 8.9 9.3 7.0 5.4 1.7 5.0 13.6 15.8 
S.E. 3.6 3.8 2.5 1.9 1.0 3.0 4.8 6.0 
* T 	Trough sample: 1 hr before final do e 
P . Peak sample : 3 bra after final dose 
Table 	0.47 Platelet aggregation, MDA synthesis and plasma aspirin concentrations on the 
seventh day after Astrix 50 mg, 1 capsule daily for seven days. 
 
Platelet aggregation 
% Inhibition of control  
MDA synthesis  
Inhibition of control  
Plasma aspirin  
concentration  
u /ml 
Subject Adrenalin 
T 	P 
Collagen 
T 	e 
Arachidonic 
acid 
T 	P 
Arachidonic 
acid 
T 	P 
SEX 
T P 'I P 
RI! 80 82 0 0 - - 68 72 c 0.10 c 	0.1v 
AU 69 69 16 16 - - 85 85 < 0.10 < 0.10 
MS 62 56 10 10 - 	98 - 	61 32 77 < 0.10 0.10 
SJ - 37 - - - 48 - < 0.10 < 0.10 
WM 71 77 0 21 - 	100 - 	53 29 97 < 0.10 < 0.10 
KR 21 54 14 14 - - - 53 100 < 0.10 < 	0.10 
IC 78 83 8 8 - 	96 - 	56 19 98 < 0.10 0.10 
HW - 34 34 - - - 77 99 < 0.10 < 	0.I0 
MEAN •63.5 70.2 14.9 14.7 98.0 - 	56.7 51.4 89.6 < 0.10 < 0.10 
S.D. 21.8 12.8 14.0 10.8 2.0 4.0 23.9 11.7 
S.E. 8.9 5.2 5.0 4.1 1.1 2.3 8.4 4.4 
*T 	Trough sample: 1 hr before final dose 
P 	Peak sample : 3 hrs after final dose 
Table 	MR 	Platelet aggregation, MDA synthesis and plasma aspirin concentrations on the 
seventhday after Astrix 100 mg, 1 capsule daily for seven days. 
Platelet aggregation  
Z Inhibition of control 
MDA synthesis  
% Inhibition of control 
Plasma aspirin 
Concentration 
(cg/m1) 
Subject Adrenalin 
T 	P 
Collagen 
T 	p 
Arachidonic 
acid 
T 	P 
Arachidonic 
acid 
T 	P 1 
SEX 
P T P 
KS - - 53 53 - 	100 93 82 83 < 	0.10 < 	0.10 
EN 59 62 15 28 - - - - BO 89 < 	0.10 0.15 
DK 75 56 52 50 - 	98 52 73 84 < 	0.10 < 	0.10 
SS 62 68 39 32 - - - 90 97 < 	0.10 0.60 
DR 39 r 47 8 31 - 	99 88 63 77 0 	0.10 < 	0.10 
HE 59 62 0 16 - - - 82 100 < 	0.10 0.20 
SC 2 26 4 0 - 	100 82 70 100 < 	0.10 < 	0.10 
KW - 62 - 17 - - 87 99 < 	0.10 0.25 
MEAN 49.3 54.7 24.4 28.4 99.2 78.8 78.4 91.1 a 	0.10 0.15 
S.D. 25.9 14.3 22.9 17.6 1.0 18.6 9.0 9.1 0.21 
S.E. 10.6 5.4 8.6 6.3 0.5 9.3 3.2 3.2 0.07 
• Troneh sample: 	I hr before final dose 
- • : f ,ILor 
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Platelet aggregation, MDA synthesis and plasma aspirin concentrations.on the 
seventh day after Astrix 20 mg, 1 capsule daily for seven days. 
	
Platelet aggregation 	 MDA synthesis 	Plasma asoirin 
% Inhibition of control % Inhibition of control 	concentration 
(uR/m1) 
176 
Table 	A49 Platelet aggregation, MDA synthesis and plasma aspirin concentrations on the 
seventh day after Astrix 200 mg, 1 capsule daily for seven days. 
Platelet nggreation  
% Inhibition on control mnA Synthesis  Inhrbirlon or control, 
Plasma asoir::: 
concenrratic- 
f:-C/ ,11) 
Subject Adrenalin 
T P 
Collagen 
T P 
Arachidonic 
acid 
r 	e 
Arachidonic 
acid 
r 	P 'I 
REM 
P T P 
RH 67 69 34 37 - 100 93 - 87 a 0.10 0.30 
AU 71 77 33 • 33 - - 83 90 < 0.10 a 0.1e 
MS -. - - 100 89 - 90 a 0.10 - 
Si 86 92 34 60 - - 87 93 a 0.10 0.20 
WM 77 79 32 31 99 88 89 96 < 0.10 0.25 
KU 74 69 28 30 - - - 92 a 0.13 0.30 
JC 88 82 46 55 98 68 70 78 < 0.10 < 0.10 
Hid - 56 58 - - 88 89 < 0.10 0.33 
MEAN 77.2 78.0 37.6 43.4 99.2 84.7 83.4 89.4 < 0.10 0.21 
S.D. 8.3 8.7 9.8 13.6 1.0 11.1 7.8 5.3 0.15 
S.E. 3.4 3.5 3.7 5.1 0.5 5.5 3.2 1.2 0.05 
.T . Trough sample: 1 hr before final dose 
P Peak sample : 3 hrs after final dose 
Table 	A5° Platelet aggregation, MDA synthesis and plasma aspirin concentrations on the 
seventh day after Astrix 650 mg, 1 capsule daily for seven days. 
Platelet aggregation 	MDA svntnesis • Plasma asoirin 
Inhibition of control % Inhibition of control 	concentration 
(sR/m1) 
Subject Adrenalin 
I P 
Collagen 
T P 
Arachidonic 
acid T 
P 
Arachidonic 
acid 
T P 1* 
REM 
e T P 
KS - 56 64 96 100 97 97 84 99 < 0.10 0.25 
EH 45 38 23 24 97 100 92 98 92 100 < 0.10 0.15 
OK - 64 70 100 100 97 97 90 97 < 0.10 0.1t 
SS 52 67 40 48 100 100 96 96 89 100 < 0.10 2.2, 
DR 67 73 19 31 89 93 90 76 90 95 < 0.10 0.63 
HE - 19 52 90 94 91 79 79 94 a 0.10 0.25 
SC 49 49 11 19 . 86 85 99 96 82 97 < 0.10 1.35 
MW - - 0 6 86 98 96 95 83 96 < 0.10 0.53 
MEAN 53.2 56.7 29.0 39.2 93.0 96.2 94.7 91.9 86.1 97.2 4 	0.10 0.65 
S.D. 9.6 16.1 22.3 22.7 5.9 5.4 3.3 8.9 4.7 2.2 0.73 
S.E. 4.8 8.0 7.9 8.1 2.1 1.9 1.2 3.1 1.7 0.8 0.26 
4,1 • Trough sample: I hr before final dose 
P Peak sample : 3 bra after final dose 
Table • A51 Platelet aggregation, MDA synthesis and plasma aspirin concentrations on the 
seventh day after Astrix 1300 mg, 1 capsule daily for seven days. 
 
	
Platelet aggregation 	 MDA Synthesis 	Plasma asniri:  
% Inhibition of control Inhibition of control 	concentration 
(ug/ml) 
Subject Adrenalin 
I P 
Collagen 
T P 
Arachidonic 
acid 
1 P 
Arachidonic 
acid 
T P T 
REM 
P 'I e 
RH - 34 43 92 99 97 97 90 99 a 0.10 3.0 
AU 76 64 24 21 95 100 88 93 81 88 a 0.10 0.30 
MS 55 62 19 26 99 100 83 99 94 99 a 0.10 0.4 
Si - - 21 65 97 100 94 98 92 96 a 0.10 1.0 
WM 69 77 45 69 100 100 81 91 84 97 a 0.10 1.51 
KU 63 64 23 24 97 100 71 - - - a 0.10 0..4 
IC - 67 64 100 100 91 73 86 93 s 0.10 1.0 
Hid - 67 71 100 100 82 - - - a 0.10 4 . 2 $ 
MEAN 65.7 66.7 37.5 47.9 97.5 99.9 85.9 92.0 87.8 95.0 a 0.10 1.51 
S.D. 8.9 6.9 20.0 21.8 2.9 0.3 8.3 9.7 5.0 4.2 1.4 
S.F. 4.4 3.4 7.1 7.8 1.0 0.1 2.9 4.0 2.0 1.7 0..0 
•T • Trough sample: 1 hr before final dose P • Peak sample 	: 	3 hrs after final dose 
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Table A52 Effects of nitroglycerin infusions on the 
cardiac output and mean arterial blood 
pressure of sheep just before termination 
of the infusion. 
 
Rate of 	% chan g e 
Infusion in cardiac 
pg/min/kg output 
% reduction 
in mean 
arterial blood 
pressure 
0.4 	
• 
7.1 	0 
	
1.6 2.6 
5.4 	1.6 
5.7 	+ 2.7 14.5 
+ 5.3 	9.1 
7.6 3.6 
22.1 16.7 
6.4 
18.8 
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